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Brief Summary 
The translation of discoveries in basic science into safe and effective clinical applications is 
essential for improving health care. Unfortunately, translational research is a long, arduous 
and resource intense process filled with high levels of uncertainty and renown for resulting in 
a series of failures before succeeding in its goal. This is particularly true when cutting-edge 
medical technologies are translated into improved diagnostic tests or better and safer 
therapeutic options. The aim of this doctoral research project was to describe the challenges 
involved in the translational research of medical applications of nanotechnology with a 
particular focus on first-in-human (FIH) trials. 
 This exploratory research project was situated in a larger study and included in-depth 
qualitative interviews to gain insight into the perspectives of various stakeholders involved in 
planning, conducting or evaluating FIH trials in nanomedicine. Translational research is a 
multi-stakeholder enterprise and often requires the negotiation of various conflicting values 
and goals. FIH trials mark the moment in translational research when an experimental 
intervention is tested in human beings first time and poses the highest level of uncertainty 
with regard to the safety and efficacy. In-depth interviews conducted with expert stakeholders 
based in Europe and North America led to a greater understanding of the various challenges in 
translational nanomedicine and potential solutions. 
 The key results of this research project indicate a number of challenges in the current 
practices of translational research. The results are mainly focused on insights obtained from 
stakeholder interviews and point to issues such as (1) diverse definitions of nanomedicine and 
its impact on the translational research, (2) financial, ethical and regulatory challenges in the 
translational research, (3) inconsistent disclosure practices with regard to the ‘nano’ nature of 
investigational products in patient information sheets and informed consent forms, (4) 
implications of the current practices of the researchers of including patients with end-stage 
cancer and no effective treatment options in FIH trials on the scientific value of the early 
phases of the translational research and (5) factors such as public health emergencies that can 
accelerate decision making and mobilize resources to initiate FIH trials with investigational 
products despite significant uncertainty related to their safety and efficacy.  
 To understand all the complexities of translational research in nanomedicine, there is a 
need to further investigate the role of various regulatory guidelines and to define ‘meaningful’ 
public engagement in science and drug development. Both these aspects critically hinge upon 
scientific integrity and the public’s trust in science and regulatory mechanisms. Although 
these topics were not investigated in this research project, our results clearly indicate the need 
to explore them further. We conclude that while discussing the regulation of nanotechnology, 
careful attention must be paid to each application on a case-by-case basis. We argue for the 
critical examination of current procedures in regulatory assessments rather than creating new 
and special regulations for nanomedicine. Finally, we believe that the challenges in 
translational nanomedicine discussed in this project are also applicable to any cutting-edge 
medical technology.    
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Thesis outline 
Chapter one situates this research project within the existing scientific literature on 
translational research, nanomedicine and ethical issues of first-in-human (FIH) trials, 
identifies the knowledge gaps and defines objectives of the study. It also lists peer reviewed 
publications included in this doctoral thesis and outlines doctoral student’s contribution to 
each of those manuscripts. 
Chapter two elaborates on the methodological approach of the study and the experience of 
field work and data collection; discusses implications of the methodology on the 
interpretation of results in terms of strengths and weaknesses; and reflects on ways in which 
doctoral student’s presence could have influenced the study and how the study influenced the 
student.  
Chapter three demonstrates the diversity in the definition of nanomedicine and critically 
examines its impact on the funding policy, drug regulatory approvals, ethical review, patent 
procedures, large pharmaceutical industry, patient population and the general public.  
Chapter four discusses the particulars of financial, ethical and regulatory challenges faced by 
stakeholders of translational nanomedicine and proposes a few solutions. 
Chapter five critically examines the views of ethics committee members, investigators and 
trial physicians on the explicit mention of the ‘nano’ nature of investigational molecules in 
trial related documents (patient information sheets and informed consent forms) of a FIH trial.  
Chapter six problematizes the current practice of enrolling patients with end-stage cancer and 
no treatment options in FIH trials of cancer nanomedicine. Drawing on the views and 
experiences shared by the investigators, physicians and ethics committee members, an 
alternative category of patients that could be considered for such trials is proposed. 
Chapter seven looks at the circumstances which could accelerate translational research. Public 
health emergency of the 2014 Ebola epidemic necessitated fast track FIH vaccine and drug 
trials with modified trial designs in affected countries, thus raising important ethical questions 
regarding trial design and participant selection.  
Chapter eight critically examines the clinical research guidelines issued by the Indian Council 
of Medical Research. Until recently, India has been a prominent hub of international drug 
trials though not necessarily FIH trials. This chapter problematizes the adequacy of India’s 
clinical research guidelines to facilitate scientifically sound clinical research and to protect its 
human subjects.   
Chapter nine focuses on an overall discussion of this PhD thesis. In addition to linking 
discussions related to each of the previous chapters, it reflects on limitations of the study, and 
elaborates implications for future research.   
 
 Chapter 1 Introduction 
 
Priya Satalkar 
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Background 
All countries around the globe are concerned about mounting health care costs, irrespective of 
their economic strength. Health care systems address the population’s health care needs in 
three main ways. First is disease prevention, which is generally cost effective, but also 
challenging to implement. The second is developing sensitive and specific diagnostic tools for 
early detection of diseases and complications and to monitor disease progression. The third is 
the development, approval and availability of affordable, safe and effective drugs to cure or 
treat diseases and complications.  
 All abovementioned health care approaches rely on basic science research in multiple 
scientific disciplines. It has been noted that less than 10% of basic research with significant 
potential to improve human health and well-being is translated into clinical applications1,2. 
Inadequate and inefficient research translation is well illustrated by considering the 
development and licensing of a new drug, which is estimated to cost approximately 
$800million3-5. The drug development process takes 15-20 years and requires screening and 
testing approximately 8000 molecules/compounds to ‘hit’ one new effective drug. Though 
annual research and development costs incurred by pharmaceutical industries have grown 
exponentially over last decades, the number of new drugs approved each year by the US FDA 
has remained more or less static (average 30/year) or declined6. Among newly approved 
drugs, only 20 to 25% are actually “new”, while the rest are reformulations or new 
combinations of drugs already approved. There is a growing concern about the huge profit 
margins of the pharmaceutical industry, improper drug pricing and disproportionate 
expenditure on marketing and advertising as compared to research and development (R&D) 
costs7. Pharmaceutical drug development has become a time consuming, resource intense and 
inefficient process with significant impact on health care needs of global populations (e.g., 
there have been only four new classes of antibiotics developed since 1960s in spite of growing 
concerns about microbial resistance to number of key antibiotics currently in use8). In 
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addition, despite a significant focus on R&D in cancer chemotherapy, there are few effective 
drugs for cancers of the lungs, ovaries and pancreas that can significantly improve treatment 
outcomes in patients while minimizing adverse effects9. It is in this context that cutting-edge 
biotechnology is expected to play a significant role by stimulating the development of highly 
sensitive diagnostic, screening and monitoring tools and targeted therapeutic options7.   
 
Nanotechnology: An example of cutting-edge technology 
Biotechnology, nanotechnology, cognitive science, and information technology are 
collectively referred to as converging technology. The term converging technology implies 
that these four rapidly growing technologies can have synergistic applications to improve 
health care delivery and provide personalized medicine10.  This research project is focused on 
nanotechnology and in particular its medical application. There has been a surge of funding in 
the field of nanotechnology11 with a corresponding increase in basic science research and calls 
for heightened scrutiny and regulation12. Nanotechnology is expected to have a significant 
impact on the field of medicine. One study identified approximately 40 approved 
nanotechnology-based medical products (drugs and contrast agents for imaging studies) on 
the world market13. Another study identified 40 devices and 33 drugs based on 
nanotechnology approved globally14. It is important to reflect on the ethical, legal and social 
issues related to nanotechnology and nanomedicine while the field is evolving. This will 
allow for a better informed regulatory and policy framework to harness nanotechnology’s 
potential to meet the most important population needs without compromising disadvantaged 
populations or the environment15. This doctoral research is situated in a larger project that 
focuses on risk benefit evaluation of nanomedicine and synthetic biology. Brief description of 
nanotechnology below will continue with the discussion on its specific contributions to 
medicine and health care.  
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 The word ‘nanotechnology’ comes from the Greek word ‘nanos’, which means dwarf. 
Nano is a scale to measure particle size that is one billionth of a meter16. The word 
nanotechnology was first used by Norio Taniguchi in 1974, but many regard Richard 
Feynman’s address in Caltech in 1959 to have ushered the era of nanotechnology17. The most 
influential definition of nanotechnology that has shaped funding decisions, policy and 
regulatory frameworks and patent approvals around the world was provided by the National 
Nanotechnology Initiative of the US18, which states that nanotechnology is,  
 …the understanding and control of matter at dimensions between approximately 1 and 
 100 nanometers, where unique phenomena enable novel applications. Encompassing 
 nanoscale science, engineering, and technology, nanotechnology involves imaging, 
 measuring, modelling, and manipulating matter at this length scale.  
Although nanomedicine is generally defined as the medical application of nanotechnology, 
there is vast diversity in definitions from various scientific and drug regulatory authorities. 
The impact of these definitions is discussed in chapter 3. By virtue of the nano-scale size and 
unique physical, chemical, optical, electric and magnetic properties, nanomedicine is expected 
to have a significant impact on all three approaches to health care mentioned in the opening 
section of this chapter. Nanomedicine can produce improved and more sensitive diagnostic 
tests to facilitate early disease detection 9. It has the potential to produce improved and 
targeted therapeutic modalities with fewer side effects and improved efficacy13. It can provide 
the tools to continuously monitor individuals’ health.  It can also facilitate theranostic 
applications, which are approaches to produce  “more specific, individualized therapies for 
various diseases, and to combine diagnostic and therapeutic capabilities into a single agent”19. 
Finally nanotechnology has the potential for miniaturization and increased sensitivity and is 
expected to significantly improve the efficiency of pharmaceutical drug development7.   
However, there are also critical voices concerned about nanotoxicity and the long-term 
effects of nanoparticle exposure on humans and the environment20-22. Concerns have been 
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raised about the fair and just distribution of improved diagnostic and therapeutic tools across 
the world, and nanotechnological advancements in high-resource countries (HRC) that could 
create further health inequality and disparity between HRC and low-resource countries17. 
Some scholars have also raised questions about the potential for a dual-use of nanotechnology 
and its possible misuse in bioterrorism17. Others have highlighted the possibility that 
nanotechnology could be used as a tool for human enhancement and its most prominent 
application would be in military research to create super-soldiers for combat warfare23. The 
public’s perception of nanotechnology has been mixed, but so is the public’s knowledge of 
nanotechnology. Experts have called for public engagement and participation while regulating 
nanotechnology24 mainly to avoid a societal backlash as was the case of genetically modified 
organisms (GMO) in Europe. Even in nanomedicine, there is significant uncertainty regarding 
long-term toxicity of nanoparticle exposure, the validity and reliability of existing 
toxicological assessment tests to fully characterize nanoparticle risks, and whether patients 
enrolled in clinical trials of medical applications of nanotechnology are capable of providing 
truly informed consent given the complexity of technology involved25.   
Research in cutting-edge technology in isolation is not going to be effective for health 
care purposes unless systematic efforts are made to facilitate translation of those 
breakthroughs into concrete applications for human health. This realization has compelled 
many national and international scientific and regulatory bodies to focus on the translational 
research of any cutting-edge technology including nanotechnology 26,27.  
 
Translational research and first-in-human trials 
The Institute of Medicines’ ‘Crossing the Quality Chasm’ report 28 divides translational 
research into two distinct (T1 and T2), yet inter-related phases. The first phase, T1, is 
typically described as translational research from the ‘bench to the bedside’ and involves 
“..transfer of new understandings of disease mechanisms gained in the laboratory into the 
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development of new methods for diagnosis, therapy, and prevention and their first testing in 
humans”29. Thus T1 ends with the approval of new drugs or diagnostic tests. The second 
phase of translational research, T2, involves the translation of interventions (proven in clinical 
trials) into clinical practice and eventually into health care policy. Both these phases are 
equally valuable to ensure provision of evidence-based health care.  
However, there is another arm of translational research, which is from ‘bedside to 
bench’. Here the challenges or limitations experienced in health care practice initiate basic 
science research in search of solutions30. This research is generally driven by the patient 
needs. Bedside-to-bench translational research requires that feedback from unsuccessful 
clinical trials is given to the bench researchers for further modification of investigational 
products and preclinical testing. This aspect is often ignored when investigational products are 
completely abandoned after failed initial clinical testing30. To be successful, translational 
research requires collaboration between basic scientists, physicians and a large number of 
stakeholders in spite of their conflicting and competitive interests and goals.  
 In bench-to-bedside translational research, most critical and highly uncertain step is 
first-in-human (FIH) clinical trial. This is when an investigational product is tested in humans 
for the first time31. The high degree of uncertainty is attributed to the limited validity and 
reliability of preclinical research,32,33 questions concerning the appropriateness of animal 
models,34 and the lack of clarity regarding the investigational product’s mechanism of 
action.35 The goal of FIH trials is to gather information on the drug’s mechanism of action, 
toxicity and safety profile, and to determine a safe and tolerable dose in humans (the starting 
dose for clinical trials wherein the efficiency of the drug is tested).36 The dose escalation 
design of FIH trials makes it highly unlikely that patients participating in such trials will 
receive clinically relevant therapeutic benefit, at least in the earlier cohorts using low drug 
doses.37 Trial participants are likely to experience side effects and harm of various type, 
magnitude, and probability.38 Some harm can be predicted from preclinical animal data. 
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However, data from animal models cannot always be reliably extrapolated to human beings 
and substantial uncertainty and ignorance persists while assessing the risks of FIH trials.39  
The death of Jesse Gelsinger in a FIH trial of gene transfer technique for ornithine 
transcarbamylase deficiency in 1999 had a significant impact on the field of gene transfer.31 
This example shows the highly uncertain context in which the decision is made to start a FIH 
trial of a novel medical technology. It compelled scientists, clinicians, drug regulatory 
authorities, ethics committees and scientific review boards to undertake comprehensive and 
careful assessment of all the risks and uncertainties before initiating a FIH trial.  
 
Exploring first-in-human trials in nanomedicine  
Nanomedicine with inherent novel properties and potential to improve health and well-being 
has created many expectations in the minds of patients seeking solutions for their health 
concerns. The same novel properties of nanomaterials have also created fear and concerns 
about their long-term impact on human beings and the environment. While some stakeholders 
ask for a streamlined regulatory environment to harness the full potential of technology, 
others advocate for stricter regulation given the high level of inherent uncertainty and risk. 
This scenario has significant implications for translational research in nanomedicine, 
particularly in relation to planning and conducting FIH trials.  
Though there is a large number of scientists exploring ethical issues of nanomedicine 
and nanotechnology, most of this literature is speculative or focused on futuristic scenarios 
such as human enhancement and nanorobots flowing through the body and selectively 
destroying cancer cells23. Such scenarios are striking enough to gather the public’s attention 
and initiate an ethical debate, but they tend to further polarize public opinion.  
On the other hand, there are a number of products in the clinical development pipeline 
that are likely to get tested in humans in the next three to five years. It is critical to understand 
the challenges to translate these promising nanomedicine discoveries into clinical applications 
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in the context of heightened hopes, fears and hype. Since translational research is a long 
process over many years, I focused on FIH trials that pose the highest level of uncertainty and 
require thorough ethical and regulatory reviews to protect human research subjects.  
 Translational research is a multidisciplinary enterprise and each stakeholder has their 
own interest. These interests could be competitive or even contradictory to the interests of 
other stakeholders. There is limited empirical research that assesses the knowledge, 
perception and views of various stakeholders engaged in nanotechnology and nanomedicine. 
One study examined the attitudes and knowledge of nanoscientists in Portugal about ethical 
issues40. Two ethnographic investigations examined critical decision making in a 
nanotechnology laboratory to understand how nanoscientists engage in ethics in day to day 
research environment 41,42. Large surveys in the US and in the UK have looked at experts’ and 
general public’s knowledge and attitudes towards nanotechnology and found a relation 
between exposure to information and risk perception 43,44.  
To the best of our knowledge, there is no other study where the perspectives of 
multiple stakeholders involved in FIH trials in nanomedicine have been explored empirically. 
To understand how diverse interests of various stakeholders are negotiated and decisions are 
made to initiate a FIH trial in nanomedicine, and to explore the procedure of the ethical and 
regulatory review of proposed trials and informing and recruiting trial participants, an 
empirical qualitative enquiry was used. This doctoral research project is situated in a larger 
research project which envisioned an interdisciplinary, multi-stakeholder risk-benefit 
evaluation of four concrete FIH trials in nanomedicine and synthetic biology.   
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Research objectives 
The goal of this exploratory interdisciplinary research project (subpart of the original project) 
was to describe and explore challenges of translational research in medical applications of 
nanotechnology (this choice is explained in greater details in the next chapter on 
methodology) with a particular focus on FIH trials. These challenges were investigated from 
the point of view of stakeholders involved in translational nanomedicine. The main research 
questions of this study were: 
1. What challenges do the stakeholders in translational nanomedicine face while 
planning or conducting a FIH trial? 
2. What are the ethical challenges in planning or conducting FIH trials in nanomedicine? 
3. What factors or circumstances could facilitate translational research, in particular FIH 
trials? 
4. How do the ethics committee members review proposals of FIH trials when significant 
uncertainty and ignorance exists in respect to risk assessment? 
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Contribution to project related publications. 
Prof. Elger wrote the original project within which this doctoral research project is situated 
and she also received the funding. I conducted 46 interviews, transcribed and analyzed them. I 
received some inputs in data analysis from Dr Shaw. There are six publications included in 
this thesis. In each one of them I took the lead, thought of an idea, conceptualized the 
structure, and wrote the first draft. I received feedback from Prof. Elger, Dr. Shaw and from 
Prof. Hunziker (for one paper). Dr. Shaw reviewed each manuscript before submission as a 
native speaker.  
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Outline 
This PhD project is part of a larger research project funded by the Swiss National Science 
Foundation, a grant obtained by Prof. Bernice Elger. In this chapter, I will describe the 
methodological approach of my doctoral research, elaborate on my experience of field work 
and data collection, and outline the methodological limitations that need to be kept in mind 
while interpreting the findings of this study. This chapter is intentionally written in first 
person singular (i.e. I format) as it mainly describes on the process of field work and data 
collection as part of this research project and involves self-reflection as a researcher.  
Original research project 
The focus of the original research project was on ethical issues of cutting edge medical 
technology, envisioned as an interdisciplinary research project in empirical ethics to 
understand the procedure of risk/benefit evaluation of first-in-human (FIH) trials in synthetic 
biology and nanomedicine. It was designed as a mixed method study, conducted by two 
doctoral students, each looking at one medical technology with concrete examples of FIH 
trials, either ongoing or those at the stage of planning.  
Defining my doctoral research project 
Though there is a significant surge in the academic literature on ethics of nanomedicine, 
nanotechnology, and synthetic biology, we realized that there was limited empirical 
investigation of the ethical issues. We were interested in understanding the ethical issues 
faced by stakeholders involved in translational research and to gather their views on possible 
solutions. Nanomedicine, as a scientific field, is further along the translational pathway as 
compared to synthetic biology, which is still mainly at the stage of preclinical research. My 
linguistic limitations to communicate in German made it logistically convenient that I would 
interview expert stakeholders in both translational nanomedicine and synthetic biology while 
my German speaking colleague would do surveys with patients at a local hospital and we 
would work together on data analysis and summarizing results on both data sets.  
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 To narrow the scope of my project while keeping in line with the original project, I 
decided to focus on FIH trials, which pose the highest level of uncertainty during translational 
research. In-depth interviews facilitated by a semi-structured interview guide allowed me to 
explore the views and experiences of stakeholders while giving them the opportunity to 
describe their rationale, arguments, and concerns.   
 The original plan for me was to conduct a total of 40 in-depth interviews.  Half of 
these interviews would be with the stakeholders based in Switzerland (since the project was 
funded by the Swiss National Science Foundation) and the remaining 20 could be situated 
anywhere in the world. I was to interview 20 scientists who had either conducted or were 
planning to conduct FIH trials in nanomedicine or synthetic biology and 20 ethics committee 
members who had evaluated such FIH trials, thus having equal representation of these two 
stakeholders in the study sample.  
 An extensive literature review undertaken in the first year of my PhD helped clarify a 
number of aspects of my research project. My first realization was that translational research 
and clinical trials are a multidisciplinary enterprise and a category of “scientist” is too 
restrictive. To gain a complete picture of the challenges of conducting FIH trials, I decided to 
elicit the views of different stakeholders who are integral in translational research and not 
necessarily just scientists working on nanotechnology. Second, conducting the literature 
review helped me shift the focus of my research question from risk/benefit evaluation to 
general challenges of taking a promising medical application from “the bench” and successful 
animal studies to “the bedside” and clinical practice. Third, to accommodate diverse 
categories of stakeholders in translational research, my interview guide had to be 
comprehensive yet flexible so that depending on the profile and exact role a potential 
respondent plays in translational research, I could smoothly transition to questions that were 
relevant to that respondent. Finally, the review reinforced our original assessment that 
nanomedicine, as a field, has matured more than synthetic biology and hence it would be most 
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relevant for me to solely focus on the medical applications of nanotechnology rather than it 
and synthetic biology.  
Experience of field work and data collection 
In the first year of my PhD, apart from undertaking periodic literature searches, refining and 
pilot testing my interview guide, and getting necessary ethics approvals, I carried out 
“participant observation” at four key nanomedicine conferences and meetings in Switzerland 
and France. The focus of this participant observation was to understand the current state of 
nanomedicine along the translational research pathway, assess who has conducted or is 
planning to conduct FIH trials and to introduce myself to these professionals. I actively 
participated in scientific sessions as well as evening socializing events at these conferences 
where I observed conference delegates interact with one another and openly discuss 
challenges they faced. These meetings and conferences also had heated debates on certain 
topics, such as defining nanomedicine, nanocharacterization capacity and the state of 
translational research in the US as compared to Europe. I took extensive notes of these 
observations and insights but did not use this data in my research writing for two reasons. 
First, I did not know what kind of ethical approval one needs to carry out participant 
observation at a conference in which one officially participates (e.g. is registered and presents 
a research paper). Second, I was unsure how reliable was information obtained at informal 
evening talks, over a glass of wine, where most delegates were relaxed and more open to 
share their thoughts. However, participation in these conferences improved my familiarity 
with the field of nanomedicine and provided me with a new identity conferred by the 
conference participants –“the girl studying ethics of FIH nano trials.”  
 Still, it was quite challenging to get the stakeholders to agree to do an interview with 
me. They were extremely busy and their priority was to find solutions to their challenges by 
collaborating with others and not spending 30 minutes with a doctoral student who wanted to 
understand those very same challenges. Some were concerned about talking to a PhD student 
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in ethics about their technology platform and FIH trial, worried that I might share their 
sensitive research information unknowingly while interviewing others (perhaps their 
competitors). A few of them directly and bluntly asked me what I would give them in return 
for the time they would spend talking to me. A couple of them told me the hourly fees they 
charge as consultants and asked if I could afford that kind of money. A few wanted me to 
connect them with particular hospitals in India in return for an interview. At some point in 
time, I realized that delegates were avoiding me at these conferences; they were particularly 
reluctant to make eye contact and some refused to recognize me or acknowledge that we had 
met and talked at another conference, where they had agreed to do an interview with me.  
But there were also a few who took great interest in my research, personally 
introduced me to others that they thought could be interesting for me to talk to, wrote emails 
introducing me to their colleagues and encouraged me to keep trying, especially when I felt 
defeated after having failed to recruit any respondents in the first 13 months of the study. A 
few experts confessed that they needed to keep talking about their ambitious FIH trials at such 
conferences as if they were going to take place in near future to receive the attention of 
venture capitalists and funding agencies. However, in reality, they were far from such a 
possibility and hence could not do an interview with me as they had nothing to share with me. 
The stakeholders affiliated with universities and small and medium size enterprises (SMEs) 
were more willing to talk to me and were interested in knowing more about my project while 
those from the large pharmaceutical industry were quite skeptical of me. If I introduced 
myself as a doctoral student in ethics, I could immediately notice the change in their 
interaction with me, taking on a more cautious approach. They all wanted to know my 
professional background before talking to me. When I disclosed that I was trained in medicine 
before diversifying into social science and ethics, I gained some credibility in their eyes. I 
finally started introducing myself as a physician and a social scientist working on challenges 
of translational research in nanomedicine and dropped the word “ethics” from my initial 
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interactions with potential respondents, even though my business card clearly stated my 
affiliation with the Institute for Biomedical Ethics.  
 Apart from making personal contact in conferences, I continued to write emails to 
experts in nanomedicine and requesting an interview from them. A senior expert from 
Switzerland told me that most of these experts receive hundreds of emails each day and hence 
my email being one of them is unlikely to catch their attention or fuel their curiosity about my 
research. He encouraged me to write hand written letters and mail those. Since it was already 
Christmas of 2013, I decided to combine my hand written notes with Christmas cards and sent 
out 60 letters to potential respondents. Five of my respondents later admitted that my letter 
finally compelled them to do an interview with me.  
Methodology 
The details of methodology such as study population, interview guide, interviews, 
transcriptions and qualitative data analysis have been discussed in chapters three, four, five 
and six. These chapters include manuscripts based on the empirical data from this research 
project which have either been published or are submitted to journals.  
In following pages, I will reflect on the strengths and weaknesses of the 
methodological approach of my doctoral research while paying attention to ways in which my 
presence as a researcher with my personality, training, experience, and opinions could have 
influenced the research. Additionally, I note how the research influenced my views and 
opinions about the ethical challenges in translational nanomedicine.  
Methodological limitations 
My decision to include a broad range of stakeholders in my study population proved to be a 
double edged sword. It allowed me to gather views and experience from different angles but it 
also significantly limited the generalizability of my findings. Drug development and licensing 
processes as well as ethics review is highly political and influenced by each country’s drug 
regulatory environment and ethical guidelines. It became almost impossible for me to draw 
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any conclusions in regards to specifics of drug regulatory procedures or ethics review because 
my 46 interview partners were spread across 13 countries and some countries were 
represented by only one respondent. I was uncomfortable to draw conclusions based on views 
and experience shared by one respondent as if it was representative of the reality of that 
country even though only a few FIH nanomedicine trials had taken place in that country often 
initiated by that same respondent.  
Another difficulty I experienced was to interview ethics committee (EC) members 
who had reviewed FIH trials. Contrary to my expectations, EC members were the most 
difficult category of respondents to recruit. My data set has only six ethics experts, two of 
whom are members of National Ethics Commissions, serving advisory rather than reviewer 
roles. The other four who worked as EC members claimed to have no experience in 
evaluating FIH nanomedicine trials. In fact only two of the four stated that they had ever 
evaluated any FIH trial. Taking a closer look at their work load, it became clear that the 
majority of trials they evaluate are doctoral theses, social and behavioral research, health 
systems research, as well as phase II and III clinical trials. FIH and phase I trials in particular 
are a miniscule amount of the total number of trials these committees review. Even in 
Switzerland, my efforts to approach EC members for an interview did not materialize since 
most of them replied back saying, “We have not evaluated FIH trials in nanomedicine and 
hence cannot do an interview.” This scenario correlates with the fact that in general, very few 
FIH trials in nanomedicine have taken place in Europe, and the US remains on the forefront of 
conducting such trials. Unfortunately, I did not have access to IRB members in the US. I 
would definitely like to explore this possibility in the future.  
Self-selection bias cannot be completely ruled out in this study since those who agreed 
to be interviewed for this project probably had different views and a greater interest in the 
topic than stakeholders that were not interviewed. It is not possible to assess how different 
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these views could be from those who did not want to be interviewed. Outright refusals were 
rare; often stakeholders simply did not respond back to my repeated requests for an interview.  
I initially feared that respondents would provide me with answers that they thought a 
PhD student in bioethics would like to hear. However, during the course of these interviews, I 
realized that the stakeholders were honest and open about their views and willing to explain to 
me the line of reasoning behind their beliefs. They also enjoyed being challenged on some of 
their ideas. One of the reasons for this could be that most of these stakeholders were experts 
in their field and had no reason or incentive to please a doctoral student, and instead saw the 
interview as an opportunity to engage in a scientific and ethical discussion and to exchange 
ideas and arguments. There were a couple of respondents who tried to influence and challenge 
my views during the course of the interview, leading to some serious debates.  
I believe the insights obtained from this exploratory research project are still valuable, 
especially for developing a more structured, international study using both qualitative and 
quantitative methodology for each category of stakeholder. It would be worthwhile to survey 
drug regulatory authorities or ECs from select countries to compare contexts and understand 
the magnitude of specific challenges. Additional interviews with these stakeholders could 
assist in exploring the nuances of those challenges and potential solutions to them.  
Personal reflections 
At every stage of qualitative research (e.g. data collection, analysis), the researcher must be 
aware of how his/her presence in the ‘field’ could influence the research and how the research 
could influence him/her in return. Above, I elaborated on how my presence might have 
influenced the research. Here I share reflections on how the research influenced me. 
 At the beginning of the project, I thought that nanotechnology and its medical 
applications raise new ethical questions and therefore FIH trials in nanomedicine should have 
a special status. During the course of research this initial belief underwent a significant shift. I 
still believe that nanotechnology, by its very nature, raises some interesting questions due to 
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the significant uncertainty in long term risks and risk assessment. However, I do not believe 
that there is any need to create a sub-discipline of nanoethics or special departments to 
evaluate only nanomedicine trials. One reason against creating special departments is that 
with converging medical technologies, dividing a drug or device based on underlying 
technological platform is going to be challenging. I rather believe that we need to go back to 
the basics of evaluating any FIH trial and pay critical attention to all procedures involved, 
particularly to the blind spots during drug regulatory or ethical review process. I have 
elaborated this point further in chapter nine on discussion.  
Medical science in general focuses on empirical evidence and has a strong positivist 
approach. However, I was surprised to learn how many decisions in clinical research, risk 
assessment, drug development, and ethics review are based on intuition, trust, and the belief 
that everyone involved is honest and has a strong notion of research integrity. Repeated 
reference to trust in these interviews made me curious about the role trust plays in scientific 
research. More specifically, I am curious to understand threats to trust in the highly 
competitive drug development industry and ways to nurture and safeguard trust in science and 
drug development. I do not dwell on the theme of trust during my doctoral research, but I am 
interested in exploring it further as a next step of my academic career.   
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Abstract 
Nanotechnology, which involves manipulation of matter on a ‘nano’ scale, is considered to be 
a key enabling technology. Medical applications of nanotechnology (commonly known as 
nanomedicine) are expected to significantly improve disease diagnostic and therapeutic 
modalities and subsequently reduce health care costs. However, there is no consensus on the 
definition of nanotechnology or nanomedicine, and this stems from the underlying debate on 
defining ‘nano’. This paper aims to present the diversity in the definition of nanomedicine and 
its impact on the translation of basic science research in nanotechnology into clinical 
applications. We present the insights obtained from exploratory qualitative interviews with 46 
stakeholders involved in translational nanomedicine from Europe and North America. The 
definition of nanomedicine has implications for many aspects of translational research 
including: fund allocation, patents, drug regulatory review processes and approvals, ethical 
review processes, clinical trials and public acceptance. Given the interdisciplinary nature of 
the field and common interest in developing effective clinical applications, it is important to 
have honest and transparent communication about nanomedicine, its benefits and potential 
harm. A clear and consistent definition of nanomedicine would significantly facilitate trust 
among various stakeholders including the general public while minimizing the risk of 
miscommunication and undue fear of nanotechnology and nanomedicine.  
Keywords 
Nanotechnology, nanomedicine, definition, ethics, qualitative research, stakeholders 
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Introduction 
The use of nanotechnology in medicine has the potential to significantly improve human 
health and well-being due to highly accurate and sensitive diagnostic tests (Ferrari et al. 
2009), targeted therapeutic interventions (Duncan and Gaspar 2011)and theranostic 
applications that have a combined approach to diagnose and treat a disease using the same 
intervention (Lammers et al. 2011). Nanotechnology contributes to early disease detection, 
better treatment outcomes, and reduced health care expenditures. The interdisciplinary field of 
nanotechnology and nanomedicine has gained considerable attention from academia, the 
pharmaceutical industry, various national and international funding and regulatory agencies 
and the general public (Kostarelos 2006; Wagner et al. 2006; Bawa et al. 2005; Pidgeon and 
Rogers-Hayden 2007; Scheufele et al. 2009), and has made significant progress along the 
translational pathway in the last 15 years (Etheridge et al. 2013).  
 Nanotechnology has also raised a number of questions related to risk assessment, risk 
minimization (Hogle 2012), human and environmental toxicity (Ramachandran et al. 2012), 
and cost and fair access to the improved interventions across societies (Allhoff 2009). There 
has also been tremendous pressure to accelerate the translation of basic nanotechnological 
research into bedside clinical applications in medicine (Kola and Landis 2004). However, a 
high level of uncertainty about potential risks and benefits of nanoparticles and 
nanomedicines creates significant hurdles along this translational pathway (Lenk and Biller-
Andorno 2007; Resnik and Tinkle 2007). Particularly interesting in this regard are ‘first-in- 
human’ (FIH) trials of medical applications of nanotechnology, as they pose the highest level 
of uncertainty in all clinical research (Kimmelman and London 2011).  
 The goal of our research project was to document the various challenges and ethical 
hurdles faced by stakeholders involved in the process of planning, reviewing and conducting 
FIH trials in nanomedicine. In this paper, we discuss diversity in the definition of 
nanomedicine. We begin with the definitions of nanotechnology and nanomedicine proposed 
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by international scientific bodies and key drug regulatory authorities. Next, we describe and 
discuss definitions provided by stakeholders who were interviewed in our study as compared 
to official definitions. Finally, we highlight concerns that arise due to the variety in definitions 
used by the stakeholders on ethical and regulatory review process of FIH trials in 
nanomedicine.  
Methodology 
We used exploratory qualitative research methods to gather insights from various stakeholders 
involved in translational nanomedicine. In-depth interviews were considered valuable and 
appropriate for this exploratory research since there are only a handful of empirical studies 
that investigated issues in translational research in nanomedicine.   
Study population 
Stakeholders in translational nanomedicine for the purpose of this study are scientists 
affiliated with universities, small and medium size enterprises (SMEs) and large 
pharmaceutical industry, members of national ethics advisory committees and institutional 
ethics committees (EC), physicians, representatives of the drug regulatory authorities, patient 
advocacy group, clinical research organizations and venture capital groups based in Europe 
and North America.  
Study instrument 
Based on available literature on this topic, we developed a list of open-ended interview 
questions to guide and facilitate interviews with the aforementioned stakeholders. The 
interview guide was pilot tested with fellow colleagues (a doctoral and a post-doctoral 
researcher with experience in qualitative research at the institute) and an expert in 
biotechnology ethics from the US to assess the clarity and validity of the questions. These 
pilot interviews were excluded from the final data set of 46 interviews. The interview guide 
allowed for a structured enquiry, but also provided interviewees with the necessary 
opportunity to elaborate on issues that they deemed critical. The interview guide was 
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approved by the ethics commission of Basel Stadt and Basel Land (Ethikkommission Beider 
Basel EKBB) in January 2013. This commission is now called the ethics commission of 
North-west and Central Switzerland (Ethikkommission Nordwest- und Zentralschweiz, 
EKNZ).  
Sample 
The interviewed experts and the stakeholders were identified through publications, university 
affiliations, contacts made at key scientific conferences on nanomedicine and personal and 
professional networks. Drug development is regulated by national(US FDA) or regional 
(European Medicines Agency) drug regulatory authorities, so we expected researchers 
planning or conducting FIH trials in nanomedicine to face distinct challenges depending on 
the regulatory environment in their country or the country where they planned to conduct a 
trial. We used a purposive sampling technique to include maximum variation in terms of the 
respondents’ experiences, professional backgrounds and affiliations, and geographic location. 
We included stakeholders with views in line with the dominant discourse and those who 
challenge the dominant views (Devers and Frenkel 2000; Kenen et al. 2004). This approach 
allowed us to explore challenges in planning, conducting and reviewing FIH trials in 
nanomedicine from the perspectives of various stakeholders working in multiple countries. It 
also facilitated a reflection on the interdisciplinary nature of nanomedicine since respondents 
had varied professional backgrounds, roles and responsibilities that could be explored in 
depth. Recruitment was further facilitated by the use of a snowball sampling technique until 
we reached theoretical saturation, the moment during data collection when researchers realize 
that no new themes are emerging (Bowen 2008). For example, in our investigation of the 
definition of nanomedicine as described by the stakeholders, we continued to interview 
respondents till the point where no new aspects related to the definitions were described. The 
theoretical saturation was reached at various points for different research questions depending 
on the diversity of opinions, stakeholder heterogeneity and scope of debate on the topic.  
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Informed consent 
The lead author of this manuscript (P.S.) conducted all 46 interviews (in person or via 
telephone or a Skype call) in English from October 2013 till November 2014. Oral informed 
consent was obtained from each respondent at the beginning of an interview, which also 
included permission to record the interview. All interviews were recorded on a hand held 
audio device except one for which the researcher was asked not to record the conversation, 
but to take hand-written notes. The respondents were informed about how their anonymity 
and confidentiality would be ensured. We removed all respondent identifiers such as name, 
affiliation, country and the details of the products they were developing to minimize 
identification. Respondents were also told that they could choose to not answer particular 
questions if they felt uncomfortable and that they could ask for audio recording to be stopped 
for particular sections of the interviews. The same procedure was used to obtain informed 
consent and permission for audio recording for the interviews conducted on the telephone or 
via a Skype call. This approach was essential to build a trusting relationship with the 
respondents since many were concerned about sharing sensitive and proprietary information 
of early clinical trials of their investigatory products with a social science researcher. Their 
concerns were also linked to the fact that the field of nanomedicine is comparatively small, 
yet specialized, and has a very close-knit scientific community. 
Interviews and transcription 
The interviews lasted between 20 minutes and about an hour depending on the respondent’s 
availability and their interest in sharing their experience; the average interview was 50 
minutes. Eighteen interviews were conducted in person, two respondents sent their answers to 
list of our questions while the remaining 26 were carried out either via the telephone or a 
Skype call since travel to different countries in Europe and North America was not possible 
due to the time and money involved. We were aware that interviewing in person compared to 
on the phone or Skype would impact the quality of the data. It is generally easier to develop 
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rapport with a respondent when interviewing in person compared to a phone conversation. We 
discuss this in more detail in the section on study limitations. P.S. with assistance from four 
team members (data assistants who had signed confidentiality agreements) transcribed all the 
interviews in full. P.S. checked all 46 interviews for accuracy against the audio recordings. As 
per our agreement with the respondents, we sent the transcript of each interview to the 
respondent to verify the accuracy of the content since some interviews (at least in part) were 
highly technical. Respondents were also encouraged to provide any additional thoughts they 
had when reviewing their transcript or thoughts that had arisen after the interview. We 
received feedback from only 13 respondents. A total of 17 respondents were re-contacted in 
person at a conference and told P.S. that they had briefly reviewed their transcripts but had 
been unwilling to go through all 20-30 pages and had assumed the transcripts were accurate. 
The remaining 16 transcripts were assumed to be correct and acceptable to the respondents. 
Data analysis   
The transcripts of all interviews formed the basic data for this research. The transcripts were 
read repeatedly to have a thorough understanding of the data. P.S. coded all interviews using 
qualitative data analysis software (MAXQDA, edition 11.0.2 licensed by the University of 
Basel) using deductive coding methods. The research questions guided the deductive data 
coding. The codes were built into subthemes and themes and compared across all respondents. 
A second author (DS) conducted a manual data analysis using the same deductive coding and 
the codes and themes were compared between the two approaches (software assisted vs 
manual). Similarity and differences in coding were discussed amongst the researchers who are 
also authors of this manuscript until a consensus was reached.  
 In the sections that follow, we first describe the characteristics of our respondents 
followed by key official definitions of nanotechnology and nanomedicine. Then we present 
the definitions of nanomedicine provided by our respondents during interviews and compare 
them with the official definitions. Finally we discuss the influence of this diversity in the 
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definition of nanomedicine on the regulatory and ethical review process of FIH trials in 
nanomedicine.   
Results 
Respondent profiles 
A total of 21 of 46 respondents were based in Switzerland, while the remaining 25 worked in 
Germany, The Netherlands, the United Kingdom, Spain, Portugal, Denmark, Norway, 
Austria, Hungary, Israel, Canada and the US. Almost half of our respondents (20/46) 
described themselves as academics or scientists affiliated with a university or research 
institution. Respondents had diverse disciplinary backgrounds such as medicine, molecular 
biology, biochemistry, material science, physics, toxicology, pharmaceutical science and 
organic chemistry. Eight respondents represented SMEs, which play a crucial role in early 
translational research and particularly in obtaining a ‘proof of concept’ in man. SMEs are 
university spin-offs, often headed by academics who start a company and are funded by 
governmental seed grants and/or investment by venture capitalists. Eight of our respondents 
represented large pharmaceutical companies either as researchers, clinical research managers, 
consultants or regulatory affairs experts. Six respondents brought in expertise in ethics either 
as members of EC or institutional review boards (IRB) or being the members of national and 
international advisory commissions on translational research. Two respondents were affiliated 
with drug regulatory authorities. We also included one representative each from a venture 
capitalist group and a patient advocacy organization. Many of our respondents had dual roles 
or experiences at least during some part of their professional career. A large number of 
academic scientists also supported SMEs as members of their advisory boards. The diversity 
of disciplinary backgrounds, geographic locations and professional roles helped us to gather 
views and experiences across a broad range of topics and issues, which was the goal of our 
exploratory qualitative research.  
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Official definitions of Nanotechnology and Nanomedicine 
National and international scientific bodies’ definitions 
To understand the evolution of definitions of nanotechnology and nanomedicine, it is 
necessary to start with publically funded research programs in this field in the US as well as in 
Europe. The National Nanotechnology Initiative (NNI) was launched, in 2001, in the US 
which led to significant funding in the field and the development of ‘centers of excellence’ in 
nanomedicine across the US. The NNI defines nanotechnology and nanomedicine as follows: 
Nanotechnology is the understanding and control of matter at dimensions between 
approximately 1 and 100 nanometers, where unique phenomena enable novel 
applications. Encompassing nanoscale science, engineering, and technology, 
nanotechnology involves imaging, measuring, modelling, and manipulating matter at 
this length scale. Nanomedicine is the application of nanotechnology to medicine 
(National Science and Technology Council 2014). 
 In contrast, the European Science Foundation (ESF) defines nanomedicine as “the 
science and technology of diagnosing, treating, and preventing disease and traumatic injury, 
of relieving pain, and of preserving and improving human health, using molecular tools and 
molecular knowledge of the human body” and further highlights five key disciplines of 
nanomedicine: analytical tools; nanoimaging; nanomaterials and nanodevices; novel 
therapeutics and drug delivery systems; and clinical, regulatory, and toxicological issues 
(European Science Foundation 2004). 
 Finally, the European Technology Platform on Nanomedicines (ETPN) defines 
nanomedicine as “the application of nanotechnology to health. It exploits the improved and 
often novel physical, chemical, and biological properties of materials at the nanometric scale. 
Nanomedicine has potential impact on the prevention, early and reliable diagnosis and 
treatment of diseases” (European Technology Platform on Nanomedicine – Nanotechnology 
for Health 2005). 
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The examples above demonstrate the diversity in nanotechnology and nanomedicine 
definitions. The European Science Foundation’s definition focuses on broad aspects and 
components of nanomedicine, but does not elaborate on nanotechnology per se. However, the 
National Nanotechnology Initiative emphasizes the defining character of nanotechnology and 
refers to nanomedicine as the application of nanotechnology in medicine. This definition is 
the only one among the three mentioned above that defines nanoscale in terms of size 
dimension, i.e. from 1-100 nanometers. The definition of nanoscale is the starting point of the 
differences in size-based definitions of nano, nanomaterials and nanomedicine as we describe 
further in our results.  
Drug regulatory authorities’ definition 
Drug regulatory authorities are closely involved with the development, research and licensing 
of diagnostic and therapeutic products that harness nanotechnology. We also examined the 
definitions provided by key drug regulatory authorities representing the geographic 
distribution of our respondents. The US Food and Drug Administration’s (FDA) recently 
finalized ‘guidance for industry regarding FDA regulated products involving applications of 
nanotechnology’ highlighted two points to consider while regulating a product based on 
nanotechnology. 
1. Whether a material or end product is engineered to have at least one external 
dimension, or an internal or surface structure, in the nanoscale range (approximately 
1nm to 100nm); and  
2. Whether a material or end product is engineered to exhibit properties or phenomena, 
including physical or chemical properties or biological effects that are attributable to 
its dimension(s), even if these dimensions fall outside the nanoscale range, up to one 
micrometer (1,000nm).  
It must be noted that these guidelines also state that the recommendations are non-binding 
(US Food and Drug Administration 2014). 
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 The European Medicines Agency (EMA) (2006) defines nanomedicine as “the 
application of nanotechnology in view of making a medical diagnosis or treating or 
preventing diseases. It exploits the improved and often novel physical, chemical and 
biological properties of materials at nanometer scale”. In the same document, the EMA 
describes nanometer scale as ranging from atomic levels of 0.2nm-100nm.  
In its application form for investigational medicinal products (IMPs), Swissmedic, the 
authority regulating medical products in Switzerland, requires investigators to elaborate and 
specify whether the IMP contains nanoparticles with at least one dimension in the nanoscale 
(1-1000nm) and whether the IMP has a function and/or mode of action based on 
nanotechnology characteristics either in the active substance or adjuvant. Swissmedic’s focus 
is clearly on size as well as function or mode of action, thus making it more specific than 
other definitions. 
Stakeholder definitions 
Our respondents were encouraged to define nanomedicine in terms of properties that they 
believed were essential. They were all aware of the various definitions provided by multiple 
scientific bodies and authorities and many of the respondents were closely involved in the 
debates surrounding nano-nomenclature in general and defining nanomedicine, in particular. 
Below we present definitions provided by our stakeholders under various themes. 
Based on size 
Material with at least one dimension in the nano scale has been the key property of 
nanotechnology and this is reflected in the definitions of nanomedicine. But there is an 
ongoing debate about defining the scale that should be limited as the nanoscale. Below are 
some of the responses from our respondents highlighting this tension. 
Everything that is in the range of one to 100nm is nanotechnology and when you apply 
it in medicine it is called nanomedicine. A lot of people don't differentiate anymore 
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between molecular medicine and nanomedicine. We have [had] molecular medicine 
for a long time. R6   
There are many definitions. One says up to 100nm, they don’t give you a lower limit. 
Other says up to 1000nm. The definition, which is applied in politics in Germany, no I 
am sorry in the EU, is between one and 100nm. R14 
However, there were also voices that were critical of a size-based definition as described 
below. 
There is no really good definition to be honest and there are several ones. I tend to 
define nanomedicine as something larger than antibodies, but that is my personal one. 
Indeed, anything defined only by size is flawed. If you define it [nanomedicine] as up 
to 1000nm, what happens to a product that is 1001nm? Drugs don’t fit nicely in a size 
dimension. This is not a step function, rather a linear function. Any attempts to spend 
more time on definition of nanomedicine to be honest are futile. R10 
Based on the properties of the material 
Most definitions provided by our respondents centered on the fundamental properties of the 
material under investigation. They attributed various properties that should be considered 
while defining nanomedicines as can be seen below.  
Physical chemical properties  
Nanomedicine is the use of nanoparticles to elicit a therapeutic response that would 
not be efficacious in the absence of nanoparticles. Nanomedicine is something that is 
beneficial because of inherent nature of nanoparticle and not just because they are very 
small. It is the inherent nature of nanoparticle that enhances or enables a high 
therapeutic efficacy, which we will not have otherwise. R11 
However, a few respondents also questioned the importance given to the properties of 
nanomaterials and their uniqueness, arguing that there are no longer any unpredictable 
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properties owing to the advances in tools and characterization techniques. They argued that it 
is fully possible to predict the behavior of nanoparticles in biological systems. 
It [nanomaterials definition] is just the size definition merely and there are no 
unpredictable properties. They are all predictable. They were not predictable may be 
10 years ago but they are now. R10 
Organic/inorganic  
Our respondents repeatedly discussed the chemical composition of nanoparticles used in 
medical applications mainly in terms of an organic or inorganic nature. This formed the 
foundation for discussion on nano-toxicity and the risks associated with the accumulation of 
nanoparticles in human body.  
I think, first we have to separate between organic and inorganic nanoparticles. Why? 
Organic nanoparticles are all these liposomes and micelles. They are well known, well 
used. And there is the nano in size only. They are generally below 100nm if you go by 
EU definition. But if you go to inorganic nanoparticles, we change their physical, 
chemical, magnetic, electric and optical properties. And from a scientific point of 
view, if you get a size where you change these properties, only then you can speak 
about nanoparticles. For example, in iron oxide particles, this happens below 20nm, 
above this size, they have same property as bulk iron oxide. And this size at which 
material shows changed properties is different for different materials. R15  
Ability to be metabolized 
When we talk about nanoparticles, we need to remember there are different classes of 
nanoparticles. Iron oxide nanoparticles have a solid core meaning they are really solid, 
but when you speak about albumin, it is a bit different. It is a polymer; it is a 
biopolymer that you already have in your body. The truth is, we need to define [the] 
classes where we put our nanoparticles and also consider whether they can be 
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metabolized by the body or not. If it takes a long time to metabolize, you need to know 
how long it will take, where in body will these particles be stored? R19 
A large number of respondents made a clear distinction between organic and inorganic 
nanomaterials and more concerns were raised about inorganic nanoparticles that the human 
body is not exposed to in its physiological function due to their interaction with biological 
systems and metabolism. Respondents were troubled by the prospect of using carbon 
nanotubes as a drug-delivery method due to their similarity to the micro-needle structure of 
asbestos and their potential to cause cancer.  
I saw so many talks on carbon nanotubes being used for drug delivery. And the 
starting point of that, they are toxic. So you are wasting your time unless you are just 
doing basic research to see what kind of toxicity you are going to see. And then to use 
those to transport drugs across blood brain barrier it’s even more ridiculous. And then 
the EU putting in a billion dollars for carbon nanotube research for medicine is beyond 
ridiculous!  So I don’t know what is going on, anymore. It’s crazy! R31 
Another respondent could see very limited potential for carbon nanotubes as a method for 
drug delivery, but anticipated significant regulatory hurdles as described below. 
I would never use carbon nanotubes as [a] drug-delivery method because it is not 
biodegradable, the body does not know that structure. What will happen? These 
materials themselves... it would not be approved by the EMA or by the FDA. Very 
simple! Maybe if you could demonstrate that with a nanotube a specific cancer can be 
cured, you have a big step in favor, superior for instance to liposomes. Maybe in 
cancer, because in cancer there is a lot allowed. It is maybe better to survive for some 
years and have a toxic substance in your body than die too early. So you could see an 
application for such systems, but still I would think you would have a lot of trouble at 
the regulatory level R24. 
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Some respondents countered that not all inorganic nanoparticles are dangerous as the human 
body is used to handling and metabolizing these particles. This was particularly discussed in 
regard to iron complexes, which have been used to treat anemia successfully.  
Pharmacodynamic properties  
Pharmaceutical scientists emphasized the interaction of nanosize particles with 
pharmacokinetics and pharmacodynamics. Their definition of nanomedicines centered on the 
pharmaceutical goal to achieve a higher concentration of active drug at a desired site by 
improving absorption or prolonging half-life. This approach could lead to a reduction in a 
required dose, and thus associated side effects as well as a reduction in the cost of treating a 
disease.  
I consider nanoparticles as a vehicle for drug delivery. When you incorporate your 
drug in a nanostructure, it changes its solubility, physical and chemical stability, and 
its interaction with the biological systems due to presence of nanostructure or a 
nanocarrier. For me that is changing [the] properties of a drug. Usually, per definition 
nano means below 100nm because below this size you have different properties of 
material. But, from the pharmaceutical perspective, reducing the size of a drug from 
micrometers to 400 or 500nm makes a significant change in the performance of a 
drug. Why? Because this drug due to its reduced size will dissolve faster, more drug 
will get absorbed in the intestine. So just by reducing the size of particles and 
increasing the surface area, you will have higher absorption of the drug. If that 
happens at 400nm, who cares? If you are increasing the bioavailability of a drug by 
reducing the size to 400nm, it is still nano. It is important for the scientist to think- 
what does nano contribute to performance of your drug? R41 
Ability to be engineered and complex multimodular assembly  
Some of our respondents specifically focused on the engineered aspects of a product or the 
manipulation of the material as essential to be qualified as a nanoproduct.  
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While defining nanomedicine, one thing is size, you are speaking about 1-1000 nm. I 
would say if you have a macromolecule, or a molecular assembly where you can put 
different targets, different carrier molecules and you can incorporate different active 
compounds inside this structure, you can make an active compound reach the target 
better, or you can improve the solubility of a compound which was previously 
insoluble. For me, nanomedicine has this complex multi-modular assembly. R25 
Nanomedicine needs to be defined on case-by-case basis. If you take monoclonal 
antibodies, they are certainly in that size range, but I won't call then nanomedicine. 
For me, nanotechnology also has engineered component to it. R39 
Sub-classes of nanoparticles  
Some respondents stated that they were not concerned about the definition of nanomedicine, 
but instead claimed that it is important to refine the sub-classification of these nanoparticles. 
They argued that as the field of nanomedicine and nanocharacterization evolves, it has to 
reflect on the classification of various nanoparticles rather than making blanket statements 
about the biodegradability and composition of nano materials. These respondents argued for 
the need to assess each new product with nanotechnology on a case-by-case basis till we have 
sufficient knowledge and experience with different classes of particles and over a long period 
of time.  
Definition per se, I don't have any problem, but I think it is time to start generating 
sub-categories, the binning process [classifying, putting it in different bins or 
categories] I mentioned to you before. Definition of a molecule is equally broad, but 
we talk about small molecules, polymers, micro molecules, peptides, so on and so 
forth. R13  
Based on size and properties 
A few respondents highlighted the importance of considering both size and properties when 
assessing nanoparticles, since these two functions are often interdependent.  
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There might be an aspect of size in definition of nanomedicine somewhere during 
manufacturing process or in the end product. So size is important, but it is not 
exclusive. I think what is much more important is to characterize such drugs or 
particles and their behavior in biological systems because these products behave very 
differently than classic molecularly dispersed products in terms of pharmacokinetics, 
half-life and eventual elimination from the body. R32 
Other respondents stressed the need of mimicking naturally occurring molecules in the body, 
which are at the nanoscale, with the goal of enhancing drug delivery methods.  
The way that you really learn about how to deliver a drug in the body is not by 
collaborating with anybody who is using gold nanoparticles or polymers or dendrimers 
or any of this other stuff, it is to see what nature does. So the way nature delivers some 
of its hydrophobic materials like cholesterol, which actually forms a crystal, is to turn 
it into more amorphous material called cholesteryl ester or cholesteryl oleate and form 
nanoparticles which are called low density lipoprotein (LDL) molecules. They are 25 
nm and if you want to deliver something to cancers, cancers don’t eat gold. They don’t 
eat plastics, calcium, and phosphate. What they eat is LDL particles. R7 
Based on discipline 
Nanotechnology and nanomedicine are highly interdisciplinary fields and this is clearly 
reflected in the definitions of nanomedicine.  
Interdisciplinarity of the field 
Yes, the definitions of nanomedicine are diverse and that is probably due to the fact 
that the field in itself is highly interdisciplinary. We have chemistry, physics, and 
material sciences and then we have applications in biology, microbiology, 
biochemistry, medicine and pharmaceutical sciences. So, everybody of course has his 
or her own disciplinary background even though they work in nanomedicine and they 
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work with different definitions as far as understanding of the field is concerned. That 
is only natural. R35 
In the context of this interdisciplinarity, a few respondents argued for defining the parent 
technology rather than the medical application.  
I am not sure if nanomedicine exists as a separate thing. I believe there is 
nanotechnology that is used in nanomedicine. But nanomedicine should not be a 
discrete branch of therapeutic endeavor. So, the important thing is to try and define the 
technology rather than trying to partition a separate area in medicine because then 
technology can offer a huge range of different applications in different clinical 
circumstances. R36  
A few respondents were critical of the focus on changed physical and/or chemical properties 
of matter at the nanoscale even though they understood its origin in the respective disciplines. 
They argued that biological properties are essential and more important than particle size to 
fully assess the breadth and scope of the field of nanomedicine.  
For me biology has to be considered as well, especially the behavior and change of 
properties of these materials in interaction with biological systems. And I am fighting 
for increasing the upper limit from 100 to a few hundred nm; perhaps we could go up 
to 500nm because in biological systems, even particles larger than 100nm demonstrate 
the behavior of nano. Only if you double that, you go to one micron or 1000nm, they 
change. They don’t penetrate the cell membrane like many nanoparticles do. So as far 
as the interaction of nano with biological system is concerned, the limit is higher, it is 
higher than 100nm. R14 
Many of our respondents were vocal about the semantics of nanomedicine and how the 
terminology has evolved over last few decades.  
Liposomes have been around since 1960s, but in last 20 years, they have been 
rebranded as nanomedicines or liposomal nanoparticles. I would say that for me it 
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should be below 150nm. What I do with real (emphasis added) nanotechnology is 
develop the materials whose properties are different because of nanoscale, for 
example, quantum dots. That is really nanotechnology in the sense that something 
happens to these materials because of their size. But, these things are much smaller; 
they are below 10nm. But, if you are in pharmacology, you can say that these 
nanoparticles follow the pharmacokinetics of a therapeutic compound and that is what 
I want to achieve. But, if you look at them from the perspective of physical chemistry, 
which I am also involved in, it becomes only interesting and truly nano at a scale 
about 10nm where the materials actually change their properties. So, it all depends on 
your perspective. R28 
The view expressed above also shows the tension between the disciplines. The ‘real’ 
nanotechnology as perceived by professionals working in the field of physical chemistry as 
compared to the ‘applied’ nature in pharmaceutical sciences, which tends to be more open and 
inclusive of larger molecules up to a micron level, as long as these larger molecules can help 
achieve a desired therapeutic or pharmacodynamic effect. 
Nano is an academic phenomenon 
Respondents affiliated with large pharmaceutical companies often discussed the ‘buzz’ of 
nanomedicine as an academic phenomenon and pointed out that the label ‘nano’ has less 
importance in terms of drug development. 
Another problem is that this definition of nanomedicine is not really accepted by 
pharmaceutical industry. [The] “nano label” is dropped in industry when they begin 
drug development. Drugs are not developed as nano drugs; they are developed as 
drugs. R11 
There is a typical pharmaceutical approach to this definition. They consider all that is 
below micron that is below 1000nm as nano. So in that sense, their definition is not 
even compatible with the EU definition. R15  
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The definition of nano as one to 100nm comes from National Nanotechnology 
Initiative. But it has no relevance to drugs or pharmaceutical products because drug 
companies don't care about size. They are more interested in creating safe, effective 
and superior drug formulations. So I think it is more accurate to use definition as one 
to 1000nm or below micron as far as drug development is concerned. R31 
Based on audience 
One of our respondents described how the audience he is talking to determines which 
definition he would use.  
From scientific (material science) point of view, we refer to nano if we have real 
change in properties and I use this definition when addressing scientific audience 
because they understand exactly what I am talking about. But, when I talk to the 
general public or medical doctors, I use the EU definition which states that half of the 
particles must be below 100nm because our more scientific definition is too 
complicated for them since we have a different value for each material at which the 
properties change. For iron oxide it is 20nm whereas for titanium di oxide it is about 
10nm. To go further, while talking to pharmaceutical science people, I have to talk 
about definition, which is below a micron even though that definition is not 
compatible with EU definition. And then again, there is this political discussion about 
REACH [Registration, Evaluation, Authorization and Restriction of Chemicals] 
regulation. If you claim that the material you are working with is nano and has new 
properties, you are in danger that you have to show that this new material is safe and 
have to go through whole accreditation process under REACH.  R15  
Based on pathology and route of administration 
An alternative definition of nanomedicines takes into account the pathology under 
consideration.  
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The size definition is really arbitrary; nano aspect relates to the opportunities that the 
nature offers. If you think about an enhanced permeability and retention (EPR) effect, 
it won't work with your molecule, which is below 1000nm. You will need molecules 
that are in rage of 100 to 150nm or 50nm or even smaller. So I had rather use a more 
dynamic definition of nano related to what nature is enabling nano to do. If you have 
to treat a bacterial infection which is primarily located in macrophages in liver, then 
may be a formulation at 500nm is more appropriate in this situation because these 
particles containing drugs will get sequestered in the liver and you can also include 
higher amount of drug in these particles thus providing more effective treatment. R24 
Another participant demonstrated how the route of drug administration would influence the 
definition.  
The particle size of below 100nm is crucial to achieve desired biological or therapeutic 
properties only when we inject the formulation systemically. But if you have an 
application where you can actually acquire particles locally, size is not as important as 
it is in case of intravenous application. In such a case, having larger particles is an 
advantage for they can accommodate more active drug ingredients. So for this specific 
application, I would say nanomedicine is to produce particles below 500nm. R16  
Discussion 
Nanomedicine is an interdisciplinary field and clinical translation involves multiple 
stakeholders. A crucial finding of our study is the extent to which stakeholders have described 
the tension between disciplines, target audiences and regulatory bodies when discussing the 
definition of nanotechnology and nanomedicine. This also highlights how difficult and 
challenging communication can be among stakeholders, especially if each has their own 
definition or understanding of nanotechnology or nanomedicine. We argue that clarity in the 
definition of nanomedicine and the consistent use of a single definition is critical to facilitate 
translational research in nanomedicine in ethical and transparent ways and to ensure a fair 
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distribution and utilization of available resources. As the field of nanomedicine acquires more 
knowledge and experience with different classes of nanoparticles, it is also critical that we 
start focusing on different classes of nanomedicines while discussing toxicity or drug 
regulation pathways, rather than assessing the whole range of nanomedicinal products with 
the same tests and against same standards. In this section, we discuss how various 
stakeholders have influenced the definition of nanomedicine, as well as the impact of multiple 
definitions on key stakeholders involved in the clinical translation in nanomedicine.  
National and international scientific bodies and funding agencies 
The establishment of the NNI in the US has clearly fueled research in nanotechnology and it’s 
the medical applications. The NNI also created ‘Centers of Excellence’ in nanotechnology 
across the US and generated significant funding for research in nanotechnology (Roco 2011). 
Unlike biotechnology, which has mainly been supported by start-ups and private companies, 
nanotechnology has received significant public funding (Paull et al. 2003) as well as fostered 
a lager industry-academia collaboration (McComas 2012). Similar trends have been seen in 
Europe with funding from the European Science Foundation and the European Research 
Council as well as governmental funding schemes in Japan and South Korea (Roco 2005). As 
funding in the field has improved drastically, so has the number of grant applications. 
Scholars have also pointed out inadequacies in the current model of peer review based grant 
assessment and questioned whether commercialization of research is the best way to 
optimally utilize public funding in science and technology especially when some 
commercially non attractive yet needed research might never get supported by the industry 
(Spier and Bird 2003).   
Many scientists working in various scientific disciplines have realized that the work 
that they have been doing for decades now could fall under the purview of nanotechnology 
based on nanoscale or if attributed to novel physical, chemical, or quantum properties of 
material (Drexler 2004). The work that was not originally labeled as nanotechnology or 
 
 
54 
 
nanomedicine has begun to be re-framed along these lines with the increased availability of 
funding. Increased funding in the field, coupled with increased media attention and broad 
definitions of nanotechnology and nanomedicine can create significant challenges for funding 
agencies to draw a cut-off point based on a definition alone when assessing these grant 
applications.   
As shown in our results, many experts working in nanotechnology and nanomedicine 
have argued that a mere focus on size of particles is detrimental to a common definition 
because the change of properties in relation to size of the particle is a continuum rather than 
distinct size cut-off. They also claimed that in terms of an intervention sometimes size 
matters, sometimes changed properties are important and sometimes both size and change in 
properties are crucial to achieve a desired action. Clarity and consistency on a definition and 
special attention to size-based characteristics and changed material properties are crucial for 
funding agencies to distribute available funds across applications with the potential to 
improve healthcare and ensure transparency in the evaluation of submitted grant applications. 
Patent authorities 
Increased global funding for nanomedicine also has the underlying aim of improving and 
facilitating successful commercialization of technology to facilitate good returns on 
investments through public funding (Roco et al. 2011) This heightened focus on the 
innovation and commercialization of nanotechnology is also reflected in the increase in the 
number of broad patent applications related to investigational medical products, some aspects 
of the technology or the process of producing the product. Inconsistent definitions of 
nanotechnology and nanomedicine create confusion in the assessment and qualification of 
patent claims as well as drastically increased pending patent applications (Bawa 2007). Patent 
protection is particularly important for SMEs as it improves their chances of obtaining 
funding as well as enhancing the value of their product in the competitive world of drug 
discovery (Bawa et al. 2005). Patent related issues will become increasingly important as the 
 
 
55 
 
field anticipates the expiration of nanomedicine patents licensed in the 1990s and the future 
development of nanosimilars (Bremer-Hoffmann et al. 2015; Tinkle et al. 2014).  
Regulatory authorities 
Nanomedicines and their definition have significant implications for international drug 
regulatory authorities as well as industrial regulatory and environmental protection agencies. 
For drug regulatory authorities, it is crucial to account for the complexity of some of the 
investigational products based on nanotechnology. The drug-device distinction is not always 
clear, and with the advent of regenerative medicine, one could expect to see complex 
biological entities with cell-based components on a nano surface or nano scaffolds and other 
active molecular or chemical entities (Niemansburg et al. 2013). The characterization of 
nanoparticles has significantly improved over the last two decades, but the long-term toxicity 
of some nanomaterials still needs to be carefully assessed and will require stronger post-
marketing surveillance. As described in the results section, various definitions of 
nanomedicine influence whether a molecule is approved in specific countries, depending on 
local drug regulatory authorities. Some authorities might be seen as less rigid and more 
inclusive in terms of the definition of nanomedicine as compared to the others. This could 
have an impact on the geographic location where trials will be conducted and new drugs will 
get licensed. Drug development and clinical research is an international enterprise and 
uniformity in a definition of nanomedicine across key drug regulatory authorities will 
facilitate translation of nanotechnology into clinical applications. The regulatory authorities 
need to carefully assess and monitor the use of nanoparticles in food additives, food 
packaging, and cosmetics as they fall into distinct categories of regulatory pathways and are 
often less strict than for the drug approval process.  
Pharmaceutical industry and SMEs 
As described in our results section, it appears that the label ‘nano’ is not significant for large 
pharmaceutical companies. However, it is crucial for SMEs that often work towards 
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producing ‘proof of concept’ in man (Eaton et al. 2015). SMEs depend on external funding to 
conduct early clinical translation studies, particularly for FIH trials. This funding comes from 
international grants or venture capitalists. Only on a successful ‘proof of concept’ in man can 
an SME out-license their product to the pharmaceutical industry or take the product further 
into phase I-II trials. The latter requires a large financial investment that SMEs can rarely 
manage to attract (Eaton 2012). Clarity and consistency in the definition of nanomedicine can 
improve the assessment for funding and allow SMEs to contribute to translational research.   
Ethics committees 
Clarity and uniformity in the definition of nanomedicine and the consistent use of nano 
terminology are critical for the ethical review of submitted clinical trial protocols. The role of 
EC is to ensure human subject safety while evaluating trial protocols involving patients or 
healthy volunteers. The EC needs to undertake a detailed risk assessment to balance the risks 
against the potential benefits before approving a clinical trial (Anderson and Kimmelman 
2014). The EC also needs to carefully assess the informed consent forms and ensure that the 
risks and benefits of trial participation are clearly and accurately described in a language that 
is easy to understand (King 2012). If investigators do not describe the nanomedicinal product 
under investigation in all the necessary detail, it is likely to adversely affect the ethical review. 
Whether nanoparticles should be explicitly mentioned in the trial protocol, investigators 
brochure and informed consent form is a matter of debate and is beyond the scope of this 
paper. However, to ensure transparency and integrity in research, it can be argued that full 
disclosure of the nature of the molecule under investigation is needed for a rigorous ethical 
review (Dresser 2012) and to obtain a valid informed consent. Clarity and uniformity of the 
definition of nanomedicine would be important to facilitate transparency in clinical trials as 
well as in the ethical review of this research. 
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Patient population 
Most nanomedicine has been developed for cancers where there is an unmet need for 
treatment. However, other chronic diseases are slowly being targeted by nanotechnology 
based improved therapeutics. In clinical translation and particularly in FIH trials, new 
interventions are often tested on patients who have no other treatment option (Hug and 
Hermerén 2011). Patients approached to participate in clinical research need to be provided 
with all the necessary information regarding the technology and the characteristics of the 
proposed treatment to make a truly informed choice. Many patients trust their physicians and 
hope to receive all the relevant information about the product under investigation from them 
(Anderson and Kimmelman 2014). But some may actually undertake internet research on 
their own. For patients to provide a meaningful informed consent, it is critical that they have 
all necessary information about the product they will be given and clarity on the 
nanotechnology-based formulation should be part of this information. 
General public 
Public acceptance of a technological intervention is essential for its implementation, 
improvement and access. The debate on genetically modified organisms in Europe, where the 
public was not clearly or adequately informed, showed the importance of honest and open 
communication. Literature on public engagement in nanotechnology has pointed out the need 
for such engagement (Cormick 2012; Cormick and Hunter 2014; Krabbenborg and Mulder 
2015; Cacciatore 2014) and has also raised critical questions such as; what is the public? How 
does one engage those who are unengaged and what tools could be used to improve public 
engagement (Cormick 2009). Educating the public with the scientific evidence related to 
nanotechnology, and being transparent about the possible advantages and potential harms of a 
new technology is important (Priest 2009). Public opinion shapes the political and regulatory 
environment and influences the level of funding available for particular technology. Some of 
our respondents argued that nanotechnology is too complicated for the general public to 
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understand and that attempts to inform the public about the potential risks and benefits is 
likely to negatively polarize their opinion. However, this line of thinking is dangerous. Even if 
some patients and citizens do not understand the complexity of nanotechnology, assuming 
that no one needs to be informed compromises the public’s right to information. With access 
to information and research databases, the public can obtain more information about a product 
or technology and might even feel deceived if certain information was underplayed by the 
scientists and experts. This action would erode public trust in science and prove detrimental to 
research and development (Master and Resnik 2013; Resnik 2011). It is important to find 
innovative ways to explain the complexity of nanomaterials and nanoparticles, and their 
potential use and risks to the public in scientifically accurate yet understandable ways. This 
could be achieved through various means such as school education and introducing children 
to basic concepts of nanotechnology, participatory interactions between the scientific experts 
and general public and by ensuring a balanced and scientifically accurate coverage of 
nanotechnology-related debate in media.   
Limitations 
To the best of our knowledge, no other empirical studies have looked at diversity in the 
definition of nanomedicine. Our purposive sampling technique allowed us to access a wide 
spectrum of viewpoints and strengthened our findings. However, there were 12 stakeholders 
who did not reply to our emails, phone calls, and letters. Whether the views of those 12 are 
drastically different from those of the 46 who were interviewed is unclear. The stakeholders 
we interviewed explained the refusal of the others in terms of extremely busy schedules and a 
preoccupation with higher priority tasks than contributing to this research project.  
The aim of our exploratory qualitative research was to document the diversity in 
definitions of nanotechnology and nanomedicine and to examine how this affects translational 
research. Our research only focusses on stakeholders in Europe and North America and we 
are clearly missing the voices from China, Japan, Australia, India and other Asian countries 
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where research in nanotechnology and nanomedicine is ongoing. We do not claim that our 
findings can be generalized to all stakeholders of translational nanomedicine across the world. 
Further research with homogeneous populations such as SMEs, large pharma, scientists and 
academics using quantitative research methods is warranted.  
The fact that one interviewer conducted all the interviews might raise a concern of 
systematic bias in the collected data; however we also believe that the consistency and 
standardization of the interview technique was an advantage. Open-ended interview questions 
allowed respondents to elaborate on their viewpoints and these expert stakeholders were 
unlikely to be influenced by the viewpoint of the interviewer. The difference in opinion of the 
interviewer and the interviewee in fact led to interesting debates that further teased out the 
nuances of the topic. Analysis of the interviews by generating codes and building themes was 
carried out by the research team to further minimize systematic bias that could have arisen if 
the data had been analyzed by only one researcher.  
Conclusion 
Nanomedicine is more than the application of nanotechnology in medicine and health care. It 
is a key enabling technology drawing on expertise and techniques from many scientific 
disciplines. It has attracted significant attention from funding agencies, policy makers and the 
general public, and has also been criticized as a buzzword or hype. For successful translation 
of basic science research in nanotechnology into clinical applications, transparency at each 
stage of technological development and trust among various stakeholders and general public 
are critical. This is where a clear, scientifically comprehensive and consistent definition of 
nanomedicine and further sub classification of nanoparticles used in medicines has a role to 
play. This definition and sub-classification will facilitate progress along the translational 
pathway without being too restrictive and improve communication across the stakeholders. 
This is not an easy balance. Convenient usage of one definition over others or dropping of 
word ‘nano’ when deemed unfavorable will prove dangerous in the long run as it will 
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adversely affect the public’s trust and transparency in scientific research. An open and honest 
dialogue across the stakeholders, the general public and politicians is essential if we truly 
want to exploit the potential of this key enabling technology to improve human health and 
well-being.  
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Abstract: 
Clinical translation of breakthroughs in nanotechnology and nanomedicine is expected to 
significantly improve diagnostic tools and therapeutic modalities for various diseases. This 
will not only improve human health and well-being, but is also likely to reduce health care 
costs in the long run. However, clinical translation is a long, arduous, resource intensive 
process that requires priority setting, resource mobilization, successful national and 
international collaboration, and effective coordination between key stakeholders. The aim of 
this paper is to describe various challenges faced by the stakeholders involved in translational 
nanomedicine while planning and conducting first-in-human (FIH) clinical trials. We draw on 
insights obtained from 46 in-depth qualitative interviews with key stakeholders from Europe 
and North America. 
 
Key words:  
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Background  
Translation of basic science research into clinical applications is known as translational 
research, and is crucial to improve human health and well-being.1 Translational research 
facilitates the availability of improved diagnostic tests and treatment options, enabling early 
diagnosis, better treatment, and a consequent decrease in disease related morbidity and 
mortality. However, less than 10% of basic science research gets translated into clinical 
applications with a large proportion of promising experimental therapies not crossing the 
“valley of death”.2 This makes translational research a long, ineffective, and expensive 
enterprise which significantly increases health care costs.3 In 2004, the US Food and Drug 
Administration (FDA) launched the Critical Path Initiative with the aim to improve the 
availability of new diagnostic and therapeutic modalities by systematically addressing some 
of the key obstacles in existing translational research processes.4  
First-in-human (FIH) trials mark a critical juncture in translational research because it 
is at this point that experimental products get tested in human beings for the very first time. 
Though translational research in general involves significant levels of uncertainty, it peaks 
during FIH trials.5 FIH trials get further complicated when the products under evaluation 
involve cutting edge medical technologies such as nanomedicine, synthetic biology, gene 
therapy, or cell therapy due to a lack of clarity on the mechanism of action and the exact 
target of the experimental product, and limited reliability and validity of preclinical animal 
models.6   
The aim of this paper is to describe and discuss the challenges faced by stakeholders 
involved in translational research in nanotechnology. We chose medical applications of 
nanotechnology as a prototype and decided to focus on FIH trials. Nanotechnology has the 
potential to develop highly accurate and sensitive diagnostic tests,7 targeted therapies,8 and 
theranostic applications. 9 At the same time, there is a national and international focus on 
funding and research in nanomedicine with the hope that it will revolutionize our 
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understanding of diseases and advance our means to treat them.10 Thus, researchers working 
in translational nanomedicine have to deal with high levels of uncertainty, the novelty of the 
technology, limited prior experience with nanoformulations and toxicity assessment, 
challenges in applying for and obtaining regulatory and ethics approval, increased media hype 
and heightened requests for scrutiny, while keeping in mind the unmet and pressing needs of 
patients living with chronic and terminal illnesses. A number of researchers and experts have 
reflected on challenges of translational research in nanomedicine 11-23 but our goal is to 
document these challenges by exploring the experiences and perspectives of key stakeholders 
who have either conducted a FIH trial or are planning one, and to propose possible solutions.   
 
Methods 
Qualitative research methods are employed to investigate topics where previous empirical 
research has been scarce.24 We used semi-structured, in-depth interviews for this exploratory 
research project. We drew up a list of open ended questions to facilitate conversations with 
expert stakeholders involved in translational nanomedicine. This enabled respondents to 
freely narrate their experience and bring up topics, themes, and challenges that they deemed 
relevant. Three pilot interviews (with colleagues experienced in qualitative research and 
ethics of new technology) were carried out at the beginning of the project to validate and 
refine the interview guide, but were excluded from analysis. The research project, including 
the interview guide (attached in an annex), was approved by the ethics commission of Basel 
Land and Basel Stadt (EKBB) in January 2013.  
We identified key stakeholders in translational nanomedicine through literature search 
and PS’s participation in nanomedicine conferences such as CLINAM Basel, Swiss 
Nanoscience Convention and a meeting of the European Technology Platform (ETP) - 
Nanomedicine. These European conferences attract key stakeholders and researchers in 
nanomedicine from around the globe and reflect collaborative efforts made by the EU, the US 
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and other countries to accelerate translational research in nanomedicine.  Rather than focusing 
on a homogeneous study population, we used purposive sampling to obtain maximum 
variation in views and experiences of respondents.25 We contacted them either via email or in 
person during conferences and explained the aim of the research project, the process to be 
followed, and ways in which their confidentiality and anonymity would be ensured. We 
realized that building a relationship of trust with the respondents was crucial given that many 
of them were working on cutting edge research, were concerned about information they 
would share with us, and most importantly wanted to know how the data from the interviews 
would be used.  
PS carried out 46 stakeholder interviews in English between October 2013 and 
November 2014. She obtained oral informed consent from each respondent before starting the 
interview. Whenever possible, she conducted interviews in person as this helped create a 
better rapport with respondents. She carried out 26 interviews either via telephone or Skype 
call when it was not possible to arrange timely travel to the location of the respondents. In line 
with qualitative research methods, we stopped recruitment when theoretical saturation was 
reached. Theoretical saturation is a point in time when the research team believes that in spite 
of interviewing more respondents, no new themes emerge for research questions being 
investigated.26 All interviews were transcribed in full and we sent the transcript to each 
respondent to check the accuracy of technical details. Together with DS, PS analyzed all 
interviews by creating systematic codes and sub-codes, building them further into themes that 
were related to particular research question. Codes and themes were discussed within the 
larger research and author team to improve the rigor of the qualitative data analysis. Our goal 
is to discuss the range of views and experiences rather than the frequency of similar views. So 
instead of quantifying the results, we describe them in general terms (e.g. “a few,” “some,” 
“many,” “all”). For elaborating specific challenges in translational research, we chose the 
most comprehensive and detailed quotation from the respondents instead of providing four to 
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five quotations from different respondents who expressed similar views or experiences. We 
have described the methodology of our research projects in greater details elsewhere.27 
 
Results  
Our respondents were located in Switzerland, Germany, The Netherlands, Denmark, Norway, 
Austria, Hungary, Spain, Portugal, the United Kingdom, Israel, the United States and Canada. 
Their professional roles/affiliations and geographic distributions are shown in Figure 1 and 
Figure 2. Respondents were trained in medicine, molecular biology, biochemistry, material 
science, physics, toxicology, organic chemistry, pharmaceutical science, law, and ethics and 
had at least seven years of work experience in their respective field. Out of 21 investigators 
(affiliated with universities, SMEs or large pharmaceutical industries), 11 had conducted a 
FIH nanomedicine trial while the remaining 10 were in various stages of preclinical research. 
Nine out of 21 investigators were working on nanotechnology based cancer drugs, seven on 
immune mediated diseases and five were targeting infectious diseases. While the majority of 
our respondents were working with various types of liposomes (immunoliposomes, pH 
sensitive liposomes, thermosensitive liposomes), others had experience with gold and silver 
nanoparticles, super paramagnetic iron oxide particles, polymeric micelles, and SiRNA. The 
diversity in disciplinary background, geographic locations, and professional roles enabled us 
to gather views and experiences across a broad range of topics related to translational 
nanomedicine.  To ensure anonymity of the respondents, we will use respondent numbers 
(e.g. R1, R2…) while describing results of this study. Nanomedicine is a small and close-knit 
community and detailed description of respondents in terms of their location or professional 
role can reveal their identity. Though this limits extent of our analysis, we believe that this is 
the most practical solution for our concerns regarding anonymity of respondents.  
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Figure1. Professional affiliations of respondents (N=46) 
 
Figure2. Geographic distribution of respondents (N=46) 
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Financial challenges 
Academic researchers and members of small and medium size enterprises (SMEs) 
experienced difficulty in securing the required finances. University researchers begin their 
basic science research with grants but developing it further into clinical trials requires 
additional funds. A researcher who conducted an FIH nanomedicine trial in a university 
hospital without an external sponsor told us that most of his team worked on this trial in their 
spare time. Scaling up good manufacturing practice (GMP) production at higher dose levels 
for this FIH trial required 9 to10 production cycles, each cycle requiring one complete week 
of work for five to six people. He stated that without any industry support, his team could not 
scale-up production and move further into phase II trials.  
Scaling up GMP production of highly specialized nanomedicine products also requires 
substantial financial resources as described by a representative of a contract manufacturing 
organization (CMO). 
.. the supply chain can be a challenge because we are working in a niche, and can’t get 
the raw materials from 10000 different suppliers. (…) we need to get all the 
documents needed for GMP production such as the Bovine Spongiform Encephalitis 
(BSE) certificate or certificate of origin for each raw material. (…) sometimes the 
client does not want to invest too much money at the beginning but wants from us the 
highest quality. And high quality needs full traceability right from the beginning. R27 
 
Another university researcher further elaborated why one needs money to conduct a trial in a 
public institution.  
You need money to compensate volunteers, for the time they invest or the night they 
need to spend in the hospital (….) and you need money for insurances, because you 
need to cover any possible side-effects that you could cause to the volunteers. So, even 
if all the people involved are not requesting any payment, you need money. R41 
 
Some university researchers secured more money by launching SMEs. SMEs play a crucial 
role in translational research but they continue to face funding challenges as well as pressure 
to complete trials quickly.  
74 
 
And for a small company like ours, time is maybe the most important thing because 
…we have to show that we progress. We have limited amount of money from 
investors which does not last that long and before we can get more money from them 
we have to show that we have done something. And then we can’t have two or three 
patients a year and then wait for five years to complete the study. That’s impossible. 
Time is maybe the most important issue -to be able to get patients in as quickly as 
possible. R34 
 
Several respondents mentioned that lower than expected patient recruitment prolonged trials 
and made them more expensive. Low recruitment was attributable to various reasons as 
described in the Table 1.  
Table1. Slow/low patient recruitment  
 
 
 
 
 
 
 
 
 
While a large majority of nanomedicine has been developed for cancers, some 
respondents were working on other diseases such as arthritis, atherosclerosis, and diabetes. 
Unlike cancer trials, the primary and secondary endpoints for these trials are different and 
often require sophisticated imaging techniques within protocols, making the trials more 
expensive.  
In cardiovascular diseases, to look at these trials, they usually include 10000 patients 
with general cardiovascular drugs but with nanomedicine it is not possible, it is too 
expensive. We want to look at vessel wall, (…) rather than looking at the morbidity or 
mortality. That is a real challenge. These are very technical procedures so in addition 
to getting approval for a trial, you also have to integrate these imaging end points. And 
that makes it even more complex and even more expensive. R28 
 
• (…) we agreed with the ethics committee to decrease the starting dose. But in the 
end that caused us a delay of a year because patients were hard to find. The dose level was 
so low that physicians were not keen on enrolling patients at low dose. R2 
 
• One of the challenges, (…) is tumor heterogeneity. (…) we are taking advantage of 
the overexpression of a specific protein; we have to stratify the patients who actually 
overexpress on their tumors, that specific protein. And (…) it requires pretty strict and 
specific inclusion criteria or your particle won’t work. R16 
 
• The main challenge was that we did not get any patients. (...) the problem is our 
technology can only be used in a subset of patients. And you have to have quite strict 
inclusion/exclusion criteria. (...) It’s logistically challenging (...). You have to have 
clinicians; a laser and everything which people are not used to using. This differs very 
much from hospital to hospital and the treatment such as ours involves different times and 
doctors. (...) So that’s the challenge maybe especially for us because we have a technology 
that has to involve different kinds of medical professions and they do not always work well 
together. R34 
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Interviewees mentioned that many national and international funding bodies continue to 
heavily invest in nanotechnology and nanomedicine through collaborative funding schemes 
and by establishing centers of excellence. Many respondents said they benefited from these 
opportunities but a few questioned the ‘rationale of priority setting’ at the policy level and the 
utility of spreading available money across many players in the field which they considered 
inefficient. 
 Researchers in large pharmaceutical industries also reported difficulties in attracting 
companies’ attention towards their nanomedicine projects.  
Companies are not investing. If they have their own product already in the market they 
will not invest because they don’t want to take risks. And new companies are very 
focused on their own products. The big pharma is buying products only if it is in 
advanced clinical status and very promising. R24 
 
Another respondent explained how the pharmaceutical industry’s traditional approaches to 
drug development do not encourage novel approaches in therapy and cure.  
In the past, the industry was prepared to produce chemicals; chemicals to kill some 
bacteria (…). Here in nanomedicine, we are confronted with something that is even 
more different. (…) We will need to rethink and produce. (…) Usually a 
pharmaceutical company would like to sell a product that is in a box and that has a 
very long shelf life. R29 
 
Instead, stakeholders perceive large pharmaceutical companies to be interested in buying truly 
promising products developed by SMEs only after they have a strong ‘proof of concept’ in 
man. Which products developed by SMEs will gain the interest of large pharmaceutical 
companies and investors depends on their potential market share, competitive edge over 
existing products, and unmet treatment needs as shown in Table 2.   
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Table 2. Market interest 
• I suppose the issues are rather market specific. … In some diseases, there are some really 
effective drugs under development, so it will be better to avoid those or your drug may not 
be competitive. Cost is very important. R10 
 
• (…) USP means there must be a clear advantage against today’s solutions. There are many 
possibilities why it is better. It could be cheaper, it could be quicker, it could be smaller, it 
could be more effective…depends! It must be in some way clearly better than what we 
have. R17 
 
• …(one) problem is a lack of diversity. We have people developing very similar concepts 
for cancer. (…) The question of portfolio management as well is very difficult given the 
fact that many people abide the academic freedom. (….) relatively small number of drugs 
go to the market each year. If thousand people are doing drugs for cancer using the EPR 
effect, 999 of them won’t be successful. Unless, they are having a really good idea, they 
should not be going in this area. R10 
 
• People focus on clinical studies but it is not the goal and the end goal. For example if there 
are already three products on market, which work perfectly OK and you bring on the 
fourth, that product is not going to make any sales. So you have to know how the market 
is and your product has to be significantly better in some parameters than the products 
which are out there and also the cost has to be significantly reasonable. If the cost of your 
drug is astronomically high, then it won’t sell. R48 
 
Finally, patent protection for products under investigation was mentioned as another 
crucial point that determines investors’ interest and researchers’ chances of success in 
procuring the necessary funding to take the product further into clinical translation, as shown 
in Table 3.  
Table 3. Patents and IPs 
• IP is quite weak on this. This is not patented (.…) because there are so many steps 
involved which are already patented, on liposomes, on antibodies, on construction. (…) 
there are more than 3000 conflicting patents so we were not able to have a strong patent 
and then you don’t find funding from industry or interest of the investors. R12 
 
• The technology is already very complicated because it involves also the heating 
equipment. So lot of companies will not be fond of that especially the pharma companies. 
And I believe that if it is not patented it will be really difficult to get the interest of pharma 
companies. R8 
 
• I mean patents last only for twenty years. And if you don’t have a patent then you use ten 
years of these years, probably even more to get a patent. Patents are often filed quite early 
in the preclinical studies and then you use some years for developing pre-clinically and 
then you use a lot of years for getting it approved clinically. And there are not that many 
years left. R34 
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Ethical challenges 
Risk/benefit evaluation serves as the foundation of ethical review. Most FIH trials in 
nanomedicine are conducted in patients who have exhausted all other treatment options. Due 
to the design of these trials, patients are unlikely to receive therapeutic benefits but the data 
gathered is valuable in terms of knowledge gained. In early clinical trials of cutting edge 
medical technology such as nanomedicine, assessing risks, benefits/harms, and knowledge 
gain poses significant challenges.  
The biggest single challenge is the problem of risk. Now in life and in all sectors of 
human activity, (…) we encounter risk that is in a sense calculable. And when you are 
working within a realm that is highly novel like gene therapy or novel stem cells 
approaches or nanomedicine, you are dealing with circumstances where it is very 
difficult to calculate the risk. And it is also unclear what the appropriate evidence to be 
used is, on which one can base their risk decisions. In addition it’s also difficult to 
calculate utility, to calculate value. And it’s hard to know which kind of evidence to 
draw on to calculate the value. So it’s a realm that is ripe with arbitrary decision-
making (…) And because there is no clear well-developed framework or structure for 
making the risk benefit decisions, one of the biggest challenges is trying to control or 
limit extent to which decision-making is utterly arbitrary. R42 
 
Our respondents were divided on role of ethics committees in translational nanomedicine. 
Some had smooth interactions with ethics committees while others perceived them to be risk 
averse and paternalistic, thus slowing down translational research. Some of our respondents 
believed that ethics committees do not intentionally block translational research but their role 
requires them to be “cautious” and to strictly follow available guidelines to ensure human 
subject safety. Others criticized the tendency of ethics committees towards what they 
considered to be “exaggerated caution”, especially when there were no treatment options for 
the suffering patient population; argued for meaningful patient involvement in the ethical 
evaluation of trials; and highlighted the need for a broad stakeholder discussion.  
Long term implications of new medical technologies are often poorly understood. This 
in turn, possibly creates a climate erring on the side of caution. (…) there is a 
perception that maybe the ethical choice is to do nothing rather than to allow the 
proposed trial to go ahead. Whereas from a patient perspective, those living with or 
caring for someone with a life limiting disease (…) would like to have the opportunity 
to make that choice for themselves. The regulators and ethics committees tend to be 
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cautious as they have a role in protecting patient safety. But the balance between 
benefit and risk needs to swing. (…) If you are dealing with people with a life limiting 
disease, then they may have a different view on the amount of risk that they are 
willing to take in return for the possibility of a benefit which they would value. So it is 
important to look at the issues from the perspective of patients as well.R36 
 
Physicians interviewed in this study agreed that patients had an important role to play in 
translational research. But they also described their struggle to explain to patients the trial 
design, risks and the unlikely possibility of benefit from the FIH trial. One of their major 
challenges was to provide technically correct information without completely destroying 
patients’ hope. They often wondered if patients really fully understood the procedure and 
provided truly informed consent.  
What I personally find a bit difficult is that you have to explain the trial to the patients. 
(…) patients may be hopeful that the trial is doing something good, (… but) as an 
investigator you (…) know chance of 10% or 20% of any benefit. (…) And you have 
to tell them, (…) you won’t have any benefit, but you will have toxicity. I think it's 
quite a difficult discussion, because you don’t want to take away any hope from the 
patients, but at the same time you have to tell them that there is a fair chance it's not 
going to help. R3  
 
Regulatory challenges 
All respondents acknowledged the critical role played by drug regulatory authorities in early 
clinical translation. Most of them had established contact with the authorities early on in trial 
planning and found it extremely useful to keep regulators “on board.” They felt that the 
scientific advice and pre Investigational New Drug (IND) consultations with the authorities 
were extremely valuable for them to prepare for their trial. But they also criticized regional 
and national differences within and between regulatory authorities and their individual 
requirements, which were often quite distinct. This posed a significant challenge for 
researchers running multicentric international trials. Depending on local regulatory 
requirements, they sometimes needed to amend their protocols but then ended up with 
different protocols at different sites.   
79 
 
Respondents planning to conduct trials in developing countries reported having 
received less support and guidance from regulatory authorities, which they attributed to the 
fact that these authorities do not have much experience with nanoparticles and formulations 
and take a rather precautionary stand. Researchers using nanotechnology to work on therapies 
for neglected diseases particularly saw this as a significant challenge.  
 Respondents mentioned nanocharacterization and toxicological tests as another major 
challenge. European researchers mentioned this problem more often than their American 
colleagues. European scientists working on nanoparticles reported having been required to 
bring the tests and assays to prove that the particles under investigation are safe, but also 
acknowledged the EU’s efforts to strengthen nanocharacterization capacity in Europe in 
collaboration with Nanotechnology Characterization Laboratory (NCL) of the United States.  
(…) besides GMP-production, we have to show that the typical tox-tests which are 
developed for chemicals and molecules, are also useful for nanoparticles and if not we 
have to propose to drug regulatory authorities an alternative method to check the 
toxicity of the particles. This is the big, big hurdle. For example, a lot of tox-tests are 
based on colorimetric methods and iron oxide is brown. So a lot of colorimetric 
methods simply do not work for our particle. R15 
 
While discussing FIH nanomedicine trials conducted in Europe in early 2000, one of our 
respondents highlighted the distinct regulatory pathways for drugs and devices. These 
regulations change over the course of time and can significantly affect the progress of certain 
products along the translation path.   
(…) they are working now 20 years in this field. And at that time (emphasis in 
original) they were able to show that their particles are a device because they inject it 
directly into the tumor and particles stay in the tumor. With a device, much easier! 
Swiss and European authorities now handle nanoparticles even for diagnostic 
application as a medicament. So we have to do more preclinical work with the 
nanoparticles even if it's a device as compared to at the earlier time (emphasis in 
original).  R11 
 
Another respondent raised concerns about regulatory pathways to govern follow-on versions 
of licensed nanomedicines and nanosimilars.  
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…one of issues with either the biologics, the non-biologics and clearly as well with the 
nanomedicine is that the approach of the regulatory agencies is similarity approach 
than the sameness approach. Meaning that for follow-on versions, we will never have 
the same but some similar products, which could lead to question- what is similar 
enough to get a kind of therapeutic alternatives or therapeutic equivalence allowing 
even to switch between the test and reference product or even interchange them? 
(…)This is big challenge and contrasts the generic paradigm. (…) one has to go to 
clinical head to head analysis for comparability evaluation which could finally make 
follow-on products not a cheaper alternative. R32 
 
Discussion  
Slow and scarce translational research is a global concern due to its adverse impact on the 
availability of affordable and effective treatment options. The financial, ethical, and 
regulatory challenges presented in this paper have been discussed extensively in the literature 
on translation of other cutting edge biotechnologies such as gene transfer,5 cell therapy,28-31 
and regenerative medicine,32-33 but our study is the first to actually investigate the experience 
of those involved in translational nanomedicine. This allowed us to understand the tensions 
underlying these challenges and to seek solutions which will be relevant for medical 
applications of any cutting edge biotechnology.  
 In spite of increased national and international collaborative funding schemes, all 
respondents of this study, irrespective of their affiliation with the universities, SMEs or large 
pharmaceutical companies, perceived it challenging to procure the necessary funds to initiate 
a FIH trial. Though many academic researchers are successful in basic science research, they 
often lack the capacity, experience and insight necessary to launch FIH trials.34 Personnel 
experienced in clinical research are often in short supply in university hospitals due to 
existing high workload in patient care and priority on treatment over research. Furthermore, 
the turnover of hospital staff can adversely affect quality standards in clinical trials. These 
challenges significantly affect translational research in university settings in spite of 
availability of interdisciplinary expertise and access to patients.  In this context, it is important 
to find ways to motivate academic researchers to continue working in translational research 
and create an environment in universities which is more conducive to conducting early 
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clinical trials. Another approach could be to strengthen the capacity of academic medical 
centers to undertake translational research through dedicated funding schemes and 
infrastructure development. Hospital pharmacies need to be strengthened to produce needed 
quantities of doses under GMP conditions. A certain percentage of hospital staff could be 
designated for clinical research. This would require innovative funding avenues that go 
beyond National Science Foundation grants which have reduced significantly in both size and 
number in recent years due to changes in policies for public funding in education and 
research.35-37 Philanthropic organizations could play a financial role in strengthening the 
translational research capacity of university hospitals and academic medical centers.  
 Many university researchers have tried to overcome financial hurdles by establishing 
SMEs. In spite of having an increased chance of being funded by venture capitalists, SMEs 
struggle to procure enough funding to obtain a “proof of concept” in man. As our results 
show, the interest of venture capitalists in products heavily depends on their potential market 
share and returns on financial investment. This means that only products that can provide a 
good return on an investment are likely to get funded in the first place. This implies that 
treatment options for certain diseases or conditions that are financially lucrative are more 
likely to progress along the translational pathway, while treatment options for neglected and 
rare diseases will continue to remain on the periphery. Some universities have tried to 
overcome financial challenges by commercializing technology developed in-house through 
‘tech transfer’ departments, but this leads to other intellectual and financial conflicts of 
interests38-39 when investigators and inventors become too closely involved in translation 
research as was the case in 1999 with the gene transfer trial for ornithine transcarbamylase 
deficiency.5, 40 
 Large pharmaceutical companies are probably best placed to take on a major role in 
early translational research. However, as respondents of this study reported, the 
pharmaceutical industry seems to be rather reluctant to venture into early clinical translation 
82 
 
of nanomedicine. Given the high uncertainty involved in novel technologies and financial 
stakes, they are willing to buy only promising products for which a “proof of concept” in man 
has already been obtained.  But it is extremely difficult for the academic researchers or SMEs 
to produce a “proof of concept in man” without substantial funding and technical support, 
thus creating a catch 22 situation. It might be worthwhile to think of ways to motivate large 
pharmaceutical companies to take a more facilitatory role in translational nanomedicine 
research.  
 Drug regulatory authorities undoubtedly play a major role in facilitating translational 
research in nanomedicine. As scientific knowledge evolves at a rapid pace they need to keep 
themselves up-to-date on all the technological developments in the field as well as advances 
in regulatory science. 41 The US FDA and European Medicines Agency (EMA) differ in their 
definitions of nanomedicine and their requirements for the evaluation of new investigational 
drugs. If every national or regional drug regulatory authority has its own understanding of 
what constitutes a nanomedicine and what regulatory pathway such a product should follow, 
it becomes challenging for researchers to coordinate FIH trials in multiple jurisdictions. Some 
regulatory authorities might be seen as less restrictive and hence such countries can become 
“favorite” destinations for conducting FIH trials. It will also become more challenging to 
distinguish between drugs and devices as multiple technologies converge to produce medical 
applications; this has already occurred in regenerative medicine where nanostructures or 
scaffolds are used in combination with biological cells. Another challenge that lies ahead for 
drug regulatory authorities is the assessment of nanosimilars in comparison with the original 
drug produced with nanotechnology.42 Drug regulatory authorities will need to prolong and 
strengthen post marketing surveillance of nanomedicinal products to monitor long term 
toxicity profile in patients, especially for chronic diseases where patients will consume the 
drugs for a prolonged period. Finally, it is critical to build regulatory infrastructure in 
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developing countries so that they can locally assess and evaluate FIH trials for disease 
indications that are prevalent in their context.  
 It is essential to simultaneously establish strong ethical oversight to evaluate clinical 
research with investigational nanomedicinal products. In some countries, ethics committees 
only evaluate ethical aspects of FIH trails such as risk/benefit evaluation and readability of 
informed consent forms while in other countries, they are also expected to assess the scientific 
evidence upon which risk assessment is based. In both cases, it is critical that at least some 
members of the ethics committee are capable of critically examining the science and accuracy 
of preclinical evidence, and of undertaking comprehensive risk assessment in a context where 
uncertainty and ignorance regarding potential harms is significant.43 In countries where few 
FIH trials in nanomedicines have already taken place, it might be worthwhile to develop 
national ethics oversight bodies that could assess proposals and systematically document the 
procedure of risk assessment as well as experience gained from these trials. That national 
experience and expertise could then percolate down to regional and institutional ethics 
committees through systematic training and knowledge transfer so that eventually such FIH 
trials can be evaluated in decentralized ethics committees. Data safety monitoring boards and 
robust reporting systems for adverse events need to be strengthened to ensure human subject 
safety.  
 Effective collaboration between pharmaceutical industry, SMEs, academics, drug 
regulatory authorities, ethics review committees, patient organizations, and policy makers is 
essential for strengthening translational research in nanomedicine. Professional organizations, 
such as CLINAM, Basel and ETP-Nanomedicine, have played a significant role in facilitating 
translational nanomedicine in Europe by generating multi-stakeholder debate, fostering 
effective collaborations within EU and globally and actively engaging with policy makers 
with the aim to find solutions and speed up clinical translation.  
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Limitations  
To the best of our knowledge, this is the first exploratory qualitative study investigating 
challenges in translational nanomedicine. The results of this research provide interesting 
insights into stakeholder experience, but generalizability is limited due to qualitative 
methodology and purposive sampling technique. Those who agreed to be interviewed had a 
certain interest in the topic and hence their views might be different than those who refused 
participation. Our strategic focus on Europe and North America means that we missed direct 
views from other countries such as China, India, Australia, and Japan. However in light of 
globalization we would have expected at least some remarks of our interviewees to point out 
huge differences in Asia and Oceania, and have therefore reasons to believe that general 
challenges related to translational nanomedicine in those countries are largely similar.  
Our study has identified key challenges in conducting translational nanomedicine 
research. We have suggested some ways to overcome these challenges. Further quantitative 
research with a global study population is warranted to systematically document differences 
attributable to national regulatory environments, funding opportunities, and experience of 
local ethics oversight.  
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Abstract  
Background: Obtaining valid informed consent can be particularly challenging in first-in-
human (FIH) trials of medical applications of nanotechnology due to the complexity of 
interventions, the hype and hope concerning potential benefits, and fear of harms attributed to 
‘nano’ particles.  
Aim: The aim of this exploratory qualitative research paper is to describe and analyze the 
opinions of expert stakeholders involved in translational nanomedicine regarding explicit use 
of ‘nano’ terminology in informed consent documents. 
Methods: We draw on content analysis of 46 in-depth qualitative interviews with key 
stakeholders in translational nanomedicine based in Europe and North America.  
Results: We received a spectrum of responses ranging from reluctance, across more 
ambivalent reactions, to absolute insistence on explicit mention of ‘nano’ in informed consent 
forms. A variety of reasons for these beliefs were offered by participants.  
Conclusion: Our analysis concludes that consistent, clear and honest communication 
regarding the ‘nano’ dimension of investigational product is essential in patient information 
sheets and consent forms for FIH trials. Complete exclusion or underplaying ‘nano’ for any 
reason is dangerous. It would not only threaten the validity of informed consent but also 
adversely affect public trust in science, technology and the clinical research enterprise. 
Key words 
Informed consent (IC), participant information sheets, First-in-human (FIH) trials, 
nanomedicine, nanotechnology, qualitative research   
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INTRODUCTION  
Many international [1-3] and national [4-5] ethical guidelines mandate that researchers obtain 
valid informed consent from research participants. For informed consent to be valid, the 
individual must be competent, comprehend the information provided and agree to participate 
voluntarily. The investigators are required to provide complete and correct information about 
the investigational product, anticipated risks and benefits and disclose any conflicts of 
interest, in language that is understandable by lay people. It is not always easy to fulfil all the 
criteria mentioned above and scholars have highlighted various challenges involved in 
obtaining valid informed consent [6-10].  
It is particularly challenging to obtain valid informed consent in first-in-human (FIH) 
clinical trials. These trials pose the highest level of uncertainty in terms of risk, and the trial 
participants are unlikely to receive any clinically relevant therapeutic benefit as most of them 
receive sub therapeutic dose in this dose finding study [11]. FIH trials are often conducted on 
healthy volunteers or terminally ill patients who do not have any treatment options. Scholars 
have analyzed extensively whether these groups of trial participants are capable of giving a 
truly informed consent and ways to minimize the threats to informed consent due to the 
financial motivation of healthy volunteers and the inability of terminally ill patients to 
distinguish between research and treatment, when their misplaced and overtly exaggerated 
hope can lead to the therapeutic misconception [12-15].   
In this research, we investigated the ethical challenges experienced and perceived by 
stakeholders involved in FIH trials of nanomedicine. Nanomedicine, which is usually defined 
as applications of nanotechnology in medicine, is considered to be a key enabling technology 
with the potential to significantly improve sensitivity of diagnostic tests, allowing early 
disease detection and development of highly effective and targeted drugs providing better 
treatment options [16]. The last two decades have witnessed tremendous hope and hype 
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around the potential of nanotechnology and nanomedicine [17]. There are also critical voices 
concerned about nanotoxicity and the long term effects of nanoparticle exposure on humans 
and the environment [18-21]. ‘Nano’ has become a buzz word and has been associated with 
two extreme ‘images’- one as a magic bullet that can solve a number of problems faced by 
humanity and the other, darker ‘grey goo’ scenario with uncontrolled replication of 
nanoparticulate material destroying humanity. We wanted to explore how the word ‘nano’ 
plays a role in FIH trial related documents such as grant applications, research protocols, 
investigator brochures, informed consent forms and scientific publications.  
The aim of this paper is to analyze the reasons provided by respondents in favor of and 
against explicitly mentioning the fact that FIH trial involves ‘nano’ (nanocarrier, nanoparticle, 
nanoformulation or nanoproduct) in informed consent (IC) forms, and to discuss its 
implications on validity of informed consent as well as trust in clinical research.  
METHODOLOGY  
Our exploratory qualitative research aimed to investigate the ethical challenges faced by 
stakeholders involved in FIH trials in nanomedicine. In-depth interviews allowed us to gain 
insight into the experiences, values and arguments of stakeholders, rather than quantitatively 
assessing their views. 
Study population 
We identified stakeholders in translational nanomedicine in Europe and North America 
through a literature review, participation in key nanomedicine conferences, university 
collaborators and professional networks. We interviewed scientists working in universities, 
large pharmaceutical companies, small and medium size enterprises (SMEs), ethics experts 
from national ethics advisory committees and institutional/hospital ethics committees, 
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representatives of drug regulatory authorities, clinical research organizations (CROs), contract 
manufacturing organizations (CMOs), patient advocacy groups, and venture capitalists.  
Study instrument 
A literature review on ethics of translational nanomedicine helped us to develop a list of open 
ended questions that we used to facilitate the interviews. It steered the discussion and also 
provided the respondents an opportunity to describe issues that they considered relevant to the 
topic under discussion. The interview guide was pilot tested and validated with three 
colleagues (experienced in qualitative research and the ethics of medical technology). The 
pilot interviews were excluded from the final data set. 
Interview and transcription 
Between October 2013 and November 2014, PS1 conducted 46 stakeholder interviews in 
English either in person or through a phone or Skype call using a maximum variation 
sampling and a snowball technique [22]. She obtained an oral informed consent and 
permission to record the interviews from each respondent before the interview. We 
anonymized the data to ensure confidentiality of participants’ identities and views. The 
interviews lasted on an average for 50 minutes depending on the time availability of the 
respondent, their interest in the topic and willingness to share their experience. We continued 
to recruit respondents for interviews till theoretical saturation was reached. Theoretical 
saturation is a point in qualitative research when the researchers feel that no new themes 
relevant to topic under discussion emerge in spite of continuing interviews with more 
respondents [23]. PS together with research assistants transcribed all interviews in full and 
sent the interview transcript to each respondent to check the accuracy of technical content. 
                                                          
1 PS is a physician and medical anthropologist. She is trained and experienced in qualitative 
research methods and is a doctoral researcher on this research project. 
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Data analysis 
PS carried out research question guided deductive coding of qualitative data using software 
MAXQDA. DS undertook a similar coding exercise manually. The research team compared 
and discussed the codes and the themes generated by these two approaches till a consensus 
was reached. This was one of the ways to improve the rigor of content analysis by minimizing 
misinterpretation of data and influence of researcher’s personal biases.  In line with reporting 
format of qualitative research, we will present our results using select quotations from the 
respondents to highlight various perspectives of the stakeholders. Since it is an exploratory 
research study, our aim is to show the spectrum of perspectives rather than quantifying their 
frequency. We use a limited number of quotations from our data set that are most 
comprehensive and provide interesting insights and exclude similar thoughts expressed by 
other respondents to avoid repetition. To protect the anonymity of stakeholders from close 
knit translational nanomedicine community in Europe and North America, we present their 
perspectives with respondent numbers such as R1, R2 rather than describing their profile in 
details such as physician from the Austria working on thermosensitive liposomes or ethics 
expert from Swiss National Ethics Commission. Though, it limits the extent of our data 
analysis, we believe this is the best way to ensure confidentiality and anonymity of our 
respondents.  
Ethical approval for the study 
The research project and the interview guide were approved by the local ethics committee in 
January 2013.  
RESULTS 
Our aim was to assess the views of respondents regarding explicit mention of nanoparticles or 
nanoformulation (referred to henceforth as ‘nano’) in participant information sheets and 
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informed consent forms of FIH trials. We received a spectrum of responses ranging from 
‘there is no need to use word nano’- (reluctance), across more ambivalent reactions, to ‘it is 
absolutely necessary to be honest and explicitly mention the word nano’-(insistence). In this 
section, we present some of the responses that represent different contextual arguments and 
also highlight challenges in ‘informing’ a trial participant and being an ‘honest and 
transparent scientist’. 
Reluctance  
Reluctance to explicitly mention ‘nano’ was attributed to two main reasons. First, the 
complexity of the technology makes it difficult to adequately inform trial participants without 
overwhelming them with information. The second reason was the failure of the general public 
to distinguish between highly regulated nanomedical and nanopharmaceutical products and 
the unregulated (or minimally regulated) use of nanotechnology and exposure to nanoparticles 
in everyday life ( in cosmetics, toothpastes, food packaging, lightweight bike frames, 
detergents, wrinkle free clothing, stink free socks, water resistant paints, stain free fabrics, 
traffic pollution, dust generated while printing, waterproofing shoe sprays) which often leads 
to misplaced fear about nanotechnology and nanoparticles.  
I don’t think the patient understands what nanoparticles are. It is hard for us to 
understand what that means. I would not be able to explain to a patient what a 
nanoparticle is except that it has a size of 55nm and it is between 1 and 100 nm and 
that is why we call it nanomedicine. R6 
So if there is nothing useful to gain by putting ‘nano’ in informed consent form, I will 
not (emphasis added) because people don’t understand anyways. There is a big 
difference between the nano pharmaceuticals sector and nanomaterial side and we 
have to make a clear boundary between the two because one is unregulated sector and 
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pharmaceutical is highly regulated sector. So the danger is that people confuse 
between the two. R10 
Ambivalence 
The responses taking the middle ground regarding the use of ‘nano’ reveal the ambivalence 
and conflict felt by stakeholders. Most of our respondents fell into this category, for various 
reasons described below. 
Attributes of nanotechnology and nanoparticles in investigational product 
Respondents referred to the technological aspects of nanoparticles, such as size, changed 
physical, chemical and electric properties, their impact on targeted drug delivery and potential 
adverse effects. Respondents said that they were more likely to explicitly refer to ‘nano’ if the 
desired characteristic of investigational drugs could not be achieved without nanotechnology.  
I would say that 50% of myself goes to each side. I agree that you could just describe 
the formulation and say it is composed of polymer which contains a drug and so on. 
So you don’t tell all the truth. But then if you are really exploiting the beneficial 
features of the nano, I think at that point you need to specify that to the volunteers, 
because otherwise it’s not fair. You need to be clear enough for them to understand 
what you are doing. But again maybe you don’t need to explain too much. R41 
I mean if the nano doesn’t mean that you are going to put the volunteers or the patients 
at risk then you could avoid mentioning that. But then if you are in a situation where 
the nano could be really the key in adverse effects, so yes. I would probably tend to 
mention this in a very smooth way not to make people concerned or be alarmed. R7 
We are producing nano and what happens to it in the body? Is it still nano there? Or 
does it agglomerate? And from that point of view, I would probably give it an artificial 
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name like we say aspirin. We do not say Salicylic acid. Because it does not matter 
what it is exactly in its form or in its chemistry. If for the patient, it is recognizable 
with a name, and he or she knows “this is the good medication that I need or this is the 
compound that is active...” Then that’s fine. R35 
Context of the trial participants/patients 
Other factors that influenced whether or not to mention ‘nano’ in trial documents were 
characteristics of trial participants (patients vs healthy volunteers) and the type of disease. 
Often our respondents advocated for a case by case approach to assess the needs of each 
group of participants.  
Right... if it’s a nanotreatment, it depends on the situation of that person. He or she 
will consider it either as something: “yes, let’s try it” or “oh my god!” But on the other 
hand, I mean any compound that is currently used for chemotherapy for instance, they 
are toxic, they are not really good. And if you look at the side effects, it’s enormous 
and still these compounds are being accepted as treatment. They cure the cancer but 
they also do a lot of other damage in the body. And yet it is accepted. So I guess, if it 
is then called nano or something else, it would not matter in this kind of first trials. 
R17 
I guess that is partially right, but on the other hand nanomedicine opens new 
perspectives and innovation and could be in a way a personalized medicine’s 
approach. In addition patients affected by severe chronic diseases often know a lot 
about their illness and ongoing research. So informed consent might be very important 
to explain such trials and patients understand the trial quite well. In addition if the 
patient gets some knowledge about the potential drug he will be exposed, he will 
probably inform himself e.g. on the internet but a large part of this information might 
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not be peer-reviewed and it makes it difficult to get right information and conclusions 
drawn by the patient might not be correct.... And to do that, I guess you have to inform 
participants respecting their knowledge and understanding but probably as well the 
urgency of this kind of treatment for these patients... So again probably a little more 
individualized approach is needed. R32 
Hope, hype and buzz of ‘nano’ 
Some of our respondents highlighted the semantics around nano and nanomedicine, arguing 
that liposomal drugs were licensed and used before the terms nanotechnology and 
nanomedicine became mainstream. It was seen appropriate to refer to nanotechnology and 
nanomedicine with a scientific audience but not with patients or trial participants.  
Ah…I don’t know...But maybe no. I don’t think I would call it a nano product. Why 
should you? (Giggles)...I mean....Nanotechnology.. Maybe it’s important to use the 
word in scientific settings, but for the patients I don’t think it should matter whether 
it’s a nano or whatever it is as long as you have the necessary tox studies and the 
necessary approvals and so on. But maybe, maybe one should do that because people 
could come afterwards and say to you: “Why didn’t you tell me this was a 
nanotechnology product?” But...I don’t know. At the same time there are of course a 
lot of nanotechnology products further down the translational pathway.. in market: 
liposomes, that kind of things which are nanotechnology products but which were 
there even before they invented the nanotechnology term in a way. R34 
That’s a very tricky question. This has to do with the word nano. And the way it is 
being abused all the time and scaring people all the time. And...So I think as a 
scientist, you can just describe the particle. However, as a person, I would not feel 
correct if I would do so. So..if I had designed such particle, I would just choose for the 
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word nanomedicine, but I would describe it such that I would explain it very clear in a 
layman language to the patient that, it has been investigated very properly and that we 
have a good hope that it would work, if that’s the case of course. Because I don’t like 
to lie to patients at all. So I would use the word nanomedicine and I would take the 
risk in having fewer patients or make more effort in getting patients to enroll. R26 
Insistence 
Those who strongly believed that they will explicitly mention the word ‘nano’ in informed 
consent forms attributed it to honesty and transparency on the part of scientists and its crucial 
link with building public trust in science, technology and clinical research enterprise.  
Absolutely, absolutely! I think the worst we can do is to be not transparent. We need 
to be transparent as scientists. I feel if you ask patients to volunteer, they have an 
interest in knowing what is being done. And some patients might also be very proud; 
oh we are testing something very new. So why not provide that information to the 
patients. If it is a nano drug then it’s a nano drug and we should be transparent. And I 
think any efforts to be non-transparent in any community on a long-term always harm 
the community. R40 
No, I think this is not fair. I don’t know if our ethics committee would allow that. I 
would stand up there and say: “no”. If you have a patient or a healthy volunteer 
offering his or her help to you so you can perform your experiments or your trial, you 
have to inform people. You can convince them; you can tell them and just provide 
them with the data which are available. But I think you should not hide anything. 
Could you imagine a year later, or half a year later, this is found out? No, I think there 
you have to be transparent. R20 
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Yes, I would definitely use that word but thereby also explain it in very general 
knowledge language, not very scientific language … nano is only the reference to size 
and has nothing to do with very dangerous materials that can induce cancers… and 
based on the data we have obtained in the animals, we have seen improved added 
value. I think one should be honest about it and not put it under the table. R21 
DISCUSSION 
To the best of our knowledge this is the first empirical qualitative enquiry to investigate 
stakeholder’s opinions on explicit mention of word ‘nano’ in informed consent (IC) forms and 
the arguments underlying them. It was also an opportunity for respondents to reflect on their 
beliefs and share their concerns about being completely honest, as explicitly mentioning 
‘nano’ in IC forms could mean challenges in patient recruitment due to fear. At first glance, 
the reluctance regarding mentioning ‘nano’ demonstrated by a few researchers and the 
ambivalent position taken by a majority of respondents could be considered disappointing 
given that we would expect researchers to have a better understanding of the requirements for 
informed consent [13,24], but the reasons provided by them point to larger conflicts that need 
systematic attention, including the hype and hope generated by nanotechnology, funding 
politics, public engagement in science, balanced science communication, involvement of 
multidisciplinary teams in translational research and training of drug regulatory and ethical 
oversight authorities [25].  
 It was not surprising that those who were reluctant to mention ‘nano’ were concerned 
about the complexity of technology and fear about nanotechnology in society, whereas those 
who argued for explicitly mentioning ‘nano’ in trial related documents often referred to 
transparency, honesty and research integrity. When asked about ways to address public fear so 
that scientists can be honest and transparent in trial related documents, all of them advocated 
better public engagement, responsible and balanced media coverage and highlighted the role 
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of scientists in science communication. They felt that underplaying the word ‘nano’ for short 
term goals such as faster patient recruitment, would not only compromise their research 
integrity but also adversely affect public trust in nanotechnology and clinical research in the 
long run. They saw a significant role for themselves in public engagement and science 
communication and were seriously concerned about the unbalanced media attention received 
by any cutting-edge medical technology or biotechnology [26]. Small breakthroughs and 
success in preclinical research published in prominent scientific journals can be 
sensationalized in mass media as if similar success in humans is just around the corner, thus 
wrongly raising the expectations of patients and falsely fuelling their hope. It was also a 
shared experience of these stakeholders that negative results (especially when a particular 
nanoparticle is proven to be safe in humans) are difficult to publish, unlike the research that 
proves toxic effects of particle under investigation, further polarizing the media and common 
man’s image that most ‘nano’ particles are dangerous and toxic. Their recommendations to 
minimize public fear included ‘case by case’ assessment of each nanoproduct and 
development of robust systems to monitor and evaluate long term effects of nanoparticles in 
human beings and the environment. 
The other main interesting finding of this study is the ‘ambivalence’ felt by the 
stakeholders regarding explicit mention of the word ‘nano’ in trial related documents. Their 
arguments were more diverse, covering semantics of ‘nano’ in nanotechnology and 
nanomedicine, the contribution of nanotechnology towards beneficial and toxic effects of 
investigational products, and whether the product was used on healthy volunteers or 
terminally ill patients. Their opinions were rather fluid and were likely to swing more towards 
‘reluctance’ than ‘insistence’ as far as IC forms were concerned, implying that as long as the 
participants understand the stakes, it was secondary whether the word ‘nano’ was mentioned 
explicitly. This could also mean that the trial participants would be less likely to get distracted 
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by the technical jargon of ‘nano’ and images associated with it and understand the trial 
information better. But it still remains debatable whether the word ‘nano’ should be 
completely omitted from participant information sheets and IC forms for convenient (if 
perhaps unethical) reasons, or whether it should be mentioned and then simplified to make it 
understandable for trial participants.  
We are of the opinion that the word ‘nano’ should not be omitted completely from 
participant information sheets and IC forms, especially if it has been used in grant 
applications, investigator’s brochure, trial protocol and documents submitted to the regulatory 
and ethical oversight authorities. To disclose the nano nature of a trial to everyone involved 
except trial participants would normally be unethical [24]. Furthermore, it is critical that all 
the risks, uncertainty and ignorance related to the nanoformulation being investigated in FIH 
trial are discussed in detail, and (as in all FIH trials) it is made clear that participants are 
unlikely to benefit from their participation but the knowledge gained may have significant 
scientific and social value, so that participants as well as ethics committees get complete 
information on potential risks and benefits. Otherwise, there is a danger of selective and 
convenient use of ‘nano’ terminology when it serves a beneficial purpose such as procuring 
grants and publishing results in prominent journals, but withholding it from the trial 
participants, regulatory authorities and ethics committees.  
Most nanomedicine is being developed and licensed for cancer chemotherapy, and 
such products are always tested on patient groups who are terminally ill and who have 
exhausted all other proven treatment options. Cancer chemotherapy often induces many side 
effects and does not improve patients’ survival beyond a certain limit. In this context, 
nanotechnology can play a significant role but ‘nano’ should not be presented as ‘lesser evil’ 
as compared to standard chemotherapy. Nano might indeed reduce chemotherapy related 
toxicity but in FIH trials, it also has high potential to cause harm to the participants owing to 
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limited reliability of animal models and preclinical data based on which such trials are 
initiated in humans [26]. Nanomedicinal products achieve better targeting due to their nano 
size, penetrability into deep tissue spaces and transport across biological barriers. They also 
improve drug concentration at desired sites by altering pharmacodynamic properties. Targeted 
drug delivery reduces unwanted side effects but certain characteristics of nanoparticles can 
also produce new and unanticipated side effects. There is a thin line between beneficial 
aspects of nanoformulations and the toxicities they can produce especially when the product is 
being tested in FIH trials and it is essential to be open and honest about both these aspects in 
participant information sheets rather than only highlighting improved targeting as a potential 
benefit. The suggestion of giving a nanomedicinal product a neutral name (aspirin vs acetyl 
salicylic acid) might work to reduce fear associated with nanotechnology, but it would only be 
correct to do so after a drug has been licensed and robust post marketing surveillance over 
many years has proved its safety and efficacy. This is not the case for most nanomedicinal 
products at the moment. The earliest licensed nanomedicinal products have been now around 
for about 20 years but most products under translational research are very recent and there is 
limited safety as well as efficacy data available for them.  
Finally, participant information sheets and informed consent forms are sources of 
scientific information that are based on peer reviewed evidence, reviewed by the drug 
regulatory authorities and ethics committees and provided by the enrolling physician to the 
participant. Patients often tend to trust their physicians and these trial related documents 
should also be trustworthy in terms of its completeness and correctness. As pointed out by one 
of our respondents, there is plenty of information accessible via the internet but its reliability 
and accuracy is questionable [27] unless it is published in peer reviewed scientific journals. 
Not many members of the public or patients have access to such journals and are more likely 
to receive distorted information from other non-peer reviewed sources. Even if they receive 
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scientifically correct information, interpretation of this information will also influence their 
decision making. Hence the accuracy, transparency and understandability of participant 
information sheets and informed consent are crucial and should not be compromised [13, 28]. 
This is indeed an opportunity for the scientists and investigators to ‘inform’ and ‘educate’ the 
potential trial participant about nanomedicine and empower them to make informed choices. 
CONCLUSION 
One of our respondents rightly referred to dilemma of use of ‘nano’ terminology in trial 
related documents as ‘starting one’s journey with left foot forward’. It is challenging to 
achieve the necessary balance between providing correct information and making it 
understandable, describing all the risks and benefits, and not give false hopes or 
overemphasize the harms and the risks. Each participant is different, their attitude, values and 
experience with clinical research are different and their personality is unique which will 
influence how they receive the information and the way they make a decision. The recruiting 
physicians need to be aware of these factors but the decision regarding whether to include 
terminology ‘nano’ in participant information sheets and IC forms should not be based on 
such individual traits of either the participant or the researcher. These documents need to have 
consistent, clear and honest communication regarding study design and investigational 
product. We believe that total exclusion or underplaying ‘nano’ for any reasons is dangerous 
and will threaten the trust of the public in science, technology and clinical research enterprise.  
Scientists and investigators have a significant role to play in public engagement and 
science communication but there is only little that they can achieve on their own. They need 
to receive the necessary support from policy makers, funding agencies, drug regulatory 
authorities, ethics oversight, media professionals and general public to be able to carry out 
translational research without compromising on either research integrity or the safety of trial 
participants.   
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ABSTRACT 
Background Participant selection for first-in-human (FIH) trials involves complex 
decisions. The trial design makes it unlikely that participants will receive clinically relevant 
therapeutic benefit, but they are likely to experience risks of various magnitudes and types. 
The aim of the present paper was to describe and discuss the views of investigators and ethics 
committee members about the choice of trial participants for FIH trials in cancer 
nanomedicine. 
Methods We drew insights from an exploratory qualitative study involving thematic 
analysis of 46 in-depth interviews with key stakeholders in Europe and North America 
involved in FIH nanomedicine trials. The present work draws on subset of 21 interviews with 
investigators and ethics committee members who have either conducted or reviewed a FIH 
cancer nanomedicine trial or are planning one. 
Results Investigators and ethics committee members are aware of the ethical standards for 
recruiting patients with end-stage cancer into FIH trials, but they nonetheless questioned the 
practice and provided reasons against it. 
Conclusions Although it is a standard and ethically accepted practice to include patients 
with end-stage cancer and no treatment options into FIH trials of investigational 
chemotherapeutic molecules, doing so can threaten the validity and generalizability of the 
trials, thereby weakening translational research. Another possibility is to stratify and include 
patients with less-advanced disease who demonstrate certain biomarkers or cancer genotypes 
and who have a disease profile similar to that tested in preclinical studies. The latter approach 
could be a step toward personalized medical research and targeted drug development. Such a 
patient selection approach requires multi-stakeholder discussion to reach scientific and ethics 
consensus. 
Key Words First-in-human trials, trial participant selection, nanomedicine, qualitative 
research, empirical ethics 
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BACKGROUND 
First-in-human (FIH) trials are crucial in translational research for experimental clinical 
applications, but they also pose the highest level of uncertainty with respect to potential risks 
to trial participants 1. That uncertainty is attributed to the limited validity and reliability of 
preclinical research 2,3, to questions concerning the appropriateness of animal models 4, and to 
the lack of clarity about the mechanism of action of investigational products 5. The goal of FIH 
trials is to gather information about the mechanism of action, to study the toxicity and safety 
profile, and to determine a safe and tolerable dose in humans, which will be the starting dose 
for further clinical trials in which the efficiency of the intervention is tested 6. The dose-
escalation design of FIH trials makes it highly unlikely that patients participating in such trials 
will receive clinically relevant therapeutic benefit, at least in the earliest cohorts testing low 
doses of the experimental molecules 7. Trial participants are likely to experience side effects 
and harms of various types, magnitudes, and probability 8. Some of the harms can be predicted 
from preclinical animal data. However, data from animal models cannot be reliably 
extrapolated to human beings, and substantial uncertainty and ignorance persists in 
assessments of the risks of FIH trials 9. 
Compared with later-stage trials, FIH trials often involve fewer trial participants, thus 
reducing the number of individuals who could be harmed 6. But if the participants selected for 
such trials are inappropriate, translational research is harmed in two ways: First, individual 
participants, even though few in number, are harmed. Second, human and financial resources 
are consumed in conducting trials that do not generate valid, reliable, and generalizable 
scientific knowledge that can guide further translational research or necessitate additional 
preclinical research 6,10. 
The literature on participant selection for FIH trials mainly discusses 3 different 
categories of trial participants: healthy volunteers; patients with stable disease on standard 
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therapy, but who suffer nonetheless; and patients with terminal illness who no longer have 
any standard therapy options 11. Researchers working with novel medical technology such as 
gene transfer and regenerative medicine have pointed out another category of potential FIH 
trial participants: individuals who are currently asymptomatic carriers of certain genetic or 
degenerative conditions that will manifest as a disease in future 12. Participants in FIH trial are 
vulnerable for various reasons: therapeutic misconception 13–15; undue hope and optimism that 
the investigational product will improve their health, or at least their quality of life 16; 
perceived pressure to accept what their treating physician feels is good for them; and 
inadequate appreciation of unlikely benefits but likely harms 11. The choice of trial 
participants for FIH trials involving cutting-edge medical technology such as gene transfer, 
regenerative medicine, cell-based interventions, and nanomedicine is further influenced by the 
novelty of the intervention under investigation, the limited reliability of disease models in 
animals 17, and the huge hype and hope that such technologies generate in the minds of 
patients and the general public 18. The hype and hope make trial participants further prone to 
succumbing to the therapeutic misconception and underestimating the risks and likelihood of 
harms. 
The choice of trial participants for FIH trials involves a delicate balance between the 
requirements of the study protocol and design (protocol-driven factors) and participant-related 
factors from the perspective of patients and healthy volunteers. A significant body of 
literature has explored the motivations, hopes, and expectations of healthy volunteers and 
patients who participate in various clinical trials, including FIH trials 19–25. Patient-related 
factors influencing the decision about whether to participate in FIH trials include unmet need 
for treatment options, lived illness experience, suffering and impact on quality of life, 
willingness to accept higher risks in the hope that the experimental treatment might provide at 
least symptom relief if not cure, and familiarity with and understanding of clinical trials and 
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investigational molecules. We believe that the patient perspective on trial participation merits 
its own investigation. Our research project has two separate arms: one focusing on patient 
perspectives and the other on expert stakeholders. In the present work, we specifically explore 
the perspectives of expert stakeholders about the selection of FIH trial participants. 
The goal of our paper is to summarize and discuss the views and thought process of 
principal investigators (PIs) and ethics committee members (ECMs) about the “ideal or most 
appropriate” trial participants for their FIH trials in nanomedicine. We are aware that FIH trials 
constitute a heterogeneous group of trials and encompass a large spectrum of scenarios, from 
FIH testing of a slight modification of an already licensed drug at one end, to the testing of a 
completely novel investigational molecule based on cutting-edge technology that has never 
before been tested in humans at the other. For the purpose of the present work, we focus on 
the latter end of the spectrum, where novel investigational products or molecules are being 
tested in humans for the very first time, and safety or toxicity data for humans from prior 
experience with other similar products are unavailable or limited. 
We used medical applications of nanotechnology as a prototype for our investigation 
into the challenges of clinical translation of cutting-edge medical technology. Because of their 
size or unique physical and chemical properties (or both), nanomedicines allow for the 
development of highly sensitive and specific diagnostic tools that could facilitate early disease 
detection and improved monitoring of disease progression. They provide efficient drug 
delivery mechanisms and platforms, with better targeting to disease lesions and delivery of 
higher concentrations of drugs at desired sites, thus improving drug efficiency and reducing 
side effects 26,27. Though nanotechnology-based diagnostic and therapeutic interventions are 
expected to revolutionize the understanding of disease mechanisms and the ability to treat or 
cure the diseases, significant concerns and uncertainties also pertain to the risks and harms 
caused by nanoparticles to humans and the environment 28. That tension between immense 
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hope and hype about the potential of nanotechnology in medicine, and the fear and reluctance 
attributable to its feared toxicity makes nanotechnology an interesting case study, especially 
to discuss the challenges it poses in translational research. 
Here, we describe and discuss insights from a subset of 21 of 46 in-depth interviews 
with translational nanomedicine stakeholders based in Europe and North America who have 
either conducted or evaluated a FIH trial or who are planning one in the near future. 
Stakeholders discussed mainly nanomedicine-based cancer chemotherapeutic drugs because 
most of the approved nanomedicines are anticancer agents. Although there is a vast body of 
literature on participant selection for FIH trials in general and cancer trials in particular, we are 
not aware of any other empirical investigation in which trial participants for FIH cancer 
nanomedicine trials have been discussed. We believe that the present work will shed further 
light on the concerns expressed by scholars working on the ethics of nanomedicine and 
physicians caring for cancer patients. It will in particular help to clarify the reasons and 
arguments stakeholders use to justify their choice of FIH trial participants. 
METHODS 
For this exploratory qualitative research, we used in-depth interviews to elicit the views and 
experiences of stakeholders involved in FIH trials in nanomedicine in Europe and North 
America. In-depth interviews were facilitated with a semi-structured list of open-ended 
questions and focused on understanding the various challenges (including ethical challenges) 
faced by the stakeholders of translational nanomedicine. Interviews allowed us to build a 
dialogue with the expert stakeholders and provided them the necessary space to highlight 
arguments and experiences that they found pertinent and worthy of discussion. All the 
respondents discussed financial, ethical, patent-related, and regulatory challenges that are 
applicable to translational research in any cutting-edge medical technology 29. But a subset of 
the respondents who had either conducted or were planning to conduct FIH nanomedicine 
cancer trials reflected extensively on specific challenges they faced while justifying their 
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preferred choice of trial participants either to themselves or to the ethics committee. The 
present work focuses on the reflections of those stakeholders and on the specific dilemmas 
they faced in the choice of trial participants while ensuring scientifically and ethically sound 
study design and the generalizability of knowledge gained. 
Respondents 
We interviewed scientists affiliated with universities, academic centres, small- and medium-
size enterprises, and large pharmaceutical companies; physicians and PIs of trials; ECMs or 
members of institutional review boards; representatives of drug regulatory authorities, patient 
advocacy groups, clinical research organizations, and venture capitalists. Those roles are not 
necessarily mutually exclusive. The heterogeneity of the respondents allowed us to 
understand the challenges of translational nanomedicine from the perspectives of the various 
stakeholders involved and the specific roles they play in the process, but it also posed a few 
specific methodological challenges such as theoretical saturation and quantifying responses 
according to the roles the respondents played. Some of those challenges are described in 
subsections that follow. The present work draws on a subset of 21 of the 46 respondents and 
includes the experiences and opinions of scientists, physicians, PIs (collectively referred to as 
“investigators”) and ECMs or institutional review board members who had either conducted or 
evaluated a FIH nanomedicine trial or were planning one in the near future. Their profiles are 
summarized in Table I. The remaining 25 respondents did not have specific comments or 
reflections on choosing trial participants either because they had not considered the topic and 
were still focused on preclinical research or their role in translational research did not include 
having to choose participants for FIH trials. 
Interview Guide 
An extensive literature review helped us to create a list of open-ended questions for the 
interviews with key stakeholders. This semi-structured interview guide steered the discussion 
and allowed respondents to describe salient issues, experiences, and thoughts. Stakeholders 
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involved in translational research were expected to have varied professional backgrounds and 
to play a specific role; hence the interview guide had to be flexible and to address questions 
relevant to the role the stakeholder played in a particular trial. The guide thus had to be 
adapted while interviewing an expert in nanotechnology–nanomedicine patent law, who might 
not have had specific views about participant selection, but who would highlight challenges 
linked to patent evaluation and granting, which are linked to the interests of the investors or 
venture capitalists and hence connected with the ability of an investigator to generate financial 
resource to move from preclinical research to early human trials. 
The interview guide was pilot-tested with 3 colleagues experienced in qualitative 
research and the ethics of medical technology. The pilot interviews were excluded from the 
final data set. The interview guides were approved by the local ethics committee and are 
published as supplementary material to one of our published articles 
http://www.sciencedirect.com/science/article/pii/S1549963415006218 (subscription required). 
Interviews and Transcription 
All stakeholders were interviewed in English by PS between October 2013 and November 
2014—in person whenever possible or over the telephone—using purposive maximum 
variation sampling 19. Oral informed consent was obtained from all participants before the 
interview, and permission was asked to record the conversation on an audio device. The ways 
in which the confidentiality and anonymity of their views would be ensured were explained. 
Interviewees could refuse to answer any question or could ask for the recording to be stopped 
for particular sections of the interview. Interview durations ranged between 20 minutes and 60 
minutes, with the average time being 50 minutes. We continued interviewing stakeholders 
until data saturation was reached (a stage at which the research team was convinced that no 
new themes relevant to the aims of the study were emerging with additional interviews) 30. 
Given the heterogeneity of the sample, theoretical saturation was reached at varying time 
points for the various themes under discussion; timing depended on how many of our 
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stakeholders had views on the particular topic. Together with research assistants, PS 
transcribed all interviews verbatim and in full; PS also checked all interviews against the 
audio recording and sent the transcripts to respondents to check the contents and the accuracy 
of technical details, as well as to solicit additional thoughts or suggestions. 
Data Analysis 
At the beginning of data collection, PS simultaneously undertook a preliminary data analysis, 
the insights from which were included in subsequent interviews. She used the qualitative 
analysis software MAXQDA (Verbi GmbH, Berlin, Germany) to carry out deductive data 
coding. DMS undertook a similar exercise manually. The resulting codes were built into 
themes and discussed using manual and software-assisted data analysis until the research team 
reached agreement. 
The research team extensively discussed the advantages and disadvantages of deductive 
and inductive data coding as an approach for the data analysis, but eventually agreed on 
deductive data coding in light of time and funding constraints. For the present work, the goal 
was to discuss the range of views and experiences rather than the frequency of similar views. 
So, instead of quantifying the results, they are therefore described in general terms—for 
example, “a few,” “some,” “many,” “all.” 
Ethics Approval 
The ethics commission of northwest and central Switzerland (Ethikkommission Nordwest und 
Zentralschweiz) approved the research project and the interview guide in January 2013. 
RESULTS 
Of 46 respondents, 25 were working on various stages and aspects of clinical translation in 
nanomedicine such as bench research, animal experiments, toxicity assessment, and 
manufacturing of the required investigational compound under the conditions of good 
manufacturing practice; the remaining 21 had direct involvement with FIH trials in various 
capacities (investigator, trial physician, trial coordinator, ethics committee member, 
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representative of a drug regulatory authority). The FIH trials were focused on nanotechnology-
based drug delivery platforms in cancer, diabetes, immunologic disorders, cardiovascular 
disease, and infectious disease. 
With those 21 stakeholders, we explored views about the “ideal or most appropriate” 
trial participant for their FIH trial in nanomedicine and the underlying reasons for their choice. 
All 21 stakeholders advocated for a case-by-case assessment of participant selection for FIH 
trials with various interventions or experimental molecule and referred to various ethics 
guidelines such as Declaration of Helsinki 
(http://www.wma.net/en/30publications/10policies/b3/),  regulatory guidelines from the U.S. 
Food and Drug Administration for the investigation of new drugs 
(http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm) and the European 
Medicines Agency 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00
0564.jsp&mid=WC0b01ac05806403e0), and clinical research guidelines such as the 
Guideline for Good Clinical Practice from the International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use 
(http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R
1_Guideline.pdf), which provide guidance on participant selection and clear formulas for 
calculation of the starting dose for FIH trials.  
Because most nanomedicines have been developed and approved for cancer treatment, 
the focus of the discussions was on nanomedicine-based cancer trials, but respondents also 
mentioned other trials involving stem-cell therapy and gene transfer when making their 
arguments. We describe our results using select quotations from the subset of 21 interviews to 
highlight most important aspects of the theme under discussion. Our aim was to demonstrate 
the spectrum of arguments rather than to quantify how often a particular argument was used. 
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To protect the confidentiality and anonymity of respondents (Table I), we tag each quotation 
with a respondent number (R1, R2, ...), followed by their role. 
“Ideal” Participants Might Not Always Be the Most Ethical Choice 
All stakeholders were aware that most FIH cancer trials include patients with no treatment 
options, per the international ethics standards. 
You will never, never accept a study that is a healthy volunteer study with a 
chemotherapeutic agent. You test it in tumours, immunocompromised mice 
with tumours, then in patients who are extremely sick with metastasis, tumours 
which cannot be cured by any other existing drug. You try it first on such 
patients and then you slowly go backwards to less sick patients.- R6, ECM 
We ideally would have a patient who is partially previously treated, because 
that is also logical. It is also ethical that you should first give the patient a well-
known treatment—the standard of care so to say—and if the first and the 
second line is not working anymore, only at that point, it is ethical to go on 
continuing with something novel, either for the sake of science or for it might 
really have an added value in that specific patient. 
- R21, scientist planning a FIH nanomedicine trial 
Some stakeholders highlighted the constraints and challenges of including only the 
sickest patients in FIH trials. 
[They have had] a lot of other treatments before. They often are not in a good 
condition. They have very limited life expectancy. These are patients who 
always have problems—lot of the adverse events and serious adverse events. 
These are not randomized controlled trials, so many of these adverse events are 
attributed to the disease itself and not to the drug. So this is not the best way. 
But when a patient has treatment options with proven benefit, it is not ethical 
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to use a drug where you don’t know first the dose, the efficacy, and it is 
debatable if patient will have any benefit. This is why most of the new drugs in 
oncology are tested on dying patients. It is not ideal for the drug, but it is not 
ethical to give patients a treatment which might be inferior to an existing 
treatment. - R12, physician and PI who conducted a FIH nanomedicine trial 
Other stakeholders argued that the ideal participants are actually newly diagnosed cancer 
patients, or even better, patients with specific mutations or those who are known to have 
particular biomarkers that can be detected using imaging techniques. 
Ideal patients are the new patients that get diagnosed with the tumour because 
they have no prior treatment and no resistance. Those will not be allowed to 
join such trials of course. You have to do your trials in terminal-stage cancer 
patients, after which you can decide that it is safe enough to apply this 
technology and then you need to find a certain group of patients that will 
participate in the phase II trials when the efficacy will be studied. Even at that 
stage, you won’t get new patients but pre-treated patients. But there you can try 
to get some cure. It is logical especially in phase I trials where we only focus 
on the risks and toxicity, tolerable dose, etc. But in the next phases, you would 
like to treat the right patients that could benefit from this particular application. 
- R8, scientist planning a FIH nanomedicine trial 
Bear in mind that we have stage IV patients with metastasis all over. So 
anyway it will be palliative treatment that they will take. In that context, 
sometimes we can have a strong rationale that these patients might benefit 
from this new drug. Let’s say we have patient with stage IV lung cancer with a 
particular molecular marker. So if we know that these patients do not respond 
to any other treatment, and that we have found in pre-clinical study that, in cell 
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model and in animal models, tumours with these specific mutations respond to 
the treatment that we want to test, we have a rationale that may be strong 
enough to go in naïve patients [treatment-naïve patients whose cancers have 
been diagnosed late]. - R23, trial coordinator from a large pharmaceutical 
company 
Choosing treatment-naïve, recently diagnosed cancer patients for FIH trials was 
perceived as ethically challenging by all stakeholders, but they also pointed out the 
importance of other factors such as type of cancer, availability of standard therapy, prognosis, 
and time available to intervene. 
We often discuss whether the knowledge you want to gain requires a study in 
patients with end-stage disease or [whether] you can test it on patients who are 
not that sick. It is a very difficult decision. What you don’t want is to give false 
hope to patients with end-stage disease. You can also do part of the study in 
newly diagnosed patients or patients in between on the spectrum of disease 
progression, depending on life expectancy of the patient with his or her 
particular type of cancer. If we use newly diagnosed patients to study toxicity, 
one must assess if they have a possibility of trying other existing established 
therapies three or four weeks later or they have to start immediately with the 
accepted standard therapy. If we know that the experimental therapy under 
investigation is not going to negatively influence the standard established 
therapy after a few weeks. If here is no cross-reaction, or resistance, and we 
can have that time gap, it can be a good case. - R9, ECM 
Another argument for testing new drugs in relatively healthier cancer patients is to better 
assess side effects and toxicity. 
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In the first- or second-line treatments, it depends on the disease but when the 
patient is still fit and still has higher chance to benefit from the drug. On every 
drug, there is a ratio between the efficacy and side effects. And if you go to the 
patients, who are in worse physical condition, the side effects will be more 
pronounced than the efficacy. This will not be the case if the patients are fitter 
and if you treat the patients during the first or second line. - R12, physician 
and PI who conducted a FIH nanomedicine trial 
Stakeholders also noted the specific character of particular cancers: some have very 
rapid progression and do not have many treatment options in the first place. 
It depends on the disease, actually. For example, non-small-cell lung cancers, it 
is matter of debate. We know that non-small-cell lung cancer is a disease with 
rapid progress, and patients deteriorate quite quickly and only about 60 per 
cent to 70 per cent of all patients receiving first-line therapy get the second-line 
therapy. This will also be the case if you treat these patients in FIH trial with a 
new drug. And there will be one third or more of these patients not receiving 
the established first-line therapy. If you have a disease where most of the 
patients are dead after 12 months, this is quite different than a disease where 
you have time. For example, low malignant lymphoma when you have time in 
years. It might be the case here to test the new drug in first line, so you can 
rescue them in the second line with an established treatment. - R31, PI 
planning a FIH nanomedicine trial 
First-in-human trials are typically toxicity and dose-finding studies. Another factor that 
influences participant selection for FIH trials is the burden of risk for participants and, 
particularly, how long they might have to live with those risks. 
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Well, “ideal” is a difficult term in this context because what they usually want 
for these trials are patients who will not be bothered by the long-term risks 
because they will not survive long. So if you want to know the ideal oncology 
patients to participate in this kind of trials, it is the patient who is certain that 
there is no treatment anymore but who is in a reasonably good condition. You 
don’t want to burden someone who is really at the end of his life and in a bad 
health condition. - R22, physician and ECM 
Challenging the Standard Design of FIH Trials 
Some of our respondents criticized the traditional dose-escalation model of FIH trials, arguing 
that it might not be the best model for trials involving novel medical technology such as 
nanomedicine, stem-cell interventions, or gene transfer. One of the reasons for that stance was 
a lack of clarity concerning the dose–response relationship. Another concern was whether it 
was ethical to use the standard starting dose calculation from the animal models (as elaborated 
next, in discussing the case of stem-cell injection into a spinal cord lesion). 
But the problem is [pause] to do a FIH study with ineffective dosage which 
provides him absolutely no benefit and makes him more desperate. One actual 
example is the vaccination against the Ebola virus. I don’t think they did a 
classical first-in-man study; they probably started with the expected 
immunogenic dose and looked if it works, if antibodies are generated. They 
don’t challenge them with a dose which is one hundred times smaller than 
what you would expect to make an immune reaction. The classical first-in-man 
study is excellent with new drugs, but in these situations like the spinal cord 
lesion it is not feasible unless you believe that even a very small amount of 
these stem cells can create a malignant tumour. - R46 physician and ECM 
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DISCUSSION AND CONCLUSIONS 
The goal of FIH trials is to produce valid, reliable, and generalizable scientific knowledge that 
could guide further translational research 10. Ethics evaluation of such trials often hinges on 
balancing harms to the trial participants against the social and scientific value of research, 
rather than on a traditional risk–benefit evaluation for the trial participants 31. Scholarly 
discussion about involving patients with end-stage disease and no proven treatment options in 
FIH trials has focused on the vulnerability of such patients, the high likelihood of therapeutic 
misconception, the problems of information disclosure, and participation in decision-
making 11. 
Our results, however, highlight a significant conflict experienced by investigators and 
ECMs between doing what good ethics practice mandates (that is, enrolling only patients with 
end-stage disease and no treatment options in FIH trials, thus protecting other patients against 
unjustified and uncertain harms of exposure to unproven interventions) and what good 
scientific practice requires (that is, selecting less-ill patients for such trials so that results 
could guide further translational research). Abiding by ethics norms in terms of acceptable 
risk–benefit assessment for individual patients in turn adversely affects the clinical trial’s 
validity and reliability. Patients with advanced disease and no treatment options are fragile 
and weak. Enrolling them in FIH trials to assess an investigational product’s safety and 
toxicity profile increases their risk of experiencing severe side effects and adverse reactions. 
Because most FIH studies are not randomized controlled trials and do not involve blinding, 
many of the adverse events patients experience in such trials might not be accurately 
attributed to the investigational drug but instead to the underlying disease. That possibility 
will significantly weaken the goal of gaining scientific knowledge, either necessitating further 
preclinical testing or guiding later clinical research and potentially harming more patients who 
will be eventually tested with the same product in phase II/III trials. 
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Some researchers have argued for a modification of dose escalation FIH trials, such that 
most trial participants will receive a potentially effective dose 11. That change will be 
beneficial only if the investigational product indeed turns out to be efficacious, a finding that 
is not often the case in many FIH trials. Large numbers of investigational products fail to 
demonstrate efficacy in humans, which is required for a product license 32. If the 
investigational product has serious side effects, then the trial participants in any such modified 
FIH trials are also likely to experience more serious side effects proportional to the higher dose 
received, and thus more patients than necessary will be exposed to the harms. 
Others have argued for more rigorous preclinical research using appropriate animal 
models, and bringing randomization and blinding into preclinical animal experiments to 
achieve higher methodologic and scientific rigour so that potential harms in humans can be 
better predicted 10. 
Are there ways to move trial designs in terms of patient recruitment from terminally ill 
patients to other patients whose disease is not so advanced? That latter group of patients could 
be included in FIH trials with new drugs for a short period of time and could later be rescued 
by proven standard therapy provided there is no drug interaction or resistance related to their 
trial participation. 
Given improved understanding and assessment of biomarkers and cancer genotyping, 
and advances in imaging techniques, it will be worthwhile to stratify patients further, thus 
choosing for particular FIH trial only those who express a certain biomarker or who 
demonstrate conditions similar to those tested in preclinical animal models, regardless of how 
severe their disease is at the time of trial participation. Patient recruitment of that type could 
be a step toward personalized clinical research in a limited sense. In cancer chemotherapy 
using liposomes as a nanomedicine drug delivery platform, for example, it might be possible 
to preselect patients who demonstrate enhanced permeation and retention of liposomal 
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nanoparticles on imaging studies. Many liposomal chemotherapeutic formulations use the 
enhanced permeation and retention effect as the main passive mechanism of drug delivery to 
cancerous lesions 33. The nanoscale size of liposomes filled with active licensed 
chemotherapeutic drugs allows for their extravasation from leaky tumour vasculature into the 
tissue spaces and tumour stroma. The active chemotherapeutic compound encased within is 
then released, thus concentrating the drug locally, improving the efficacy of cellular lysis and 
minimizing toxicity to surrounding healthy tissue. Not all patients have tumour vasculature 
that is leaky enough to allow for the distribution of a sufficient concentration of liposomes 
into the tumours, but patients who have sufficiently leaky tumour vasculature can be 
identified using certain imaging techniques. Although that approach will involve more costs 
because of the inclusion of diagnostic and prognostic imaging endpoints in such FIH trials, 
researchers will be able to choose appropriate trial participants in whom the drug can be 
concentrated locally and to produce a reliable scientific understanding of the mechanism of 
action and toxicity of the investigational product and a preliminary assessment of efficacy, if 
any. Furthermore, other patients (with no demonstrated enhanced permeation and retention 
effect) who are unlikely to benefit from the liposomal investigational product will be 
protected against unnecessary harms related to their trial participation by exclusion at the 
outset of the trial. 
Finally, a discussion about appropriate participant selection is incomplete without 
meaningful engagement with patient populations or patient advocates in trial planning, 
evaluation, and decision-making. The framework for such engagement has to be flexible, 
proportionate in terms of risks and benefits, and transparent. However, it is not always easy to 
define who the appropriate representatives of patient populations are 34 and whether they 
could objectively assess potential harms and benefits for each trial. The literature describes 
the role of patient advocates in advocacy for fund mobilization, communication with potential 
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trial participants, support for newly diagnosed patients, and informing policy and 
oversight 35,36, and yet it is debatable what role—if any—they should play in ethics 
evaluations of FIH trials of cutting-edge medical technologies. Our research project focused on 
professional stakeholders and did not receive input from patients with the exception of 1 
representative from a patient advocacy group. Further research into understanding what 
meaningful patient engagement could contribute to translational research will be immensely 
valuable. 
We are aware of a few methodology limitations related to the purposive sampling 
technique in the present study. Although the results of this exploratory study have limited 
generalizability, they raise important questions about appropriate trial participants for FIH 
trials in cancer nanomedicine, thus generating an important debate. In-depth interviews also 
allowed us to gain insight into the reasons for the feeling on the part of key stakeholders of 
FIH nanomedicine trials that patients with advanced disease might not be the appropriate 
participants in early translational research in humans, even though such participants are 
justified and recommended by ethics guidelines. Further studies with larger and homogeneous 
study populations will increase the evidence base and help to determine whether these 
dilemmas about participant selection in FIH cancer nanomedicine trials are also relevant to any 
FIH trials with cancer patients regardless of whether they involve cutting-edge medical 
technology. 
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TABLE I Profile of expert stakeholders a 
Affiliation  
 Academic researcher 20 
 Subject matter expert 8 
 Large pharmaceutical industry 6 
 Ethics expert or IRB member 6 
 Drug regulator 2 
 Venture capitalist 1 
 Patient advocacy group 1 
 Industry consultant 2 
 TOTAL 46 
Experience of FIH trials in nanomedicine  
 Trial completed 11 
 Advanced preclinical and planning work 10 
 TOTAL 21 
Targeted disease  
 Cancer 9 
 Diabetes 2 
 Immunologic 5 
 Cardiovascular 1 
 Infectious 4 
 TOTAL 21 
Main drug delivery platform  
 Liposomes 8 
 Gold nanoparticles 3 
 Silver nanoparticles 1 
 Polymer micelles 2 
 SPIONs 2 
 siRNA 1 
 Silica multistage vectors 1 
 Others 3 
 TOTAL 21 
a Descriptions of the countries in which they work and the roles they perform were intentionally 
withheld to ensure anonymity. Completed FIH trials in nanomedicine are few in number, and so 
with the information about the disease target, drug delivery platform, and country, the identity of 
the respondents could be easily deduced. 
IRB = institutional research board; FIH = first-in-humans; SPIONs = superparamagnetic iron oxide 
nanoparticles; siRNA = small interfering RNA. 
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Abstract 
The Ebola epidemic in Western Africa has highlighted issues related to 
weak health systems, the politics of drug and vaccine development and the 
need for transparent and ethical criteria for use of scarce local and global 
resources during public health emergency. In this paper we explore two key 
themes. First, we argue that independent of any use of experimental drugs or 
vaccine interventions, simultaneous implementation of proven public health 
principles, community engagement and culturally sensitive communication 
are critical as these measures represent the most cost-effective and fair 
utilization of available resources. Second, we attempt to clarify the ethical 
issues related to use of scarce experimental drugs or vaccines and explore in 
detail the most critical ethical question related to Ebola drug or vaccine 
distribution in the current outbreak: who among those infected or at risk 
should be prioritized to receive any new experimental drugs or vaccines? 
We conclude that healthcare workers should be prioritized for these 
experimental interventions, for a variety of reasons. 
 
Keywords 
Africa, bioethics, clinical studies, community engagement, resource 
allocation, Ebola, disease surveillance.  
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Introduction 
The current Ebola epidemic started with the diagnosis of a two year old boy 
in Guinea in December 20131. By December 31, 2014, cases have been 
reported in four countries (Guinea, Liberia, Sierra Leone, Mali) and four 
other previously affected countries (Nigeria, Spain, the US and Senegal). 
There are 20,206 suspected and confirmed cases, and 7905 reported deaths. 
A total of 678 health care workers have been infected with 382 deaths2. The 
World Health Organization has described the epidemic unprecedented and 
estimates that it will continue to spread for another four to six months before 
it can be controlled, infecting as many as 20,000 people3 4. This epidemic is 
unique due to the very high numbers of cases compared with all previous 
outbreaks5, high infection rates amongst health care workers6 and because it 
                                                          
1 Lancet editorial. Ebola: a Failure of International Collective Action. Lancet 2014; 384: 
637.  
2 World Health Organization (WHO). 2014. Ebola response road map: Situation report 
update, December 31, 2014. Geneva, Switzerland. . Available at: 
http://www.who.int/csr/disease/ebola/situation-reports/en/ [Accessed on 05 Jan 2015]. 
3 World Health organization (WHO). 2014. Ebola response roadmap. Geneva, Switzerland. 
Available at: 
http://apps.who.int/iris/bitstream/10665/131596/1/EbolaResponseRoadmap.pdf?ua=1 
[Accessed on 05 Jan 2015]. 
4 Lancet editorial, op. cit. note 1. 
5 C. del Rio et al. Ebola Hemorrhagic Fever in 2014: The Tale of an Evolving Epidemic. 
Ann Intern Med 2014. 
6 World Health organization (WHO). 25 Aug 2014. Unprecedented number of medical staff 
infected with Ebola. Geneva, Switzerland. Available at: 
http://www.who.int/mediacentre/news/ebola/25-august-2014/en/ [Accessed on 05 Jan 
2015]. 
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has affected countries which do not have prior experience of and expertise 
in controlling Ebola outbreaks7. Fortunately, however, the overall fatality 
rate at the moment is about 39%, which is lower than in most of the 
previous outbreaks but the fatality rate among health care workers is 57%, 
which is a major concern given the limited health human resource in Ebola 
affected countries8. It might be thought that health care workers would have 
better overall health status, be diagnosed earlier and treated faster thus 
leading to better health outcomes. However, the most recent data reveals 
higher mortality rates among health care workers, which could be attributed 
to their exposure to a large number of patients while having limited personal 
protection, at least in the beginning of the epidemic. In previous Ebola 
outbreaks, amplified transmission has been documented in health care 
centers with approximately a quarter of all cases occurring in health care 
workers9.  
As in the past, transmission could be slowed and prevented by the 
basic principles of public health, such as exhaustive case and contact 
tracing, effective response to patients including supportive care, involving 
local communities while planning interventions, and robust infection control 
practices in health care settings and during burial procedures10. But there are 
many challenges in controlling this epidemic, including porous national 
borders with movement of people for work, fragile health care systems, 
                                                          
7 C. del Rio, op. cit. Note 5, p 1. 
8 WHO, op. cit. Note 2, p 1. 
9 C. del Rio, op. cit. Note 5, p 1. 
10 T. R Frieden et al. Ebola 2014- New Challenges, New Global Response and 
Responsibility. N ENGL J MED 2014. 
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weak surveillance and diagnostic facilities, cultural beliefs and practices, 
and local communities’ lack of trust in Western biomedicine and foreign 
health care workers11. The situation has been further complicated by 
delayed global support and response to the epidemic12.  
 There are no licensed and approved treatments or vaccines against 
Ebola. The complexity and magnitude of the epidemic led the World Health 
Organization to reach a consensus that ‘it is ethical to offer unproven 
interventions with as yet unknown efficacy and adverse effects, as potential 
treatment or prevention13. The WHO also highlighted the need to start phase 
I clinical trials in healthy volunteers with candidate vaccines as quickly as 
possible, along with continuing compassionate use of unproven 
interventions in patients in emergency settings, provided the data 
concerning compassionate use is meticulously collected and analyzed14. The 
first phase I trial of a potential Ebola vaccine has already begun at the 
                                                          
11 A. S. Fauci. Ebola- Underscoring the Global Disparities in Health Care Resources. N 
ENGL J MEd 2014. 
12 R. Anusumana. Ebola in Sierra Leone: a call for action.Lancet 2014. 
13 World Health Organization (WHO).12 August 2014. Ethical considerations for use of 
unregistered interventions for Ebola virus disease (EVD). Geneva, Switzerland: WHO. 
Available at: 
http://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/ 
[Accessed on 05 Jan 2015]. 
14 World Health Organization (WHO). 2014. Ethical considerations for use of unregistered 
interventions for Ebola virus disease: Report of an advisory panel to WHO. Geneva, 
Switzerland: WHO. Available at: 
http://apps.who.int/iris/bitstream/10665/130997/1/WHO_HIS_KER_GHE_14.1_eng.pdf 
[Accessed on 05 Jan 2015]. 
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National Institutes for Health in Bethesda, US with 20 healthy volunteers15, 
and another phase 1 trial in 60 healthy volunteers began in the UK in 
collaboration with Glaxo SmithKline and the NIH on 17th September16. 
Switzerland has initiated parallel trials of two candidate vaccines and aims 
to enroll 150 healthy volunteers17 18, while Mali has undertaken a similar 
trial with 40 healthy volunteers19. Use of limited doses of Zmapp, a 
combination of three monoclonal antibodies for seven patients including 
health care workers had fuelled much hope, hype and speculation 
concerning who should have access to this drug in case it is proved to be 
                                                          
15 National Institutes of Health (NIH). 28 August 2014. NIH to Launch Human Safety Study 
of Ebola Vaccine Candidate. Bethesda, Maryland. Available at: 
http://www.nih.gov/news/health/aug2014/niaid-28.htm [Accessed on 05 Jan 2015]. 
16 Reuters. 2014. First UK volunteer gets experimental GSK Ebola shot in trial. London.  
Available at:  
http://uk.reuters.com/article/2014/09/17/uk-health-ebola-vaccine-
idUKKBN0HC17K20140917  [Accessed on 25 Nov 2014]. 
17 ClinicalTrials.gov. 2014. VSV-ZEBOV Geneva Vaccine Trial. Available at: 
http://clinicaltrials.gov/ct2/show/NCT02287480?term=Ebola&cntry1=EU%3ACH&rank=1 
[Accessed on 05 Jan 2015]. 
18 ClinicalTrials.gov. 2014. A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in 
Healthy Adults in Switzerland. Available at:  
http://clinicaltrials.gov/ct2/show/NCT02289027?term=Ebola&cntry1=EU%3ACH&rank=2 
[Accessed on 05 Jan 2015]. 
19 ClinicalTrials.gov. 2014. Phase 1 Trial of Ebola Vaccine in Mali. Available at: 
http://clinicaltrials.gov/ct2/show/NCT02267109?term=Ebola&cntry1=AF%3AML&rank=1 
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efficacious20. The effectiveness of Zmapp in treating Ebola is not yet proven 
despite the recovery of two American health workers and one British health 
worker. These recoveries cannot be fully attributed to the drug alone, as all 
three of them received excellent supportive care in advanced intensive care 
settings and infectious disease isolation centers in the US and the UK 
respectively21. Furthermore, two other patients (a priest from Spain and a 
doctor in Liberia) who were also given Zmapp have died, making the known 
mortality rate for patients on Zmapp very similar to the normal mortality 
rate for this outbreak22. However, these deaths cannot be attributed to 
Zmapp being ineffective, as the drug was administered many days post-
infection in both cases and some patient-related factors such as age could 
also have contributed to a more protracted disease course23. The latest 
results of a study where 18 macaques given Zmapp early in the course of 
infection were protected against a lethal dose of Ebola has again fuelled 
hope and anticipation of a ‘magic bullet against Ebola’ in the research 
community, among health care professionals and in communities affected 
by Ebola24.  
 Even if some of the experimental drugs and vaccines are shown to 
be safe and efficacious based on expedited phase I trials, a number of issues 
                                                          
20 T. W. Geisbert. Ebola Therapy Protects Severely Ill Monkeys. Nature 2014 
doi:10.1038/nature13746; A. Rid & E. Emanuel. Ethical Considerations of Experimental 
Interventions in the Ebola Outbreak. Lancet 2014; DOI: 10.1016/S0140-6736(14)61315-5. 
21 A. Mullard. Experimental Ebola Drugs enter Limelight. Lancet;384:649. 
22 J.L.Goodman. Studying “Secret Serums”- Towards Safe , Effective Ebola Treatments. N 
Engl J Med 2014. 
23 A. Mullard, op. cit. note 21. 
24 T. W. Geisbert, op. cit. Note, 20. 
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related to available resources and capacity and ethical questions must be 
answered before making a decision to implement therapeutic or 
experimental interventions in countries worst affected by the epidemic.  The 
drug or vaccine will not be a magic bullet to halt the epidemic, and will 
have to be coupled with basic principles of public health and epidemic 
control such as strengthening continuous disease surveillance systems 
including case and contact detection, case management, isolation and 
supportive care. In addition, resources must be invested in establishing 
diagnostic facilities and building the capacity of local health care systems to 
detect and control future outbreaks before they turn into epidemics25. Such 
interventions require sustained and focused investment not only in terms of 
monetary resources but also in building human resource, technical 
competences, political willpower and global cooperation26.  
 In this paper we first argue that, independent of any use of 
experimental drugs, simultaneous implementation of proven public health 
principles, community engagement and culturally sensitive communication 
are critical in the current and any future Ebola epidemics as these measures 
represent the most cost-effective and fair utilization of available resources. 
This might sound obvious and may not appear to be an ethically contentious 
issue. Yet it is critical that the limited public health resources available in 
West Africa are  used judiciously in the current epidemic for disease 
surveillance, provision of care and the phase II vaccine and drug trials 
planned for early next year. Second, we attempt to clarify ethical issues 
                                                          
25 T. R Frieden et al, op.cit. note, 10, p.2. 
26 A. Rid & E. Emanuel. Ethical Considerations of Experimental Interventions in the Ebola 
Outbreak. Lancet 2014; DOI: 10.1016/S0140-6736(14)61315-5. 
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related to experimental treatment as even if such experimental drugs or 
vaccines can realistically be produced only in very small quantities during 
the current epidemic, will play an important role in halting the epidemics 
probably only in future Ebola outbreaks. We therefore aim to highlight the 
strengths and challenges of both these intervention strategies and lay out the 
limitations of each. We explore in detail the most critical ethical question 
related to Ebola drug/vaccine distribution in the current outbreak: who 
amongst those who are infected with or at high risk of acquiring Ebola 
should be prioritized to receive an experimental vaccine or drugs during 
phase I/II trials in countries affected by Ebola?  
 
Public health measures helped curtail previous outbreaks 
Since the first documented Ebola cases in 1976, the world has seen several 
sporadic outbreaks27. Compared with the current epidemic, all the previous 
outbreaks have been smaller in scale in terms of both the number of cases 
reported and the geographic spread of the disease. The mortality rate has 
varied from 25% to 90%28. All of these epidemics were controlled in the 
absence of a vaccine or drug with proven public health intervention. These 
intervention measures include early case detection and isolation, meticulous 
contact tracing, observing patients’ contacts for signs of illness during the 
disease incubation period, providing supportive care to patients and their 
contacts and implementing rigorous infection control procedures observed 
in health care settings29.  
                                                          
27 C. del Rio et.al, op. cit. note 5, p.2. 
28 A. S. Fauci, op.cit. note 11, p.1. 
29 T.R. Freiden et.al, op.cit. note 10, p.2; A.Rid &E.Emmanuel, op.cit. note, 26, p.1. 
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 A health care system adequately staffed with trained health 
professionals and stocked with an adequate supply of protective equipment 
such as overall aprons, masks, gloves and disinfection materials is critical in 
controlling an Ebola outbreak. But countries affected by the current 
outbreak in Western Africa (Sierra Leone, Liberia, and Guinea) face a 
number of challenges. For example, these are some of the world’s poorest 
countries, and they have been affected by long periods of political conflict30. 
They have very poor health infrastructure, diagnostic facilities and reference 
labs such as P4 biosafety labs which are required to handle highly infectious 
pathogens such as Ebola31. They have very low physician-to-patient and 
nurse-to-patient ratios32, meaning communities’ health needs are not 
adequately met even in the absence of an Ebola epidemic. Most people rely 
on informal health care providers and traditional healers to resolve most 
health issues33. Because nonspecific early symptoms of Ebola mimic those 
of other common conditions in the area such as malaria and typhoid, most 
cases take some time to be formally diagnosed in the health care system, 
having already increased the risk of disease transmission to family members 
and other community contacts34. Ongoing routine disease surveillance 
systems which could pick up such outbreak at the earliest are practically 
absent35. The population in these parts of Western Africa has grown 
                                                          
30 A.S.Fauci, op.cit. note 11, p.2. 
31 R.A.Ansumana, et.al, op.cit. note 12, p. 303. 
32 C. del Rio et.al, op. cit. note 5, p.1. 
33 Lancet editorial, op.cit. note 1, p.637. 
34 A.S.Fauci, op.cit. note 11, p.2. 
35 C. del Rio et.al, op. cit. note 5, p.1. 
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significantly in the last 4 decades and with increased human movement and 
migration36, large slum settlements and efforts to collect bush meat for 
sustenance have created an optimal environment for increased contact 
between humans and wild reserves of the virus and for circulation of the 
virus within the human population37.  
 Even though public health measures were able to stop previous 
Ebola epidemics, it is impossible to rely solely on these principles as a 
means to end the current epidemic, for two main reasons. First the epidemic 
has matured and has already spread to six countries, though Nigeria and 
Senegal are now declared free of Ebola. Second, building health care 
systems and disease surveillance abilities takes time and so does building 
the trust of local communities in formal health care and Western 
biomedicine. Efforts have already been made to set up Ebola treatment 
centers in affected communities but these are overrun by the people who 
require health care38. The high infection and fatality rates among health 
workers39 in current epidemic has further weakened the available local 
health human work force. Unfortunately, extreme actions such as ‘military 
lockdown’ to comb through the communities to locate hidden patients or 
suspected patients and forcibly isolating them created further hostility of 
local population against the public health measures40. Some of these 
                                                          
36 A.S.Fauci, op.cit. note 9, p.2. 
37 T.R. Freiden et.al, op.cit. note 8, p.2. 
38 Lancet editorial, op.cit. note 1, p.637. 
39 WHO, op.cit. note 6. 
40 Lisa O'Carroll. 2014. Sierra Leone's planned Ebola lockdown could 'spread disease 
further'. The Guardian 6 September.  
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challenges can be tackled by coordinated global response of humanitarian 
and medical aid organizations, as well as through provision of adequate 
supplies for supportive care, supply of personal protective equipment 
(PPEs) in required quantities with training on how to use these correctly to 
avoid infections in health care workers41. Other supportive measures to 
build the trust of local communities in foreign aid organizations and health 
workers include provision of food for affected populations since isolation of 
patients takes away their means of sustaining the families42 and assistance in 
burial procedures43. Given all this complexity, it is no wonder many experts, 
scientists, media representatives and general populations look at 
experimental drugs and vaccine candidates as the only hope to successfully 
curtail the current outbreak. We describe some of the challenges of this 
strategy in the next section.  
We are aware that the need to build public health and disease 
surveillance infrastructure, community engagement and culturally sensitive 
communication are uncontroversial strategies that as a general idea do not 
raise ethical debates. But when it comes to deciding how many resources 
should actually be channeled towards those structural aspects, there is 
disagreement. Therefore, we want to highlight the importance of these 
                                                                                                                                                    
Available at:  
http://www.theguardian.com/world/2014/sep/06/sierra-leone-lockdown-ebola-outbreak 
[Accessed on 05 Jan 2015]. 
41 W.A. Fischer et.al. Protecting Health Care Workers from Ebola: Personal Protective 
Equipment is Critical but not Enough. Ann Intern Med 2014. 
42 T.R. Freiden et.al, op.cit. note 10, p.2.  
43 Ibid:2. 
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aspects for two main reasons. Community engagement and communication 
will be even more critical when implementing phase II trials for vaccines, 
repurposed drugs and experimental drugs in affected countries in early 
2015. For successful patient recruitment as well as continued monitoring of 
research participants, it is critical that communities trust research teams and 
health workers, and essential that they understand trial design, including 
why (depending on patient randomization or stepped wedge design) some 
patients or some places will receive experimental interventions and others 
will not. It is also important to note that even if a few foreign researchers 
and clinical trial experts are deployed in the field to carry out these trials, 
most ground work and monitoring of trial participants will be still done by 
the health workers who are already working in the treatment centers. Being 
involved in research work and regular follow-up of research participants 
could impose an additional burden on the health workers who are already 
responsible for caring and surveillance activities.  
 
A race against time to develop, test and license effective drugs and vaccines 
against Ebola 
Development of a new drug or vaccine is a long process spanning many 
years to a few decades44. Most experimental drugs and vaccine candidates 
do not cross the ‘valley of death’ along the spectrum of drug development 
either because they are ineffective or they are toxic45. Apart from being a 
time consuming process, drug development and testing requires huge 
                                                          
44 A.Rid & E. Emmanuel, op. cit. note 26, p.1. 
45 J. L.Goodman, op. cit. note 22, p.2. 
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monetary resources to bring such experimental drug molecules from the 
laboratory to preclinical animal studies and eventually to the market after 
having been thoroughly investigated and tested to assess and ensure various 
safety, toxicity and efficacy parameters in humans in phase I to III clinical 
trials. Even though epidemics like this can suddenly mobilize more financial 
support, political will, international lobbying and support from the 
regulatory agencies to expedite clinical trials46 (as is the case with candidate 
vaccines or repurposed drugs) upscaling production of any new drug 
molecule under good manufacturing practice (GMP) can take several 
months if not years47. Even when a drug has been produced on a large scale, 
some such medicines require stringent handling and monitoring while being 
administered to patients. This often requires intensive care facilities which 
are mostly lacking in the countries affected by Ebola in Western Africa. On 
the other hand, drugs and vaccines against infectious diseases like Ebola can 
only be tested during an epidemic for it will be ethically unacceptable to 
inject people with highly infectious pathogens such as Ebola to test the 
efficacy of the drug or vaccine. For the same reasons, the current epidemic 
of Ebola is an ideal opportunity to test potential therapies and vaccines, 
provided a study design is used which enables accurate data gathering on 
the efficacy of experimental interventions in order to guide further clinical 
drug development, while also maximizing any prospect of benefit and 
minimizing harm to trial participants/communities. 
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 This complex situation requires many different stakeholders 
including politicians, scientists, clinical trial experts, ethicists and doctors to 
consider and address various ethical issues related to legal and technical 
issues such as licensing, production and roll-out, but also ethical issues such 
as transparency, distributive justice, and respect for autonomy. A 
collaborative, well-coordinated effort is required to curb the current Ebola 
epidemic and to make provisions for preparedness towards future epidemics 
of Ebola or other emerging infectious diseases. 
 
What potential treatment options are being investigated in the current 
epidemic? 
Experimental drugs or‘re-purposed’ drugs 
Under an international partnership, two trials are being planned in West 
Africa, with one led by researchers at Oxford University to test the antiviral 
drug Brincidofovir which is effective against Ebola in the laboratory but has 
not been tested in animals yet48. The site for this trial has not been finalized 
yet. The French National Institute of Health and Medical Research 
(INSERM) will lead another trial in Guinea to test another antiviral drug 
Favipiravir which has been shown to be effective in animals49. Interestingly, 
                                                          
48 Clinicaltrials.gov. 2014. An Open-Label, Multicenter Study of the Safety and Anti Viral 
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Zmapp is not one of the drugs under consideration to be tested in a clinical 
trial. This could be due to the time and capacity required to upscale the 
production of sufficient doses for trials but it is hoped that the sufficient 
quantities might be available by February or March 201550. Furthermore, 
drugs already approved for other medical indications could potentially be 
‘repurposed’ for Ebola virus disease (EVD) and tested in humans given the 
serious nature of the epidemic and absence of any other treatment options51. 
Scaling up the production of any experimental drug under GMP criteria 
needs time, infrastructure and manufacturing capacity. Even if 
manufacturing can be scaled up, the next challenge will be to decide who 
should be prioritized to receive the experimental treatment. The WHO noted 
clearly that use of experimental or repurposed drugs should not replace 
standard care and investigation of these interventions must not distract 
attention from the implementation of standard clinical care, rigorous 
infection prevention and control, and careful contact tracing and follow-
up52.   
 
 
 
                                                                                                                                                    
http://www.theguardian.com/world/2014/nov/13/ebola-drug-trials-liberia-guinea [Accessed 
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Passive immunotherapy with serum from Ebola survivors 
The WHO is also considering using human convalescent plasma, whole 
blood and other therapies derived from the blood of Ebola survivors as 
treatment modalities53. The current epidemic has about 9000 survivors who 
could be followed up as potential blood donors. It has also been  observed 
that many communities in Western Africa have low levels of latent infection 
through ingestion of fruits contaminated with the saliva of infected fruit bats 
and hence may have protective antibodies in their serum54. The prevalence 
of these antibodies varies from as low as 3% in the coastal population to as 
high as 34% in some of the communities living close to jungles. This might 
indicate towards some form of acquired immunity being present in 
population groups of Western Africa but the antibody titers are not high 
enough to be used as passive immunotherapy. Another challenge is to test 
the sero-prevalence of protective antibodies in the West African population 
as well as in survivors of the current epidemic. This will pose practical, 
logistic and cultural difficulties due to the meaning attributed to bodily 
fluids including blood. The Antwerp Institute for Tropical Medicine is 
leading a trial in Guinea with convalescent serum from survivors as 
treatment for Ebola patients55. Any experimental intervention with blood 
transfusion must be carefully weighed against the risk of other blood 
transfusion related infections being transmitted such as HIV, syphilis and 
                                                          
53 Ibid. 
54 D. G. McNeil Jr. 2014. Many in West Africa May Be Immune to Ebola Virus. The New 
York Times 5 September. Available at: http://www.nytimes.com/2014/09/06/health/ebola-
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55 D. Mohammadi, op.cit. note 50. 
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Malaria. Screening each blood sample for variety of infections will require 
robust blood safety infrastructure which is clearly lacking in these countries 
at the moment. Hasty and almost reactive use of blood transfusion from 
Ebola survivors to Ebola infected patients as an interim treatment option 
could do more harm than good given that we do not know whether antibody 
titers present in the blood of survivors are sufficient to protect infected 
patients, or indeed how many units of blood or plasma will be required to 
provide benefit to patients. Before being treated with Zmapp, the American 
missionary Dr Brently was given a blood transfusion from a 14 year old 
boy56, who had recovered from Ebola. His care givers at Grady Hospital in 
Atlanta stated that his recovery cannot be attributed to this blood transfusion 
or to administration of Zmapp, and may instead be due to good supportive 
care and intensive care monitoring57. (It is worth noting that more useful 
surveillance data would probably been provided had Brently received a 
transfusion or Zmapp, rather than both.) 
 
Candidate vaccines 
Two candidate vaccines are being tested in large phase I trials in healthy 
volunteers in the US, the UK, Switzerland and Mali. The goal of these trials 
is to assess safety and to attempt to determine an appropriate dose for future 
phase II efficacy trials. In order for vaccination to succeed as a prevention 
strategy, it requires adequate time for seroconversion and a certain level of 
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57 Ibid. 
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saturation in the population to break the transmission of infection via herd 
immunity.  
 
Trial design 
Thus it is clear that we do not have many treatment options that are proven 
safe and efficacious in humans, which could be produced under GMP on a 
large scale and could be transported, stored under optimal conditions and 
administered to the affected populations in Western Africa in the near future 
to curtail the current epidemic. Even if one of these treatment strategies 
reaches the stage of being tested in clinical trials, this experimental 
intervention will have to be treated as a scarce resource and priority criteria 
will need to be set before undertaking such research in a population affected 
by Ebola.  
Parallel to clinical trials in healthy volunteers it has been 
recommended that randomized clinical trials should be conducted among 
the affected population to assess the efficacy of these drugs and vaccines58. 
This is important for two reasons. First, given the sporadic nature of the 
epidemic, the candidate drugs and vaccines should be tested in settings 
where naturally occurring infection is present59. Second, randomization of 
the limited supply of experimental drugs enables optimal use of a scarce 
resource, provided we have well designed clinical trials, meticulous interim 
trial data analysis and robust data safety monitoring boards60.  
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59 Ibid 
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However, there has been ongoing debate on whether traditional RCT 
design is ethically acceptable in the context of this epidemic, or whether 
some other modified trial designs should be used in order to ensure fair 
distribution of available experimental interventions, while also providing 
meaningful results and being acceptable to all the stakeholders and 
communities involved61 62 63 64. Transparency and ethical consensus should 
guide these decisions or we run the risk of further losing the trust of the 
local communities affected by the disease65. While randomization might 
produce a higher standard of evidence, if the trial design is not sensitive to 
the needs of the community, recruitment of participants will be challenging. 
It is likely that adaptive randomized designs will provide acceptable 
solutions ensuring scientific validity of results while also meeting the needs 
of the community. 
 
Who are the health care workers? 
Many countries in West Africa have health systems which need major 
strengthening. Apart from a lack of physical infrastructure, diagnostic and 
therapeutic facilities, supply of drugs, and other materials required for 
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62 C. Adebamowo, O. Bah-Sow, F. Binka, et al. Randomised controlled trials for Ebola: 
practical and ethical issues. The Lancet 2014 ; 384(9952): 1423-1424. 
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infection control, they also have extremely limited health care work force as 
is evident from physician to patient ratio of 86,000 patients per physician in 
Liberia and 45000 patients per physician in Sierra Leone66. As we have 
already highlighted, this epidemic has taken a major toll on health care 
workers, with an average case fatality of 57% as compared to an average 
case fatality of 39% in the general population.  
A health care worker is any person involved in the provision of care 
for patients infected with Ebola in formal health care settings. There are also 
non-medical care givers in home settings, such as immediate family 
members; unfortunately, the question of whether they should be included in 
the group of “health care personnel” when it comes to defining priority 
access to experimental interventions is beyond the scope of this paper. By 
health care workers we mean everybody in a health center or a treatment 
facility providing care and treatment for patients suspected or diagnosed 
with Ebola from admission to the center till the burial in case of death. 
These include doctors, nurses, laboratory staff, cleaning staff, and other 
support staff in centers such as laundry workers, ward assistants, security 
guards, those handling hospital waste, those handling the bodies of dead 
patients in the hospital, and those involved in assisting the families in burial. 
There is also another cadre of health workers who are mostly volunteers: 
young men and women who work as community outreach staff. These 
volunteers speak the local languages and assist foreign aid workers and 
hospital surveillance teams to go into communities to identify and isolate 
suspected cases and follow up contacts. These workers play a crucial role in 
                                                          
66 C. del Rio et.al, op. cit. note 5, p.1. 
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community based surveillance and form the bridge between the community 
and health care services. Though the risk profile of each of these categories 
of people involved in health care provision varies slightly, they all form a 
team of people who are at the forefront of fighting Ebola outbreak. We also 
want to highlight that these might include a few foreign professionals and 
experts but a large proportion of these are local health care workers and 
rather than differentiating them as foreign or local, we want to consider 
them as a group of health care workers who need to be protected.  
 
Why should health care workers be prioritized? 
Our main thesis is that the health care workers who are at the forefront of 
treating Ebola patients in the countries affected by this epidemic are at 
greatest risk and should therefore be given priority for the administration of 
experimental drug or candidate vaccines during phase I/II trials, and should 
also receive priority treatment once clinical trials have established the 
efficacy and safety of these interventions. In addition to their being at higher 
risk, treating them can in turn confer the greatest benefit to others, and they 
are more likely to understand the risks of participation in early expedited 
clinical trials and its modified study design. In the following text, we set out 
the reasons underlying these three main arguments. 
Health workers working in local health facilities run the highest risk 
of being infected with Ebola due to their exposure to patients in various 
stages of disease progression and to lack of adequate infection control 
measures. Though effective, the barrier method of infection control is not 
always possible in the field because of inadequate supply of PPE, rubber 
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gloves, other barrier clothing and aprons and supplies for infection control67. 
It has been noted that physical exhaustion, mental fatigue, emotional strain 
and working in hot conditions while wearing PPE are a few reasons that 
make health care workers more likely to get contaminated particularly while 
taking off PPE at the end of their work shift in treatment centers68. Local 
Ebola experts such as Dr Khan in Sierra Leone died during the epidemic, 
further weakening local expertise69. Many health care workers have seen 
their colleagues become infected and die through weeks and months of this 
epidemic and that has taken emotional toll on them resulting in many who 
decided to leave their jobs. But there remain others, such as one nurse who 
is still continuing to fulfil her responsibility even after witnessing the death 
of 15 of her nursing staff70. Apart from provision of necessary protective 
equipment and supplies for supportive care, it is important that these 
healthcare workers themselves feel safe and cared for. The assurance that 
the global community is taking solid steps to provide them with safety and 
protection will boost their morale.  
                                                          
67 W. A. Fischer, op.cit. note 41. 
68 Ibid. 
69 A. Pollock. 2014. Opting Against Ebola Drug for Ill African Doctor. The New York 
Times 12 August. Available at: 
http://www.nytimes.com/2014/08/13/world/africa/ebola.html?_r=0 [Accessed on 05 Jan 
2015]. 
70 A. Nossiter. 2014. Those Who Serve Ebola Victims Soldier On. The New York Times 23 
Aug. Available at: 
http://www.nytimes.com/2014/08/24/world/africa/sierra-leone-if-they-survive-in-ebola-
ward-they-work-on.html [Accessed on 05 Jan 2015]. 
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 We believe that both local and foreign health care workers in the 
field should get priority access to experimental interventions if they become 
infected and to any experimental vaccines as part of the proposed clinical 
trials. This conclusion is based on the following reasoning: First, their 
continuing actions towards patient care despite major risk to their own lives 
should be valued and reciprocated. The assurance that they will be cared for 
in whatever way possible, either by vaccination or experimental 
interventions, will boost their morale and dedication to their work, and 
could prevent further loss of health workers due to fear of getting infected.  
 Second, the need for nondiscrimination within the health care work 
force while considering access to experimental interventions should also be 
highlighted. Along with local health care workers, there are some foreign 
health care workers working in Ebola-affected countries as part of various 
international health care organizations and faith based organizations. MSF 
has been vocal on the need for support to carry out their work in these 
countries71. International organizations often airlift their staff in disaster, 
emergency and epidemic situations for the sake of their safety. This was 
what happened to two American health workers who were treated with 
Zmapp and airlifted to the US. These decisions are made by the 
international organizations and the nations whose citizens are stationed in 
these field assignments often have strong political and financial 
commitment to protect their citizens. But the local health care workers and 
their governments who are struggling to combat the epidemic do not have 
such means to ensure the safety of their staff at their disposal. This is 
                                                          
71 Lancet editorial, op.cit. note 1, p.637. 
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evident in the fact that the local health work force has sustained the major 
impact of this epidemic in terms of both infection rate and mortality rate72. 
Discrimination against health care workers based on their employer or 
nationality can only demotivate local health care staff leading to loss of 
health work force due to frustration or fear and will further negatively affect 
the local health system. While foreign and local health workers have equal 
basic moral claim on access to experimental drugs, a further argument could 
be made based on the fact that foreign workers are likely to benefit from a 
superior standard of care in their own countries. This might be used to 
claim that local workers who do not enjoy such advantages should be 
prioritized to receive experimental interventions. It should be noted that not 
all foreign health workers come from the US, the UK or other developed 
countries, and it should not be assumed that they will always have access to 
better care and treatment facility in their home countries73. Therefore, rather 
than arguing in favor of foreign or local health workers, we recommend 
prioritization of all health care workers for inclusion in clinical trials of 
experimental interventions. Furthermore, some foreign workers may choose 
to be airlifted to their home country instead of taking the risk of being 
included in a trial of an experimental intervention and are obviously free to 
do so as long as their employers or charity organizations bear the cost of 
                                                          
72 WHO, op.cit. note 6. 
73 D Trotta. 2014. Cuban doctor in Sierra Leone tests positive for Ebola. Reuters 19 Nov. 
Available at: 
http://www.reuters.com/article/2014/11/19/us-health-ebola-cuba-
idUSKCN0J308820141119. [Accessed on 05 Jan 2015]. 
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their evacuation and treatment. If many foreign workers choose this option 
it will allow more local workers to be included in trials. 
Third, non-discriminatory access for local and foreign health care 
workers is warranted because both play important roles. We should 
remember that foreign health care workers cannot perform their medical 
duties without support and insight from locals. Local health workers not 
only provide medical care, but are also the link between the foreign health 
workers and local communities; they speak the local language, understand 
local customs and beliefs and often act as intercultural communicators. This 
is a valuable resource in itself and their vast experience of the local field 
reality will be critical to maintain the trust of local communities, to work 
with these communities to control the epidemic. This can be very well seen 
in terms of communities’ attempts to hide sick family members or 
individuals. Local health workers are much more likely to understand local 
community beliefs in addition to western biomedical and epidemiological 
principles of epidemic control. Without this expertise, it will be virtually 
impossible to put an end to this epidemic and hence this work force deserves 
protection and support.  
In addition, local health care workers are likely to return to work 
faster than the foreign health workers and will continue to work in the field 
even when the epidemic has ended and foreign experts have left the field. 
Furthermore, the local health care workers who survive this epidemic will 
be an invaluable and experienced resource in future epidemics in these 
countries as well as in neighboring countries in Africa.  However, we are 
also aware of the fact that without assistance of foreign health workers and 
Ebola experts, the local health work force alone cannot combat this 
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epidemic. Rather than prioritizing one group over the other, we argue that 
both local and foreign health care workers should be treated as valuable 
resource and provided adequate protection, opportunity and access to 
experimental interventions.   
 Use of experimental interventions (in a randomized controlled  trial, 
or modified RCT design) that have only been tested on animals or have 
limited human data also requires good understanding of the risks involved 
on the part of research participants. The severity of the current epidemic and 
the resulting loss of human life are likely to influence the ability of the 
general population infected and affected by the epidemic to fully understand 
the experimental nature of the intervention and the risk involved including 
serious adverse reactions and deaths. If an experimental intervention is used 
on a large scale in population and many ill patients die, this could have a 
serious backlash on whole effort to provide possible care and to control the 
epidemic (whatever the reason for the deaths; lack of efficiency of the drug, 
severe adverse reactions or simply because the disease had progressed too 
far before the treatment could be given). The widespread belief that poor 
patient populations in developing countries have been used unethically in 
clinical trials by Western pharmaceutical companies could be further 
reinforced, and communities might further lose their trust in Western 
medicine. Against this backdrop, health care workers are in a better position 
to understand the nuances of use of experimental interventions for the first 
time in humans in a public health emergency such as this epidemic. Their 
knowledge of medicine, disease pathology, clinical trials and risks makes it 
more plausible to obtain valid ‘informed consent’ from them, whether in a 
trial or in clinical care. This third argument applies equally to foreign and 
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local healthcare workers. We are not stating that it is impossible for the 
general population to understand the risk of such experimental 
interventions, hence making it impossible to obtain their true informed 
consent. Rather, given the impact of this epidemic on communities and 
families who have lost their loved ones and have very limited financial 
resources, the conditions under which they decide to participate in clinical 
trials are far from ideal. In contrast, healthcare workers have additional 
expertise that makes it more likely that they will be able to provide informed 
consent. 
 
Potential constraints and challenges 
We are well aware that our arguments to prioritize the health care work 
force for access to experimental interventions in case of infection may be 
criticized for a few reasons. One ethical concern will be the fact that one 
profession gets priority over all other suffering people and this could be 
seen as an utilitarian approach.  However, the point can be made in response 
that saving healthcare workers will ultimately allow more members of 
public to be saved. We do not claim that health care workers are more 
important than the general population, but we cannot protect and care for the 
general population without adequate and healthy health work force, and it is 
in the interests of ordinary citizens to prioritize healthcare workers for 
treatment.  
A second practical concern relates to the financial resources required 
to get access to the experimental drugs. We will need an international 
response including financial commitment to break the transmission cycle of 
Ebola for the simple fact that the epidemics such as these do not remain as 
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burden of only the affected countries but rather have global impact and 
hence need a global action and commitment74.  
A third challenge will be to use the resources in an ethical manner 
whether it is in terms of financial aid or supply of vaccine or drug in 
donation. Having pre-set and agreed upon criteria for fair and transparent 
distribution of drug doesn’t mean it will be implemented in the same 
manner. Local corruption, power dynamics and hierarchies among the 
health care professionals as well as between the rich and the poor of the 
country, it will take well-coordinated and well-monitored system to ensure 
optimal and just distribution of resources.  
 
Conclusion 
The transmission of Ebola cannot be combated without supporting and 
strengthening human resources in healthcare in West-Africa. Healthcare 
workers should be prioritized for enrolment in clinical trials with 
experimental drugs or vaccines because they are at greatest risk, treating 
them can confer greatest benefit to others, and they are more likely to 
understand the risks of participating in such trials of experimental 
interventions with limited or no prior data of safety and efficacy in humans.   
                                                          
74 Lancet editorial, op.cit. note 1, p.637; T.R. Freiden et.al, op.cit. note 10, p.2 ; A.S.Fauci, 
op.cit. note 11, p.3.  
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Abstract 
In 2006, the Indian Council of Medical Research (ICMR) published its 
‘Ethical guidelines for Biomedical Research on human participants’. The 
intention was to translate international ethical standards into locally and 
culturally appropriate norms and values to help biomedical researchers in 
India to conduct ethical research and thereby safeguard the interest of 
human subjects. Unfortunately, it is apparent that the guideline is not fit for 
purpose. In addition to problems with the structure and clarity of the 
guidelines, there are several serious omissions and contradictions in the 
recommendations. In this paper, we take a close look at the two key 
chapters and highlight some of the striking flaws in this important 
document.  We conclude that ethics committees and national authorities 
should not lose sight of international ethical standards while incorporating 
local reality and cultural and social values, as focusing too much on the 
local context could compromise the safety of human subjects in biomedical 
research, particularly in India. 
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Introduction 
In recent years, India has developed as a key hub for conducting clinical 
trials. This has been attributed to various factors, including: the interesting 
disease profile of its population; the rising prevalence of chronic and life 
style diseases, along with a high burden of infectious diseases like 
tuberculosis, HIV, and malaria; a vast treatment-naïve population; the 
manpower and infrastructure to conduct clinical trials at significantly lower 
cost; and weak government policies and regulations. All of these factors 
attract large number of international pharmaceutical companies to conduct 
trials here.1 This has also led to a number of controversies and protests by 
the local NGOs and health activists.2 The Government and particularly the 
Supreme Court of India have taken a strong stand against international 
pharmaceutical companies in recent months, as was evident in a lawsuit 
against Novartis, whose plea for extension of patent for Glivac was rejected 
by the Supreme Court. 345 Furthermore, the deaths of young girls in HPV 
vaccine trials has created another ethical debate concerning whether these 
trials should have been allowed to take place6 and whether procedures were 
meticulously followed to ensure safety of human subjects.7 Recently, in a 
statement issued by the Ministry of Health and Family Welfare, the Health 
                                                          
1 K.L.Bairy & P.Pereira. Accreditation of human research protection program: An Indian 
perspective. Perspect Clin Res2012; 3: 80-84. 
2 PTI. 2013. Protest against Novartis' attempt to obtain patent for Glivec in India.The Hindu 
Businessline 24th Feb: 
3 EP News Bureau. 2013. New rules on compensation to make clinical trials in India 
'virtually impossible': ISCR. The Express Pharma. 7th Feb: 
4 K. Jayraman. Gleevec loses Indian patent battle. Nat Biotechnol 2013; 31:371. 
5 K. Kulkarni & S. Mohanty. 2013. Novartis loses landmark India patent case on Glivec. 
Reuters 2nd Apr: 
6 P. Shetty. 2012. Indian HPV Vaccine Trial should never have happened. Nature Newsblog 
21June: 
7 Alliance for Human Research Protection (AHRP). 2011. Report Blasts Unethical HPV 
Vaccine Trial in India. New York, NY: AHRP. Available at: 
http://www.ahrp.org/cms/content/view/805/52/ [Accessed 24th May 2013]. 
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Secretary stated that in the last seven years 57303 human subjects were 
enrolled in clinical trials of 475 new drugs, 39022 subjects completed trials, 
and 11972 serious adverse events (excluding deaths) were reported; 2644 
deaths were reported out of which 80 could be attributed to trial drugs.8 
These numbers may be only the tip of iceberg. The ethical issues underlying 
clinical research in India are very complex and have only rarely been 
discussed in the literature. Therefore, we decided to review the ethical 
guidelines issued by the relevant Indian authorities to attempt to increase 
our understanding of the situation; what we found was troubling. 
The third version of the ‘Ethical guidelines for Biomedical Research 
on Human Participants’ was published by the Indian Council of Medical 
Research (ICMR) in 2006.9 Although no clear reasons were provided for 
developing this guideline, the introduction states that it accounts for ‘unique 
challenges faced in India to translate universal ethical principles to 
biomedical research in multicultural Indian society with multiplicity of 
health care systems of considerably varying standards’. The introduction 
also states that universal ethical standards should not be violated while 
conducting biomedical research in India and that researchers need to 
consider local cultural values while applying the universal ethical principles 
of autonomy and informed consent.  
While this intention to translate universal ethical values and 
principles into local culturally and socially sensitive values is admirable, 
there may be a danger of becoming too local and hence compromising 
                                                          
8 D. Mahapatra. 2013. 2,644 died during clinical trial of drugs in 7 years: Govt to SC. The 
Times of India. 25th Apr. 
9 Indian Council of Medical Research (ICMR). 2006. Ethical Guidelines for Biomedical 
Research on Human Participants. New Delhi, India: ICMR. Available at: 
icmr.nic.in/ethical_guidelines.pdf [Accessed 24 May 2013]. 
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universal ethical standards. Careful study of the document raises doubts 
about whether it succeeds in providing clear ‘guidelines’, both in terms of 
applying universal ethical standards and translating these into the local 
context.  
In this paper, we critically analyze two chapters of the ICMR 
guidelines and argue that the text lacks clarity and consistency, is written in 
a complex language with long convoluted sentences which can be 
interpreted in number of ways, is vague about ethical issues and standards 
and does not provide concrete ‘guidance’ for biomedical researchers. We 
highlight a few general and specific problems in these two chapters and 
argue why these could be problematic; they leave a number of loopholes in 
the guideline that would allow researchers to escape responsibility for 
unethical research. Finally, we provide suggestions for improving the 
document.  
 
OVERALL STRUCTURE OF THE ICMR GUIDELINES 
This 111 page document can be found on the ICMR website in the 
publications section under the subheading Ethics 
(http://icmr.nic.in/ethical_guidelines.pdf). The document is divided into two 
main parts: The first provides a Statement of General Principles on 
Research using Human Participants in Biomedical Research, and the second 
revolves around Specific Principles on Research using Human Participants 
in particular areas of biomedical research such as clinical evaluation of 
drugs/devices/diagnostics,/vaccines/herbal remedies/Ayurvedic, Siddha and 
Unani medicine, epidemiological studies, human genetics and genomics 
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research, research in transplantation and assisted reproductive technology. 
For the purposes of this paper, we focus on the first two chapters of this 
guideline, which are the Statement of General Principles and the ethical 
review procedure. For each of these chapters, we will first describe general 
issues and then address more specific problems. 
 
STATEMENT OF GENERAL PRINCIPLES ON ETHICAL 
CONSIDERATIONS INVOLVING HUMAN PARTICIPANTS. 
General issues 
This chapter is written in a very unusual style that was difficult to 
understand. Twelve ethical principles are provided, ranging from 
‘essentiality’ to ‘totality of responsibility’ (see Box). It is interesting to note 
that many of these principles are never used in the international literature. 
This document does not elaborate on the source of or the reasons for 
choosing these twelve principles. It could be seen as an effort to 
accommodate the local and cultural needs specific to the Indian context by 
expanding these principles. However, it remains unclear whether this long 
list actually adds anything new that is not covered by existing international 
guidelines or indeed whether it actually protects research participants in 
India. Furthermore, the language used to describe the principles is 
ambiguous. Even if we keep in mind the fact that this chapter only 
highlights the ethical principles, the use of sentences as long as a full 
paragraph leave the reader somewhat confused, even after close reading. If 
this is the situation for readers trained in ethics, a lay person would probably 
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encounter even more difficulty. As an example, here is the first general 
principle: 
Principles of essentiality whereby the research entailing the use of 
human participants is considered to be absolutely essential after a 
due consideration of all alternatives in the light of the existing 
knowledge in the proposed area of research and after the proposed 
research has been duly vetted and considered by an appropriate and 
responsible body of persons who are external to the particular 
research and who, after careful consideration, come to the 
conclusion that the said research is necessary for the advancement of 
knowledge and for the benefit of all members of the human species 
and for the ecological and environmental well-being of the planet. 
 
Research guidelines are often written for diverse audiences including 
doctors, nurses and trial coordinators; they aim to provide guidance in a 
technically correct, simple and clear format. This chapter obviously falls 
short in terms of both these objectives. Another problem with this writing 
General Ethical Principles: 
1. Principles of essentiality 
2. Principles of voluntariness, informed consent and community agreement 
3. Principles of non-exploitation 
4. Principles of privacy and confidentiality 
5. Principles of precaution and risk minimization 
6. Principles of professional competence 
7. Principles of accountability and transparency 
8. Principles of the maximization of public interest and of distributive justice 
9. Principles of institutional arrangements 
10. Principles of public domain 
11. Principles of totality of responsibility 
12. Principles of compliance 
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style is that one could interpret the same statement differently based on 
interpretation of grammar, leaving great scope for selective interpretation of 
principles. It is unclear why the opening and arguably most important 
chapter of this guideline was written in this way, given that there is a high 
risk that people might give up reading the guideline further, even though the 
rest is written in much simpler format. In short, this chapter discusses 
almost everything from the wellbeing of the planet to the mutatis mutandis 
nature of informed consent, but leaves everything extremely vague, unclear 
and prone to misinterpretation. A cynic might suggest that the guideline is 
deliberately vague so almost any biomedical research involving human 
participants being planned in India could get ethical clearance, thus 
safeguarding the interest of the research and industry lobby. 
 
Specific issues 
Although we could critically comment on each of these 12 principles, we 
will instead focus on and highlight only three of these principles and 
demonstrate how they can be misinterpreted or selectively interpreted. It 
must be noted that there is no specific mention of the individual importance 
of each of these 12 principles, so it is unclear whether they are of equal 
importance or are arranged in order of importance, or which principle 
should prevail if there is a conflict between two principles, and what process 
should guide this.  
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Principles of voluntariness, informed consent and community agreement 
This is the most elaborated principle of the twelve and has a few clear 
strengths in terms of addressing the information given to the participants, 
their right to withdraw, competence and the voluntariness of consent 
procedure. But it raises an interesting question about treating the community 
as a research participant:   
‘….Where any such research entails treating any community or 
group of persons as a research participant, these principles of 
voluntariness and informed consent shall apply, mutatis mutandis, to 
the community as a whole and to each individual member who is the 
participant of the research or experiment…’ 
The first problem with this passage is that many readers will not understand 
the meaning of this Latin phrase. The second is that it is unclear what it 
would mean to treat an entire community as a research participant. The third 
is that “mutatis mutandis” means that only aspects that need to be changed 
should be changed, which does not provide any meaningful guidance 
whatsoever. As such, this sentence is almost entirely useless. 
However, towards the end of this paragraph, the guidelines state that 
‘the nature and form of the informed consent and the evidentiary 
requirement to prove that such consent was taken shall depend on degree 
and invasiveness of research….Ethics committees shall decide on the form 
of consent to be taken or its waiver based on the degree of risk that may be 
involved.’ This raises a number of issues such as how risk should be 
evaluated by Institutional Ethics Committees or Institutional Review Boards 
(IECs/IRBs) while conducting ethical review of research projects, which is 
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in the focus of the second chapter of this guideline. This section of the 
guidelines is perhaps attempting to translate the international ethical 
standard for informed consent to the local and cultural needs of India. 
However, doing so undermines the rights of the research participant by 
stating that the IECs will decide and instruct the researchers on the nature 
and form of informed consent to be obtained and of the evidentiary support 
that such consent was obtained. In HPV vaccine trials, those in charge of the 
hostels where these young girls were living gave “informed” consent on 
behalf of the girls;1011 this was considered adequate despite clearly falling 
short of international standards. Parents of the girls were not even aware 
that the girls were part of research and were given a trial vaccine. Perhaps 
the IECs thought that vaccination as part of a phase IV trial was not a 
substantial risk and that it was therefore sufficient to obtain blanket consent 
from the hostel warden rather than contacting the parents of the girls, who 
might be illiterate and hence unable to understand the nature of the research. 
Alternatively, they may have thought that approaching parents for consent 
for the HPV vaccine could be culturally inappropriate and problematic since 
it implies sexual activity among adolescent girls (and women) which is a 
taboo subject in India, meaning that the parents would be reluctant to give 
such consent. If this is the translation of international ethical standards as 
per the local cultural norms, it feels more like an interpretation of 
convenience rather than a need- based local translation. Thus, the current 
guideline actually supports what was done in the HPV vaccine trial if 
                                                          
10 Aarti Dhar. 2012. Government warns PATH. The Hindu 25 August: 
11 SAMA: resource Group for Women and Health. 2010. Trial and Error: Ethical Violations 
of HPV Vaccination Trials in India. New Delhi, India. Available at: 
http://samawomenshealth.wordpress.com/2010/05/17/trial-and-error-ethical-violations-
of-hpv-vaccination-trials-in-india/ [Accessed 24May 2013]. 
178 
 
looked at from this perspective. But the question remains: should this be the 
intention of a national guideline designed to protect research participants?  
 
Principles of accountability and transparency 
This principle dictates that research is conducted in a fair, honest, impartial 
and transparent manner. It mandates all those involved in the research to 
fully disclose each aspect of their interest in particular research, including 
any conflict of interest. This makes perfect sense. However, the principle 
further states that ‘…., subject to principles of privacy and confidentiality 
and the rights of the researcher, full and complete records of the research … 
should be retained for a reasonable period…’ The principle of privacy and 
confidentiality is elaborated as principle number IV but there is no explicit 
mention of the rights of the researcher anywhere in this chapter; nor is there 
any reference to it. It is unclear both what these researcher rights are, and 
how are they linked to preserving all the research data and notes for a 
predefined period of time and making this data available for scrutiny by 
other researchers or the appropriate legal or regulatory bodies. The phrasing 
of the sentence, with ‘subject to’ could also be read as implying that the 
principle of privacy and confidentiality and the rights of the researcher 
prevail over the requirement to preserve the research notes and making them 
available for scrutiny by appropriate bodies; as such, this principle could in 
fact facilitate research misconduct by allowing it to remain hidden. 
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Principles of totality of responsibility. 
This interesting principle is stated as one single long statement broken down 
with numerous commas and clauses. Fundamentally, it states that the 
responsibility of ethical conduct of particular research falls on everyone 
involved directly or indirectly with the research:  
Principles of totality of responsibility whereby the professional 
and moral responsibility, for the due observance of all the principles, 
guidelines or prescriptions laid down generally or in respect of the 
research or experiment in question, devolves on all those directly or 
indirectly connected with the research or experiment including the 
researchers, those responsible for funding or contributing to the 
funding of the research, the institution or institutions where the 
research is conducted and the various persons, groups or 
undertakings who sponsor, use or derive benefit from the research, 
market the product (if any) or prescribe its use so that, inter alia, the 
effect of the research or experiment is duly monitored and constantly 
subject to review and remedial action at all stages of the research 
and experiment and its future use. 
It is commendable that this statement of responsibility is so inclusive, but 
what does this all really mean? If everyone is responsible, it is easy to pass 
the buck from one responsible member to the other till one finds the 
weakest scapegoat who can be blamed when something goes wrong. In a 
country like India, when everyone is responsible, this often translates in 
reality as no one is really responsible for anything, because everyone thinks 
that somebody else is responsible. The suggestion that those who use or 
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derive benefit from the research are also responsible is also problematic. It 
seems bizarre to argue that patients or research participants who benefit 
from having access to care and treatment by just being part of the 
research12, are also responsible for ethical conduct of the research. 
The issue of who is responsible for the ethical conduct of research 
becomes a particularly interesting question when something goes wrong 
with the research or with the research participants, resulting in serious 
adverse events or death. In many previous cases in India, the ball of 
responsibility for research/trial related deaths is often passed from one 
stakeholder to the other and eventually to research participants, and matters 
are covered up. This was the case with the lack of ethical standards around 
informed consent and deaths in HPV vaccine trials. According to this 
guideline everyone is slightly responsible and thus no one is truly 
responsible.  
 
ETHICAL REVIEW  
General issues 
Responsibilities of Institutional Ethics Committees (IECs) 
The document defines the responsibilities of IECs as follows: 
• Conducting competent and objective review of ethical aspects of 
submitted research proposals 
• Conducting scientific review of submitted research proposals in case 
there is no separate body to carry out such scientific assessment.  
                                                          
12 J. Y. Shah &et al. What Leads Indians to Participate in Clinical Trials? A Meta-Analysis of 
Qualitative Studies. PLoS one 2010 ; 5 : e10730. 
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• Advising researchers on safety and well-being of research 
participants 
• Protecting dignity, rights and well-being of research participants 
• Ensuring that universal ethical values and international scientific 
standards are expressed in terms of local community values and 
customs 
• Assisting in the development and education of research community 
responsive to local health care requirement. 
It is good to clarify various responsibilities of IECs beyond the ethical 
review process such as their advisory role and role in capacity building for 
the local research workforce, but no further details are provided how this 
can be achieved in practice. Two of the responsibilities above need further 
discussion. The first is the segregation of the scientific and ethical aspects of 
the research proposal being reviewed. It is not clear that the scientific and 
ethical aspects of any given research proposal can be separated in this way; 
scientifically weak research is itself unethical.13 The other aspect concerns 
expressing international scientific standards and universal ethical principles 
in local values and customs. We believe that this responsibility should not 
be put on IECs, which are often local and affiliated with research institute 
and public hospitals attached to medical schools. In a country as large and 
diverse as India, this might lead to varied and multiple translations of 
‘universal’ into ‘local’ thus losing the essence of universal ethical standards. 
It would be more appropriate to carry out this task at national or at least 
                                                          
13 David Shaw & Bernice Elger. The relevance of relevance in research. Swiss Med 
Wkly2013; 143: w13792. 
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regional level so that such translation of ‘universal’ to ‘local’ ethical 
standards and values is carefully discussed. 
 
Constitution of IEC/IRB 
The guideline states that IECs/IRBs should be multidisciplinary and 
multisectorial and have independence and competence as their core values. 
It is recommended that the chairman of such committee should be from 
outside the institution to maintain the independence of the committee, but 
that the secretary who is responsible for the day-to-day organization and 
function of the IEC should be from the same institution. Though an IEC 
should include experts, patient representatives and lay people, a large 
responsibility is put on the secretary. It is the secretary who assesses the 
level of risk involved in each submitted research proposal, which is the 
basis for deciding whether the proposal is eligible for exemption from 
review, or requires expedited review or complete review (see below). 
During the review process, it is also suggested that the secretary and the 
chair can review the proposals for expedited review and pass the summary 
of this review to other IEC/IRB members. Given that the secretary is 
expected to review proposals, this cannot be a mere secretarial position; a 
member of the administrative staff would lack the necessary training to 
scientifically or ethically review proposals. Even if the secretary is 
medically or scientifically qualified, one must keep in mind the particular 
hierarchical work culture in India and the power relationships between 
secretaries and their superiors. In this context, it is questionable whether a 
secretary can really speak up for him or herself especially if his/her views 
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are clearly not in line with those shared by the chairman of the committee. 
The role of the secretary also raises questions about the independence of the 
review process. In their current state, the guidelines suggest that a secretary 
could themselves review all the proposals sent to a committee by identifying 
them as minimal risk even if they were potentially very harmful; given that 
the secretary can be a staff member at the institution that wishes to conduct 
the research, this is ethically problematic.  
 
Training of IEC members 
The guidelines state that IEC members should keep themselves updated on 
all national and international developments in ethics by undergoing regular 
training. However, it is not stated who should organize, certify, or monitor 
the quality and content of these training programs, and how many hours per 
year each committee member should spend on training. The guidelines 
further state that for drug trial review, it is preferable to train IEC members 
in Good Clinical Practice, but it is not stated which GCP document is being 
referred to, given that India has its own document called Indian Good 
Clinical Practice.14 One could also ask whether being trained in ICH-GCP is 
enough for the IEC members to be able to conduct ethical review of drug 
trials competently, given the inherent weaknesses of that document.15 
Furthermore, the only mention in the ICMR guidelines of the Declaration of 
Helsinki, which is one of the key international documents on ethics and 
human subject safety, is in the form of its note on clarification on paragraph 
                                                          
14 Central Drugs Standard Control Organisation (CDSCO). 2001. Good Clinical Practices For 
Clinical Research in India. New Delhi, India. Available at: http://cdsco.nic.in/html/GCP.htm 
[Accessed 24 May 2013]. 
15 David Shaw & Alex Mcmahon. Ethicovigilance in Clinical Trials. Bioethics 2012. 
doi: 10.1111/j.1467-8519.2012.01967.x 
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30, which was added by the WMA General Assembly in Tokyo in 2004. 
The omission of any mention of the importance of this key international 
standard for the protection of research participants is troubling. 
 
Monitoring, regulation and accreditation of IRBs and IEC (Ind) 
The ICMR guidelines suggest that in cases where there is no appropriately 
constituted IEC, the researchers can submit their research proposals to an 
independent IEC (Ind). It is not clear how IEC (Ind)s are created, function 
or are monitored.  In India, anything that is independent and hence outside 
the realm of regulatory mechanisms and monitoring often features many 
irregularities. Private medical practice in India is a good example of this.  
Even internationally, the quality of ethical review process by independent or 
private IRBs and IECs has been debated.16 It is often argued that private or 
independent ethics committees, by their very structure and organization, 
could have innate conflicts of interest which could diminish their neutrality 
and objectivity in the ethical evaluation of submitted research proposals. 
Given this context, there needs to be detailed discussion on the need for 
private or independent IECs. If IEC (Ind) are perceived to be a necessity for 
those researchers who do not work at Institutions with their own IECs, close 
attention must be paid to how these IEC (Ind)s can be regulated or 
monitored. Recent controversy about trials conducted with ‘mentally 
challenged’ individuals in Indore, India from 2008 to 2010 has highlighted 
the problematic role of commercial/independent IECs in ethical review and 
                                                          
16 T. Lemmens & B. Freedman. Ethics Review for Sale? Conflict of Interest and Commercial 
Research Review Boards. Milbank Quarterly 2000;78: 547-584. 
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approval.17 Mechanisms need to be put in place to ensure that these entities 
can conduct competent ethical and scientific review of submitted proposals. 
Otherwise, there is a danger that the clinical trial organizations might start 
conducting their research and trials in the vast rural areas of the country 
which have no IECs but do have large treatment-naive populations to recruit 
in their research and hence start submitting their applications to IEC (Ind).  
The same questions can be asked about the quality and work of 
appropriately constituted IECs which are affiliated with large institutions 
and teaching medical hospitals.18 What quality control measures are in place 
to ensure that these IECs have competent and well-trained staff and the 
review process conducted by them is rigorous and well documented at every 
stage of the research?  The document suggests that an authority will be set 
up under the proposed bill on ‘biomedical research on human participants’ 
that will require all IECs to register themselves with this authority. This 
authority will be responsible for monitoring functioning of IECs and 
developing mechanisms for enforcing accountability and transparency by 
these IECs. The creation of such an entity needs to be thought through 
adequately, and mechanisms need to be in place to ensure accountability 
and transparency of this authority itself.   
 
 
 
 
                                                          
17 A. Bhan. Clinical trial ethics in India: One step forward, two steps back. J Pharmacol 
Pharmacother 2012; 3(2): 95–97. 
18 R. Kadam & S. Karandikar. Ethics Committees in India: Facing the challenges! Perspect 
Clin Res. 2012; 3: 50-56. 
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Specific issues concerning review procedure 
Definition of minimal risk and categorization of research proposals 
Minimal risk is defined as ‘one which may be anticipated as harm or 
discomfort not greater than that encountered in routine daily life activities of 
general population or during the performance of routine physical and 
psychological examination or tests’(p.11). It is further states that ‘… in 
some cases like surgery, chemotherapy  or radiation therapy, great risks 
would be inherent in the treatment itself, but this may be within the range of 
minimal risk for the research participant undergoing these interventions 
since it would be undertaken as part of current everyday life’ (p.11). No 
references are provided for this particular way of understanding minimal 
risk, which is somewhat idiosyncratic. It is true that radio- and 
chemotherapy pose great risk to patients, but to subject research participants 
to additional radiation or drugs on top of their therapy certainly does not 
constitute minimal risk. If the guideline means simply that including such 
patients in a trial with minimal intervention constitutes minimal risk, then it 
is stating the obvious. If minimum risk is defined in relation to risk in 
everyday life events, is it justified to subject Indian research subjects to 
higher levels risk than would be acceptable in the developed world simply 
because the risk of everyday life events in India is higher than in other 
countries? 
 Minimal risk actually forms the starting point for all the research 
proposals to be categorized into the distinct categories of exempted from 
review, expedited review and complete review. It is unclear how this 
happens in practice, given the vague definition of minimal risk. The 
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guideline defines three different categories of review and each of these 
categories is problematic in itself. Here, we provide few contradictory 
statements related to these categories and the review process. In the 
preamble to ‘full review’ on page 14, the document states that various 
situations and risks involved in research proposals should be evaluated in 
terms of the existing facilities at a given research site. This means that 
depending on a research site, the same research proposal could be seen to 
present minimal risk at a ‘good’ site but more than minimal risk at other 
research sites. Would it thus attract expedited or exempted review in one 
site but full review at the other? The guidelines do not address this point, 
and such a system would be highly unusual. 
 On page 12 the guideline states that the secretary and chair of the 
IEC or a designated member of a subcommittee can conduct an expedited 
review of all proposals which present no more than minimal risk and then 
lists various such situations including research in emergency situation and 
research on disaster management. On page 14, it is stated that all research 
presenting with more than minimal risk and proposals which do not qualify 
for exempted or expedited review shall be subjected to full review by all the 
members. But on page 18, under the heading of review process, it is claimed 
that it should be stated in a committee’s SOP whether the review should be 
done by all members or the primary reviewer(s), in which case a brief 
summary of the project, with informed consent and patient information 
sheet, advertisements or brochures if any should be circulated to all the 
other members. It is not clear who are the primary reviewers and how are 
they selected. How can there be a primary reviewer if all the research 
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proposals should be reviewed by all the members of the IEC? To be fair, 
this could be simply due to bad structure of the document but that seems 
highly unlikely. If we try to reconcile these statements, we could conclude 
that the proposals with no more than minimal risk which are categorized for 
expedited review actually undergo more rigorous review than “riskier” 
proposals subjected to the general review process.  
In the category of expedited review, sub point five states that in 
emergency situation like disease outbreaks or disaster, full review may not 
be possible. In these situations, an expedited review might be acceptable for 
pilot study or preliminary study to understand the safety and efficacy of the 
intervention. But then it further states that the same participants should not 
be included in the clinical trial that may be initiated later based on the 
findings of this pilot study (p12). It is not clear how it can be ethically 
justified that the same participants should not be included in later trials 
especially if the intervention is believed to be useful.  
The section on expedited review also refers to research on 
interventions in emergency situations. According to section 2.5.a., in certain 
emergency situations where no standard therapy exists, a physician might 
try an investigational drug/device/vaccine on patients as an intervention 
when consent of person/patient/responsible relative or custodian/team of 
designated doctors for such an event is not possible (p13, i). It is extremely 
questionable whether a “team of designated doctors” could give meaningful 
informed consent for an emergency intervention, whether for research or 
just for medical care and treatment. Further on, at point IV, the document 
states that such an emergency intervention is acceptable if a data safety 
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monitoring board is constituted to review the data. This confuses matters 
further because it appears that this is related to emergency intervention 
research; if it is ongoing research, why should such emergency intervention 
research not be treated like any other research proposal and require 
complete review, rather than receiving expedited review?  
 
Process of ethical review and decision making  
The document provides details of how research proposals should be 
submitted for ethical review and urges IECs to continue the review process 
after initial approval of the study through periodic, continuing and interim 
review. But the actual review process itself is hardly explained at all, and 
this small section is towards the end of this chapter. It suggests that the 
method for review should be stated in the standard operating procedure 
(SOP), but it is not clear who is responsible for developing these SOPs. This 
might be interpreted as meaning that each IEC can develop its own SOP. 
The SOP would also determine whether the review should be conducted by 
all reviewers or by primary reviewers. The guideline states that the decision 
on approval of submitted research proposal should be made by broad 
consensus but does not state how various aspects should be discussed and 
how various conflicting ethical principles should be balanced before 
reaching a broad consensus.  
 
CONCLUSION 
ICMR set out to develop this guideline with the noble intention of 
translating international ethical principles and scientific standards into 
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locally sensitive and culturally appropriate values to guide all the research 
on human subjects taking place in India. Their effort to have a large number 
of experts and various committees working together on this document, has 
led to number of different voices and writing styles in this document which 
often seems highly influenced by legal language, especially in the first 
chapter. The guideline has multiple inconsistencies and ambiguities that 
may sometimes be attributable to writing style but sometimes appear to be 
intentional and confuse the reader. The vagueness of the guidelines could be 
interpreted as being intended to facilitate research rather than to protect 
participants. At a minimum, the guideline needs to be revised to remove 
these inconsistencies and clarify some of the issues pointed out in this 
paper. We would go further and recommend that an entirely new guideline 
be written ‘from the ground up’ as an urgent priority in order to protect the 
tens of thousands of people who enroll in clinical trials every year in India.  
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Outline 
The aim of this research project was to explore and discuss challenges in the translational 
research of medical applications of nanotechnology with a particular focus on first-in-human 
(FIH) trials. This chapter describes various insights obtained from this research project in 
light of existing socio-political debate. The ecological model theory is used to explain the 
current practice of translational research in nanomedicine and interactions among the key 
stakeholders. An analysis of issues related to ethical and drug regulatory review of 
investigational nanomedicine products indicates that new and special regulation for 
nanomedicine and nanotechnology is not necessary.  Rather, the focus should be on critically 
examining all the procedures in translational research of any cutting-edge technology paying 
particular attention to the rectification of existing loose ends and blind spots in current 
practice. Finally, the discussion of various limitations of this study also indicates specific 
areas that require further research and scrutiny.  
Discussion of results 
The results of this doctoral research are based on the insights obtained from in-depth 
interviews with 46 key respondents from Europe and North America who were involved in 
planning, conducting or reviewing FIH trials in nanomedicine. There is a significant diversity 
in the definition of nanotechnology and nanomedicine and it impacts translational 
nanomedicine. This was discussed in detail in chapter three. Nanoparticles are unique in two 
aspects: the size of particles in ‘nano’ scale and the unique properties materials exhibit at that 
size1. Nanomedicine is understood as application of nanotechnology in the field of medicine. 
However, there is no consensus on what sizes define nanoscale in medical applications2. The 
upper limit of nanoscale in a general discussion of nanomedicines varies from 100nm2, 
300nm3 up to 1000nm4, which creates challenges for ethical assessment, regulatory review, 
toxicity assays and patent examinations5.   
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 Translational research of any cutting-edge technology involves a number of 
challenges. Respondents of this study highlighted three main challenges: financial, ethical and 
drug regulatory that are all discussed in chapter four. The scientists working in universities 
and small and medium size enterprises (SMEs) highlighted their struggle to obtain the 
required funding to initiate FIH trials. Therefore, it is worth exploring the constructive role 
large pharmaceutical industry and philanthropic organizations can play in financing early 
translational research. However, it is equally important to consider strategies for strengthening 
drug regulatory and ethical review processes in nanomedicine in low-resource countries.  
The term ‘nano’ is closely linked with the hype about its potential, the hope that it will 
provide a solution to many health care challenges and fears of potential toxicity6. These 
associations are also reflected in translational nanomedicine. The ‘nano’ nature of an 
investigational product is likely to be highlighted in grant applications, the drug regulatory 
process and the publication of results in eminent journals, but is likely to be withheld in 
patient information sheets and consent forms for FIH trials5. As demonstrated in chapter five, 
inconsistent and convenient use of the ‘nano’ terminology in trial-related documents is 
ethically problematic and can significantly influence patients’ and the public trust in 
nanomedicine and drug development. 
 Another important conflict raised by the responding investigators and ethics 
committee members involved the process of patient selection for FIH trials of nanomedicines 
against cancers (chapter six). The current practice mandates enrollment of patients in the last 
stages of cancer. The stakeholders interviewed in this research project questioned this practice 
and argued for the inclusion of patients in earlier disease stages to ensure the production of 
valid and generalizable knowledge from early clinical trials. 
 Translational research in any cutting-edge technology is also influenced by factors 
unrelated to the technology. In nanomedicine, these factors could be an unmet need for 
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treatment, potential to gain a large market share with a new drug, profitability from a licensed 
blockbuster or the possibility of having the drug included in health care costs reimbursement 
from insurance companies. Sometimes, public health emergencies can trigger faster 
translation of promising vaccine or drug candidates as elaborated in chapter seven. The 
analysis of accelerated clinical testing of experimental drugs and vaccines during the Ebola 
epidemic of 2014 is an example. Though vaccine and drug candidates tested in phase I studies 
during this epidemic were not based on nanotechnology, this case helps understand how a 
serious epidemic with a high infection and mortality rate and the potential to become a 
pandemic can trigger an international collaboration and facilitate policy decisions to initiate 
clinical trials in humans in spite of considerable uncertainty regarding efficacy and the safety 
of experimental interventions. 
 National and international guidelines for clinical research also have a significant 
impact on translational research. A critical analysis of the clinical research guidelines issued 
by the Indian Council of Medical Research (ICMR) was performed to determine the 
guidelines’ adequacy to regulate clinical research in India and to ensure the safety of human 
subjects (chapter 8). Though India has been an international hub for clinical trials until 
recently, the ICMR guidelines do not seem adequate to address research regulation or 
research subjects’ safety.   
Ecological model applied to translational research in nanomedicine 
The current practice and procedures of the translational research in nanomedicine can be 
described using the concept of the ecological model developed by Bronfenbrenner in the 
1970s to explain human development. The ecological model evolved into a theory over the 
next few decades and has been used extensively in ecological and public health research and 
political science7. The ecological model has multiple levels or spheres of influencing and 
interacting factors. The applicability of this model to explain the process of translational 
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research in nanomedicine became apparent during data analysis.  Various actors involved in 
translational nanomedicine were bound by higher-level structures such as guidelines and 
regulations put in place by larger entities such as governments and civic societies. The 
ecological model helped not only in understanding the dynamics among the various actors, 
but also to identify potential interventions to facilitate translational research in much of 
cutting-edge medical technology. Three levels (microsystem, mesosystem and macrosystem) 
of the ecological model critical in translational research in nanomedicine described here help 
in contextualizing the insights obtained from this research within a larger socio-political-
economic and regulatory environment.  
 
1. Microsystem.  
The microsystem is the core of the ecological model and in this study it includes the 
stakeholders who are directly involved in translational research in nanomedicine. They are 
researchers, investigators, health care professionals, clinical research professionals, ethics 
committee (EC)/institutional review board (IRB) members, drug regulatory authorities, 
funding bodies, patent authorities, pharmaceutical industry, patient advocacy groups, 
academic research centers and patients. This list is not exhaustive, but these were the key 
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stakeholders identified while mapping the field of translational nanomedicine for this research 
project. Though these groups can be viewed as 'actors' in translational nanomedicine in 
various combinations and roles, they do not operate independently of each other or out of 
context from the recommended or mandatory regulations and guidelines. 
2. Mesosystem.  
The various guidelines and regulations that control and shape the practices of actors in 
translational nanomedicine (described at the level of microsystem) constitute the mesosystem. 
Again, only a few guidelines and requirements are mentioned here as examples and the list is 
not exhaustive. Mesosystem  includes drug regulatory guidelines, national and international 
ethical standards, social policies that define and influence the focus on a particular technology 
or disease, guidelines regulating drug pricing, rules regarding cost reimbursement by health 
insurance companies, regulations related to work place safety and environmental protection, 
diagnosis and treatment protocols issued by various medical organizations and hospitals, and 
professional codes of conduct for each professional ‘actor’ identified in the microsystem. This 
research did not involve a critical examination of all the potential regulations that shape 
translational research in nanomedicine as this would require an independent research project. 
3. Macrosystem.  
The macrosystem is the largest sphere of influence in terms of scope in the ecological model; 
however, it is also the farthest from the direct influence of the actors (microsystem) in 
translational nanomedicine. This sphere generally includes civic societies and is influenced by 
political and economic environments. Strategies to create an active public support for 
translational research would be situated within the macrosystem and include: public 
engagement, transparency in scientific communication, facilitation and protection of integrity 
in scientific research and safeguards for public trust in science and technology. But there are 
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number of threats to nurturing and building public trust in science and clinical drug 
development and these also fall in the macrosystem. Our research points to some of these 
threats, but a more extensive examination would require further investigation. 
 It is important to note that there is a constant interaction not just among the actors at a 
particular level, but also between the actors from all levels of the model. For example, 
regulations and guidelines from the mesosystem clearly influence the actors in microsystem, 
however, the same actors are also involved in influencing these regulations and guidelines. 
Civic society’s political and economic orientations clearly influence the mesosystem and 
indirectly the microsystem, but both the mesosystem and microsystem can also potentially 
influence civic societies. This is a dynamic model and should be flexible in order to 
incorporate new insights obtained from research and technological development, and the 
newly identified needs of a specific patient population or a professional body. Dialogue and 
collaboration across these levels and effective communication among the members of each 
level is critical for timely and appropriate translation of promising new technology towards 
achieving society’s greater goals of health and human well-being as well as environmental 
safety and protection.   
The results from this research project explained in the beginning of this chapter mainly 
shed light on various challenges faced by the stakeholders who represent the microsystem. 
What follows further encompasses discussion on the role of regulation in facilitating or 
blocking translational research in nanomedicine, thus reflecting on the mesosystem of the 
ecological model. Final discussion on active engagement of the ‘public’ in regulatory debates 
and strengthening the trust in science and technology relates to the macrolevel of the 
ecological model and requires further investigation.  
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Need for regulating nanotechnology  
Nanotechnology—a key constituent of converging technology8 (nanotechnology, 
biotechnology, cognitive science and information technology)—is capable of influencing 
many aspects of life from medicine to energy production. Each application of nanotechnology 
(e.g. medicines, electronics, cosmetics, food industry, and aeronautics) raises unique 
(although not necessarily new) issues that warrant ethical and regulatory discussion. Potential 
harms caused to workers in the nano-electronics industry9 generate different concerns than 
exposure to nanoparticles used in food packaging in terms of the impact, severity and the 
current regulatory oversight. Similarly, when nanotechnology is used for human 
enhancement10, combat warfare, military research, or the creation of super-soldiers11, it raises 
specific ethical and societal concerns. The dual-use potential of nanotechnology to create 
highly virulent pathogens with modified route of transmission to be used as biological 
weapons must also be accounted for when discussing nanotechnology’s impact on health and 
the environment12. Ideally, each of these areas of nanotechnology should be governed by 
specific regulatory oversight; however, these areas are beyond the scope of this research 
project, which focused mainly on impact of nanotechnology on health and medicine.  
It is often noted that the use of nanotechnology in drugs and medical devices is a 
highly regulated process compared to other fields in which nanotechnology is used13. Yet, the 
general public is more concerned about the health risks of nanoparticles used in medicine and 
tends to ignore their exposure to various kinds of nanoparticles in everyday life such as 
automobile exhaust, dust generated by printing, fabrics and clothing that resists stains, paints 
used in buildings to resist dust, and the use of nanoparticles in toothpaste to whiten the teeth14. 
The application of nanotechnology in cosmetics, food packaging15 and as food additives is 
also regulated to some extent (although usually not as rigorously as medicines). One can buy 
and use cosmetics or food products off the shelf in a supermarket without the supervision of a 
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particular authority, whereas nanomedicines can be bought and used only with the valid 
prescription by a treating physician. Another distinction between the consumption of 
nanotechnology-based food additives and medicines is that food is consumed by people 
(young or old) in comparatively higher quantities and over a prolonged period of time 
whereas most nanomedicines are consumed by the patients for the short duration of their 
illness. This influences a person’s exposure to nanoparticles in terms of quantity and duration, 
both of which are clearly linked to toxicity and harm14.    
Making generalized statements regarding the risks and potential toxicity of 
nanoparticles or regulating or de-regulating nanotechnology can prove dangerous since 
nanotechnology encompasses various sub-fields that imply risks of varying types and 
magnitude. Hence different applications of nanotechnology are regulated at specific levels of 
caution16. The nuances of debates on nanotechnology regulation can be especially challenging 
for the general public who may not be familiar with the technical details of nanotechnology or 
its potential risks. Thus, the public can develop misleading or even erroneous perceptions 
about the risks and potential of nanotechnology that can significantly influence their 
acceptance of nanotechnology16,17. This is an intersection between the factors in the meso and 
the macrosystem and requires a careful deliberation and active engagement between societies 
and scientific communities. Regulations alone cannot speak to the public, but the scientists 
and the policy makers who are instrumental in drafting regulations and the policy guidelines 
can create a meaningful dialogue with the public, explain science in simple yet accurate ways 
and include the public’s concerns in their policy deliberations18.  
Nuances in regulation of nanomedicine  
Although many legislators and researchers agree that nanomedicine should be better regulated 
because of its direct impact on the health and well-being of populations19-22, it is important to 
tease out various types of risks and ethical challenges underlying these medicinal applications 
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and ways in which they are being currently regulated. The sections below summarize two key 
components of nanomedicine and demonstrate the need for the distinct approaches in risk 
assessment and appropriate regulations. 
1. Diagnostic tests 
Diagnostic tests with nanoparticles include in-vivo tests, where the nanoparticles enter human 
body, or in-vitro tests where only a sample of human tissue or blood is in direct contact with 
nanoparticles in a laboratory1. This basic distinction clarifies that in-vivo diagnostic tests 
require more rigorous testing and safety assurance before being approved for clinical use. The 
clarity on interaction of nanoparticles inside the human body is critical in this regard. It is also 
essential to demonstrate how the nanoparticles are metabolized and excreted from the body 
and the potential risks that could result from their accumulation in a person’s body over long 
periods of time. An example of an approved in-vivo diagnostic test using nanoparticles is a 
contrast agent containing superparamagnetic iron oxide nanoparticles (SPIONs) used in 
imaging studies. The use of SPIONs enhances the quality of imaging studies, and enables 
specific detection of cancer cells or inflammatory cells. The regulatory approval of SPIONs as 
a contrast agent relies on the fact that the iron oxide nanoparticles are completely broken 
down by the body and excreted.  
 A breakthrough in in-vitro diagnostic tests using nanotechnology derives from the 
possibility of miniaturizing the testing process2. This would also decrease the amount of 
required reagents, while simultaneously improving the test’s sensitivity and specificity. The 
possibility of building a test kit that could simultaneously measure multiple parameters or 
identify multiple pathogens using a single drop of blood is being investigated. These devices 
could be extremely valuable in a field setting where sophisticated laboratory facilities or 
trained technicians are not available1. This approach to in-vitro testing could decrease health 
disparity between low-resource and high-resource countries. Unfortunately, prompt and 
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accurate diagnosis alone does not address all the health care needs of a population. It is 
ethically questionable whether or not persons in low-resource countries should be diagnosed 
with multiple pathogens or blood abnormalities if no treatment is then made available. 
 Finally, nanotechnology will be critical for developing lab-on-a-chip (LOC) devices1 
that can continuously monitor certain blood parameters (e.g. blood sugar23) and relay the 
information to the patient or to the nearest health center in cases of medical emergency. LOC 
devices could also store basic health-related information about an individual on a nanochip 
that could be read electronically by health care personnel in an emergency setting1. Nanochips 
could help identify a person brought to the emergency department in an unconscious state and 
assist physicians with vital medical history and allergies to medication. LOC technology 
could improve the monitoring of certain health conditions, but its widespread use in health 
systems is still far in the future1. LOC technology raises questions about individuals’ privacy, 
confidentiality of their health-related data, and access to this data. These concerns are not 
unique to nanomedicine, since they have been raised before about electronic health data24-26 
and direct-to-consumer genetic testing27-29.  
 The improved sensitivity and specificity of diagnostic tests is an advantage for 
detecting diseases or complications early and treating them effectively at lower costs. 
However, when test sensitivity increases too much, it also challenges our understanding of 
what it means to be healthy or to have a disease10. The detection of a few cells from solid 
organs with early cancerous changes in peripheral blood sample by nanodiagnostic tests does 
not necessarily imply that the person has a cancer or would develop a cancer in next few 
years. At the moment, there are no set standard diagnostic protocols or definitions that could 
be used to differentiate between the results indicating a significant finding to warrant medical 
intervention and situations where further monitoring is needed10. Where should the boundary 
be drawn between when to intervene and when to observe a person for progression to the 
203 
 
earliest signs of a cancer actually developing? It is possible that an excessive reliance on 
highly accurate diagnostic tests will lead to over diagnosis, over treatment, and cause more 
stress and psychological harm to individuals who are diagnosed with a disease that might 
never actually develop. Adapting nanodiagnostic devices in routine health care services 
without debate, established standard protocols for their use and education of the physicians 
and the patients on their significance will only create a further medicalized society and 
medicated population30.   
2. Therapeutic modalities 
Nanotechnology enables the development of highly targeted drug-delivery mechanisms that 
require small drug doses and hence reduce treatment costs, otherwise known as 
nanotherapeutics31. Targeted drug delivery is expected to decrease side effects and provide 
better treatment outcomes. However, nanotherapeutics also encompass a large variety of 
technological platforms3 ranging from liposomes, micelles, gold or silver nanoparticles, 
carbon nano tubes (CNTs) to multistage vector assembly with silica particles “that deliver 
therapeutic cargo in sufficient quantity to a target lesion to enable a selective effect”32.  Each 
of these technological platforms has unique advantages and risks. Additionally, each platform 
is at a specific stage of development and approval by drug regulatory authorities; therefore, 
there is a varying quality of evidence and experience with the safety of these platforms. 
Liposome based drug delivery mechanism is discussed below to demonstrate the case. 
 Liposomes are the most extensively studied drug delivery methods using nanoparticles 
that are approved and available on the market today33. Liposomes are phospholipid shells with 
a surface coating of specific targeting receptors and filled with already-approved anti-cancer 
drugs. Liposomes have existed since the 1960s, but were re-labeled as nanomedicines in the 
beginning of the 1990s, when the field of nanomedicine experienced growing scientific 
interest and funding opportunities. Doxil became the first liposomal formulation to be 
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approved as a nanomedicine in 199534. Since then, various liposomal preparations have been 
under investigation and in use. Phospholipids are normal constituents of human cells and 
therefore, their preparation with already-approved anti-cancer drugs raises fewer questions 
related to their safety and risk.  
 In recent years, scientists began exploring other nanotechnology platforms to facilitate 
targeted drug delivery such as polymer micelles, gold and silver nanoparticles, iron oxide 
nanoparticles, CNTs and silica vectors35. These platforms and the nanoparticles they contain 
raise a number of questions related to safety and long-term toxicity. Gold, silver, carbon and 
silica particles are foreign to the human body. When these particles are used in 
nanoformulations, they have unique physical, chemical and magnetic properties that 
contribute to the desired therapeutic response. However, the same properties also increase 
their reactivity in biological systems and their potential to cause tissue damage. CNTs are 
particularly worrisome due to their micro-needle structure that is similar to asbestos particles 
and thus, have the potential to cause carcinogenic changes in the human body36. The human 
body does not have metabolic pathways to effectively break down gold and silver 
nanoparticles or CNTs into safe end products and completely excrete those in a short period 
of time. Thus these particles are likely to accumulate in a body for months and years and 
continue to cause cellular irritation and inflammation. Due to their nano size (from a few nm 
to few hundred nm), these particles can enter deep tissue spaces (deep brain structures, 
retroperitoneal growths, deep seated liver abscesses) and cross biological barriers (e.g. the 
blood brain barrier) that normally act as protective mechanisms by restricting the transport of 
larger particles (biological which are therapeutic substances derived from biological sources, 
larger drug molecules)12. Thus, the very attributes that make nanoparticles attractive as a 
therapeutic option to treat certain diseases, also create a concern for long-term accumulation 
and associated toxicity5.  
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 Finally, there are concerns about the reliability and validity of a battery of tests used to 
study the toxicity of investigational drug molecules comprised of nanoparticles37. Not all 
nanomedicines can be fully and adequately characterized for safety and toxicity due to 
inherent limitations of traditional toxicity assays used for testing particles that are not at a 
nano-scale. For example, iron oxide particles in bulk iron oxide, colloidal iron solution and 
SPIONs have specific physical, chemical, magnetic properties. So the tests that might work 
for characterizing colloidal iron dextran solution do not work for SPIONs. Over last few 
decades, the US National Nano Characterization Laboratory (NCL) has systematically 
developed tools to conduct characterization of investigational medicinal products using 
nanoparticles38,39. European Union has also focused on developing nanocharacterization 
capacity in Europe by facilitating active collaboration with NCL.  
 The risks and safety of an investigational molecule are normally tested in animals 
before clinical research in humans is initiated. Unfortunately, animal studies have limited 
reliability due to their study design (lack of randomization of animals, no blinding of 
investigators), the small number of animals tested, and the limited reliability of  disease 
models produced in animals40. Even if there is a biological similarity between a particular 
animal model and human physiology, the animal studies may fail to detect risks that only 
manifest in humans. The animal studies may also detect risks and benefits in animals that may 
not occur in humans41. Furthermore, animal studies are highly limited for measuring chronic 
toxicity since the animals cannot be kept alive and monitored for adverse events beyond a 
certain period of time (generally few weeks to months).  
Despite all these limitations in currently used toxicity assays and preclinical research, 
each class of nanotechnology-enabled medicines deserves thorough investigation to prove 
their potential for human health and well-being for reasons described below. However, it is 
critical that the scientists and investigators reflect on these limitations before initiating human 
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trials and the ethics committees carefully assess high level of uncertainty inherent in 
preclinical research in order to protect human research subjects.   
Unmet need for treatment 
An unmet need for treatment is often the driving force to test new drug options especially 
when patients’ standard treatment options have been exhausted or the side effects of existing 
treatments are unbearable. Cancers are particularly salient in this regard31. Many cancers (e.g. 
cancer of lungs, ovaries and pancreas) do not currently have effective treatment. Most patients 
diagnosed with these cancers do not survive more than a year or two and may not even get an 
opportunity to try existing second-line chemotherapy. Therefore, if CNTs can facilitate drug 
delivery to one of these cancers and extend life expectancy by a few years, patients might 
consider the risks and uncertainty related to the long-term accumulation of CNTs in their 
body to be of a lesser concern (than patients with other cancers and a longer life expectancy) 
and might accept such a treatment option12. This example points out to the need for 
meaningful engagement with patients while discussing regulation and scope of translational 
research. Patients’ experience of the disease and associated suffering can influence  priority 
setting in research agenda, risk assessment during the ethical review and resource 
mobilization for supporting translational research.  
Duration of treatment required. 
Cancer was targeted for nanomedicine development from the start for two reasons. The 
concern about unmet treatment need was described above and the second reason is that a 
patient with cancer takes drugs for a shorter period of time (until remission, worsening of 
condition or death) compared to a patient with a chronic life-long condition (e.g. 
hypertension, diabetes, HIV). Chemotherapy regimens are often limited to certain number of 
treatment cycles, so risks associated with long-term exposure to nanoparticles is not a 
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pressing issue for these patients, especially if a patient’s life expectancy is short and the 
cancer’s fatality rate is high. However, this situation changes when nanomedicines are 
considered for other chronic diseases with no known cure, high disease-related morbidity and 
requiring treatment till the end of life (e.g. HIV42, metabolic diseases such as diabetes43, 
cardiovascular diseases44). One example is an insulin delivery mechanism across the buccal 
membrane that is being investigated as an alternative to injectable insulin for patients with 
type II diabetes. Trans-buccal insulin delivery is facilitated by gold nanoparticles that have 
been proven safe in short-term animal studies. Unlike patients with cancer, patients with 
diabetes who begin consuming trans-buccal insulin at the age of 40 will be expected to 
continue its use for next 30-40 years. Current toxicity assays do not provide sufficient 
information about the safety and chronic toxicity of gold nanoparticles accumulated in a 
patient's body. Therefore, the advantages of improved control of blood sugar and the 
prevention of diabetes-related complications must be balanced against the potential long-term 
toxicity due to accumulation of gold nanoparticles in a patient’s body, which remains highly 
uncertain at this moment.  
Route of administration of nanomedicines 
The toxicity of nanoparticles in a particular drug delivery platform depends heavily on the 
route of administration/exposure45. This is particularly true if the medicine is injected locally 
into a lesion and is expected to remain at the site till the end of patient's life (unlike 
nanoformulations injected intravenously in systemic circulation). In the early 2000s, the 
European Medicines Agency approved a treatment platform for glioblastoma multiforme- a 
highly aggressive cancer of brain with no effective treatment options and which kills patients 
within a year of diagnosis. This new treatment modality includes a visual technology-guided 
injection of iron oxide nanoparticles into the brain tumor and externally induced focal 
hyperthermia to ablate the tumor with heat46. The iron oxide nanoparticles injected into the 
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tumor are not expected to be metabolized or excreted by the body, but rather remain localized 
at the site of injection. The advantage of this approach is that the tumor can be reheated 
externally in cases of recurrence or growth. Once again, the toxicity of the nanoparticles in a 
patient with this brain tumor must be weighed against the aggressive cancer, the lack of other 
effective treatment and the restricted potential of iron oxide nanoparticles to cause systemic 
toxicity due to their localization within tumors. 
 Based on analysis of examples above, an argument is made for a case-by-case 
discussion on each type of nanotechnology-based drug-delivery mechanism to address the 
safety, toxicity, reliability of animal disease models and the validity of toxicity studies. No 
treatment modality should be rejected outright or favored without an analysis of the larger 
context of all the procedures required for the drug’s development and approval and patient-
related factors such as diagnosis, prognosis, and expected impact on the patient’s quality of 
life. 
Need for a critical examination of current regulatory and ethical reviews 
The approval and licensing of medical devices, diagnostic tests and drugs requires meeting 
various regulatory standards, but that doesn't mean that all regulatory issues of nanomedicines 
have been addressed. Referring back to the various guidelines and regulations that constitute 
the mesosystem in the ecological model, drug regulatory and ethics review guidelines form a 
tiny part (albeit critical) of overall regulation of medical nanotechnology. A regulatory 
approach is needed that is flexible and evolving along with the technology and which includes 
comprehensive assessment of each category of nanomedicinal products on an individual basis 
within the limits of available evidence regarding uncertainties, unknowns and ignorance 
related to potential risks. Furthermore, a critical examination of the adequacy and rigor of the 
existing review processes in drug regulatory systems is also required to safeguard patient 
safety and to provide them with effective and affordable treatment options. One area that 
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definitely needs closer and critical attention is the examination of preclinical evidence 
(evidence from studies in cell cultures and animal models) on which decisions are based to 
launch FIH trials. At this moment, it is not clear who (drug regulatory authorities, ethics 
committee members), if anyone, is carefully examining this preclinical evidence47.  
 The second important question is: do ethics committees have necessary expertise and 
data available to make a thorough assessment of preclinical evidence? Not all animal studies 
are published in peer-reviewed journals and this is especially true for studies with negative 
results that might be intentionally withheld from publication48. In this context, it is important 
to create a system where all relevant preclinical data and animal experiment reports are made 
available to the ethics committees as well as drug regulatory authorities irrespective of 
positive or negative results so they do not rely solely on the investigators to provide 
comprehensive preclinical evidence.  
 Many classes of nanomedicines deserve long-term post marketing  to systematically 
gather safety and chronic toxicity data49. In the light of unmet patient needs, it is 
understandable that certain drugs are approved and licensed based on limited existing 
evidence. However, one way to strengthen post-marketing surveillance could be to provide 
conditional licenses, assign a few experts in each country or region to treat patients with the 
new drug and meticulously collect safety data before allowing all physicians to prescribe the 
drug. Which physicians should be selected for the initial limited and conditional licensing 
phase of a particular drug requires further discussion, but this approach could strike a balance 
between the patients’ unmet treatment needs and the systematic collection of evidence to 
ensure drug safety. 
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Public and patient engagement: Strengthening the macrosystem 
Finally, patient engagement is particularly important when discussing regulation of 
nanomedicine and so is the inclusion of the general public in debates related to regulation of 
nanotechnology50-52. It is challenging to determine who should represent patients or the 
public, and exactly what role these two groups should play in translational research in general, 
and not just regulation of a particular technology. Within the macrosystem, inclusion of the 
public voice and needs in social debates on the regulation of any technology (particularly so 
with medical technology) is critical for building public trust in science, technology and the 
regulatory mechanisms53. Without the public trust, no technological field can truly harness its 
full potential and risks being rejected by the same population that was envisioned as the 
potential end user. This point highlights an interaction between the mesosystem (regulation 
and policy) and the macrosystem (the public). There is an urgent need to develop strategies to 
strengthen the relationship among the stakeholders of translational research (microsystem), 
those who create regulatory policies (mesosystem) and the general public (macrosystem)54. 
These relationships must be built on trust, honesty and open communication. The findings of 
this exploratory empirical research have highlighted the complex and interconnected 
challenges and interactions of multiple stakeholders in translational nanomedicine.  Further 
research investigating specific influence of factors at the meso and the macrosystem will be 
instrumental to find solutions to those challenges.  
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Limitations and implications for further research 
This exploratory study has methodological limitations to be considered while discussing the 
results. First, the results of this qualitative study focus mainly on the microsystem of the 
ecological model presented here and should not be interpreted without considering the 
influence of the mesosystem and the macrosytem. These results point to key concerns that 
need further scrutiny but conclusive inferences cannot be made. The heterogeneity of study 
sample in terms of location, professional background and role of respondents also limits the 
generalizability of the results even though the study successfully demonstrated the broad 
scope of concerns related to translational research in nanomedicine. Our sample had a low 
representation of ethics committee members and drug regulatory authorities whose insights 
are critical to understand the complete picture of challenges in ethical and drug regulatory 
review of FIH trials with any cutting-edge medical technology. These methodological 
limitations were discussed in greater depth in chapter two. The results of this study will 
definitely help refine the research questions further so that greater insights can be obtained 
from a homogeneous sample of particular stakeholders. For example, a survey questionnaire 
designed to elicit challenges in the translational research in nanomedicine for ethics 
committee members or drug regulatory authorities will help gather insights from multiple 
countries and facilitate an examination of the influence of political and regulatory 
environments in translational research. As pointed out earlier in the discussion, exhaustive 
analysis of all possible regulations and guidelines and a comparison of their impact across 
various national jurisdictions would be valuable to better understand the challenges in 
translational research. Finally, drug development is a highly profit-driven activity involving 
multiple stakeholders with conflicting goals and interests. It is important to bear in mind that 
public trust in science and drug development is also crucial to facilitate translational research 
in medicine. Trust is a subjective concept, often assumed to be present without a full analysis 
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of the various threats to it. An investigation to examine the role trust plays in translational 
research and drug development and to develop strategies to safeguard trust in the system is 
highly recommended.  
Conclusions 
The aim of this exploratory research project was to describe the challenges in translational 
nanomedicine with a particular focus on FIH clinical trials. In-depth interviews with key 
stakeholders were conducted to understand these challenges. Main results of this study 
indicate that there is diversity in the definition of nanomedicine and it adversely influences 
the translational research. Ethical, financial and regulatory challenges in initiating FIH trials 
need to be addressed at a systemic level than at the level of stakeholders themselves. 
Stakeholders are divided in their opinions regarding the explicit mention of the ‘nano’ nature 
of investigational molecule in IC forms. They also challenge the current practice of including 
patients with end stage cancer and no treatment options as trial participants in FIH trials. 
Contextual factors such as public health emergencies can trigger accelerated translational 
research and initiate testing of experimental interventions in human beings in spite of 
significant uncertainty related to the risks and safety.  
These results mainly describe the challenges at the microlevel and point to the 
interventions that could facilitate the translational research in nanomedicine. The role of trust 
in scientific research and the meaningful public engagement deserves further investigation to 
gain the complete picture of challenges in translational research in nanomedicine.  Discussion 
on regulation of a new technology often hinges on the types and the severity of risks the 
technology might cause. Though nanomedicine does not raise new ethical questions, the 
ethical questions resurfacing in its context require a case-by-case analysis of each product and 
a focus on loose ends and blind spots in current regulatory mechanisms. An active 
engagement of the public and the patients in the translational research will help in building 
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public’s trust in science and drug development and facilitate their acceptance of 
nanotechnology to address health care needs and to minimize the health disparity and 
inequality between various countries. 
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Ethical issues of cutting edge biotechnology: embedded interdisciplinary risk 
benefit evaluation of first-in-human trials in synthetic biology and nanomedicine. 
Interview guide for Nanotechnology experts 
Information gathered about the stakeholders interviewed  
• Name 
• Institution/university 
• Present Position/post 
• Number of years in this post 
• Formal training in which domain: medicine, research, other 
• How would you describe your current professional profile in relation to nanomedicine and 
or synthetic biology?  
 
A- Understanding experts’ work/ideology/goals  
1. Please tell me about your current or on-going project/s in nanomedicine and/or synthetic 
biology. 
2. What is the added value of this technology compared with standard existing therapy? 
3. Which of your projects is a likely candidate to enter a first in human trial? 
4. When do you think this application might be tested on human beings? 
5. Are there similar projects which have already entered first in human trials or are early 
candidates for these trials? Can you tell me more about them? 
B- Assessing the risk-benefit profile of new technology 
6. You just described various potential applications of this technology for human health and 
well-being. What other aspects (direct and indirect) should we keep in mind when we are 
discussing this technology?  
7. What limitations do you consider important at this moment regarding this technology? 
8. How do you plan to address these limitations? 
9. Can we address all the limitations? If not, which limitations are acceptable given the 
advantages of the technology? In what circumstances do you think these limitations are 
compatible with starting an FIH trial?  
10. What are the potential risks we have to keep in mind in regards to the application we have 
been talking about? 
11. As an expert in this field, what differences do you perceive in risks posed by nanomedicine 
and synthetic biology as compared to other drugs or medical technologies?  
12. In your opinion, do we have to be more careful or vigilant while assessing the risks of these 
technologies compared with other technologies or medicines? 
13. In current practice various tools are used for risk assessment, like animal studies, efficacy 
and toxicity studies. Can the same tools be used for this new technology?  
14. If we need some modifications, what kind of modifications would you suggest given the 
unique nature of this new technology? 
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C- Facilitating technology from bench to bedside. 
15. What challenges do you see in the current system when it comes to bringing lab research to 
a stage where the first clinical evaluation in humans is started?  
16. Have you been part of any project in the past where clinical application was tested as a FIH 
study? What key insights will you like to share from that experience? 
17. Developing clinical applications of cutting edge biotechnology in humans is often an 
interdisciplinary task. Who in your opinion are the key stakeholders that influence whether a 
technology will reach a clinical phase? What specific roles do you envision for each of these 
stakeholders? 
D- First in human trials:  
18. What motivates you to design a FIH trial? 
19. What kind of support/collaborators do you need to plan or implement a FIH trial using this 
technology? 
20. What are the minimum conditions/criteria that need to be fulfilled to enable an FIH trial of 
this technology?  
21. Do you see any special circumstances/factors that might facilitate this technology rapidly 
entering FIH trials? What will those circumstances/factors be?  
22. In this particular example you provided, what challenges do you see in undertaking an FIH 
trial? 
23. What differences do you see between FIH trials for classical drug research and the FIH trials 
of technology that we are discussing? 
24. One of the key components of FIH trials is defining the target group of patients who could 
be considered for trial participation. For the technology that you are working on, which 
patients will you want to enrol if an FIH trial is planned? Why?  
25. In an FIH trial of the technology that you just described, what benefits do you anticipate for 
the participants? If there are no benefits to the participants, how would you justify enrolling 
them into the trial? 
26. What safeguards can be built in the trial design to minimize the risks or harms to study 
participants? 
27. Patient safety is often the biggest concern in clinical research, and more so in FIH trials; 
who in your opinion are the other stakeholders that need to be involved to share this 
responsibility of patient safety? And in what roles? 
E- Designing and getting ethics committee clearance for FIH trial (these questions are 
relevant for only those experts who might have been part of getting ethics approval for FIH 
trial or for the doctors involved in FIH trials. Since there are very few FIH trials in 
nanomedicine and synthetic biology, we will probably have to ask these questions in the 
context of any FIH trial (drugs, other technology) 
28. Have you ever been involved in designing a FIH trial or getting ethics committee approval 
for an FIH trial? In what ways? Can you tell me more about it? 
29. What challenges did you encounter in the process of getting ethical approval for this FIH 
trial?  
30. What were the main concerns of the ethics committee while evaluating your proposed trial? 
31. How did you address these concerns?  
32. How long did the process take?  
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33. What strategies can you think of to ensure that the evaluation process of FIH trials takes into 
account all relevant ethical issues and is at the same time efficient (i.e. does not induce 
undue delays or hamper research)?  
34. Who do you think is responsible for ensuring that FIH trials take into account all relevant 
ethical issues?  
35. Who shares the responsibility for resolving all the ethical issues at stake before approving 
such trials?  
36. How do you perceive the role of patient groups being involved in the ethics committee 
decision making process when FIH trials are being reviewed? What should that role be? 
37. What are the strengths and weaknesses of current ethics committee evaluation process for 
FIH trials? Could you give me some examples?  
38. What would an ideal policy for ethical evaluation of FIH trial be like? If you could draft 
such a policy, what components will you focus on?  
F- Implementation of FIH trials (only for those who are involved in conducting such trials. 
Since there are very few FIH trials with nanomedicine and synthetic biology, we might have 
to talk to people who are involved in implementing FIH trials with ordinary drugs or medical 
devices. Here we hope to find out about issues around informed consent, patient recruitment, 
explaining the design of the trial, risks and benefits to the patients) 
39. Who are the study participants best suited to be enrolled in this study, in your opinion? 
Healthy volunteers, patients with no other treatment options and likely to die as in some 
form of cancers, or patients with diseases for which the technology is being devised (stable 
patients)?  
40. What challenges do you see in explaining the details of study design to these participants? 
41. How do you address these challenges?  
42. How do you make sure that the participant has really understood what is at stake before 
agreeing to be part of the study?  
43. To what extent do you think the process of obtaining informed consent in such a trial serves 
the purpose of respecting study participants’ autonomy and safeguarding their interests?  
44. It is often a challenge to provide comprehensive information about the study design and an 
objective overview of the risks and benefits associated with it. How do you think we can 
provide such detailed information and at the same time recruit the required number of 
suitable trial participants in a timely fashion? 
 
I sincerely thank you for your time and all the inputs. Would you like to receive and read the transcripts 
of the interview? Is it ok if I contact you again in case, I have few new questions or need some more 
clarification? Please feel free to contact me again, in case you have some other thoughts/insights on this 
topic. I will be more than happy to incorporate those in relevant sections of this interview.  
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Ethical issues of cutting edge biotechnology: embedded interdisciplinary risk 
benefit evaluation of first-in-human trials in synthetic biology and 
nanomedicine. 
Interview guide for ethics committee members/ethicists 
A- Information gathered about the stakeholders interviewed  
 
1- Name 
2- Institution/university  
3- Present Position/post 
4- Number of years in this post 
5- Formal training in which domain: Philosophy, medicine, science and technology 
studies, public policy, other 
 
B- Understanding Specific contribution to ethics of nanotechnology and  or synthetic 
biology(for the ethicists who have published on nanotechnology and synthetic biology) 
6- Please tell me about your contribution/work in relation to nanotechnology and or 
synthetic biology.  
7- How long have you been working on these topics? 
8- What made you interested in this topic? 
9- How has this interest evolved over the years?  
10- Please tell me the words that come to mind in response to “nanotechnology” and/or 
“synthetic biology”. 
11- In your opinion, what ethical issues are especially important with regard to 
nanotechnology and synthetic biology? Please give me examples.  
12- What makes these particular issues so important?  
13- What potential do you see in nanotechnology and synthetic biology for improving 
human health and well-being? 
14- What aspects of these technologies, particularly their human application, make you 
concerned?  
15- Let us consider first in human trials with nanomedicine or synthetic biology. How 
would you describe them if you compare them to other FIH trials for example cancer 
drugs? 
16- Many ethicists have argued that nanomedicine and synthetic biology do not pose any 
new risks to human beings and hence existing ethical guidelines and principles should 
be used to assess these technologies. What is your opinion about this? 
17- Depending on the opinion expressed in question above, the follow-up question will be 
how these technologies and FIH trials should be evaluated. 
18- One of the concerns is that the existing ethical guidelines for FIH trial do not provide 
specific guidance to evaluate FIH trials in naomedicine or synthetic biology. What is 
your opinion on this? Is there a need to develop new ethical guidelines and 
international policies for FIH trials of nanomedicine and synthetic medicine? 
19- What components are essential in these new guidelines and policies to ensure that they 
are accepted by the international community, and ensure that they provide concrete 
guidance for decision makers (ethics committee members, policy makers and 
regulatory bodies)? 
20- In your opinion, which stakeholders are crucial in drafting such new guideline? 
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21- In your opinion, how can these guidelines be enforced?  
 
 
C- Ethical evaluation of FIH trials in synthetic biology and nanomedicine.(These 
questions are for Swiss and International research ethics committee members who might 
have been involved in evaluation of FIH trials in general and if possible for nanomedicine 
and/or synthetic biology.) 
22- Please tell me about your work as a member of ethics committee. How long have you 
been working on this committee and in what roles?  
23- Have you been involved in evaluation of FIH trials of synthetic biology or 
nanomedicine? 
24- The following questions are intended to elicit your individual opinion/perception 
regarding ethical evaluation of FIH trials. Please, describe to me the process of 
formulating your own position in the example you provided above. 
25- What factors did you focus on during evaluation of this FIH trial?   
26- What challenges did you face (in the provided example) while formulating your own 
position? 
27- How did you argue and justify your own position (in the provided example)?  
28- The risk-benefit balance is often considered crucial in ethical evaluation of research 
projects. But it is not always clear how each individual ethics committee member 
understands and defines what risk is and what benefit is. Please tell me your 
understanding/definition of risk using the example that we have been taking about.  
29-  Similarly please tell me how do you define/describe/understand benefit in the context 
of the FIH trial that we are discussing. 
30- Literature often points out that ethical evaluation is a highly intuitive and hence 
subjective process both at the individual member level and even as a committee. What 
is your opinion about this?  
31- How much role does intuition play in your own decision making process when it 
comes to ethical evaluation of research proposal? 
32- What other factors did you consider while evaluating this particular FIH study?  
33- What objective tools, guidelines models/strategies could be helpful to assist the ethics 
committee members while reaching a final decision? You might have some real 
examples from your own work as an ethics committee member which might shed light 
on this issue. Please share that example with me.  
34- What is your opinion on the utility of existing ethical guidelines and policy documents 
for evaluating FIH trials?  
35- What are the positive contributions of these guidelines and policies? 
36- What is missing from these guidelines? 
37- One of the concerns is that the existing ethical guidelines for FIH trial do not provide 
specific guidance on evaluation of FIH trials in naomedicine or synthetic biology. 
What is your opinion on this? 
38- In the UK, they have special ethics committees to evaluate FIH trials of gene therapy. 
What do you think about this? 
39- Let us now focus on the evaluation process of the FIH trial that we are discussing in 
the ethics committee setting. Please tell me how the committee reached a final 
decision when members disagreed on various aspects of the trial under consideration? 
40- In this FIH trial, which aspects/ethical issues were an absolute priority and hence non-
negotiable when it came to ethical approval? 
41-  How long did it take to make a final decision? 
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42- Do you have any examples when, even after significant discussion and deliberation, 
the members could not come to a conclusion? What was done in that case to facilitate 
a final decision? 
 
43- It is often said that ethicists are too cautious with new technologies and that delays 
progress of scientific technology. What is your opinion on this? 
44- What are some aspects of current ethical evaluation process that you think need to be 
modified to optimize ethical evaluation of FIH trials? 
45- In the trial that we have been discussing, in your opinion, who are the best participants 
for enrollment in FIH trials?  
46- What makes them the ideal candidates for trial participation in this case? 
47- In your opinion, under which circumstances is it justifiable to allow patients to be part 
of an FIH trial when there is no likely benefit but the risks are quite significant? Please 
describe at least one theoretical or practical example where this is the case. 
48- Involvement of patient group representatives as ethics committee member has been 
encouraged in recent years to bring patient perspectives to the discussions. What role 
do you see for involving patient groups in ethical evaluation of FIH trials? 
49- Do you have any examples from your own experience or from the literature where 
patient participation in RECs was attempted? How was that perceived? 
 
I sincerely thank you for your time and all the inputs. Would you like to receive and read the 
transcripts of the interview? Is it ok if I contact you by email if I have any new questions or 
need further clarification? Please feel free to contact me again, in case you have some other 
thoughts/insights on this topic. I will be more than happy to incorporate those in relevant 
sections of this interview.  
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